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ABSTRACT 
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Lysophosphatidic acid (LPA) is known to exert a diverse range of effects in humans, 
specifically in the heart where it may cause apoptosis of cardiomyocytes at 
pathological concentrations. However, at physiological concentrations LPA may 
regulate cell migration, proliferation and even differentiation. The ability to drive stem 
cells down the cardiac lineage has, however not yet investigated and the potential 
underlying molecular mechanisms that could mediate this effect also remains to be 
determined. Since LPA is reported to accumulate in acute myocardial infarction and 
may rescue cardiac myocytes, we have hypothesised it may also be able to generate 
cardiac myocytes from stem cells. This hypothesis is based on observations that the 
signalling through which it exerts its biological effects are similar to those which have 
reported regulating stem cells regulation to various lineages. The aim of this thesis, 
therefore, was to study, firstly, the effectiveness of LPA in deriving cardiomyocytes 
and then to establish the molecular mechanisms involved focusing specifically on the 
expression profile of select miRNAs including mir-145, mir-1 and mir-133 which 
respectively linked to pluripotency and lineage commitments. All studies were carried 
out using the P19 stem cell line and were maintained and cultured in supplemented 
alpha-minimal essential medium (α-MEM), comprised of antibiotics and foetal bovine 
serum (FBS). Embryoid bodies were formed from aggregates of the cells in a non-
tissue culture grade plates with or without LPA for four days. These EBs are 
subsequently plated in an adherent 6-well plate and maintained in culture between 3 
and 12 days, before being lysed for either western blotting or RNA analysis. When 
used pharmacological inhibitors of LPA receptors (Suramin (P2 purinergic/LPA 
receptor 4), H2L5765834 (LPA receptor 1, 3 & 5), H2L5186303 (LPA receptor 2 & 3) 
and TC-LPA5-4 (LPA receptor 5)), targeted protein kinases (PKC; by BIM I) and PI3-
kinase (by LY294002), they were added to the cultures 1 hour before treatment with 
LPA. In parallel studies, cells were transfected with mir-145 and mir-1 using siRNAs 
for inhibitors or mimic for overexpression. The effect on MLC-1v and OCT4 protein 
expression then determined by western blotting. Successfully, the research revealed 
that LPA could achieve differentiation of P19 stem cells, and this was concentration 
and time-dependent. The maximum response was obtained with 20μM LPA and 
peaked on day 6. Subsequent experiments were carried out using 5 and/or 20μM 
LPA. Decreases paralleled the induction of MLC-1v in OCT4 expressions. The effects 
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of LPA were mediated through its receptors, specifically LPA receptors 4 and 5 and 
partially on LPA receptors 2 and 3. The effects were also mediated through the 
kinases like protein kinase C, although the involvements of PI3 kinase was only 
partial. Expressions of mir-145, mir-1 and mir-133 elevated following treatment with 
LPA. Suramin and BIM-I inhibited these changes but not affected by LY294002, 
H2L5186303, H2L5765834 and TC-LPA5-4. Transfection studies also suggested that 
mir-1 regulate differentiation through enhanced MLC-1v protein expression with and 
without LPA. In conclusion, the program of research conducted for this thesis has 
confirmed that LPA could be an endogenous modulator of stem cells differentiation 
to a cardiac lineage, more importantly this effect is mediated through its receptors 2, 
3, 4 and 5 collectively, that may activate protein kinase PKC and PI3K and is under 
the influence of mir-145 and mir-1. Our work in this thesis suggests the active role of 
miRNAs specifically mir-145 and mir-1, which can indicate the need of further 
investigation to instigate the possible therapeutic targets and further prevent any fatal 
consequences of atherosclerosis or other heart-linked diseases. 
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1.1. Heart development: 
The circulatory system is one of the first systems to develop in mammalian embryogenesis. 
The heart is one of the primary organs to form which is originally derived from the 
mesodermal germ layer. This system was extensively studied since 1920 on chick, mouse, 
and more recently on human embryos (Van Vliet et al., 2012). The cardiac precursors are 
also found during pre-gastrulation, which is tested on cultured mouse explants by looking at 
the main cardiac transcription factors (Auda-Boucher et al., 2000). 
 
 
There are several transcription factors found to be involved in the formation of the cardiac 
mesoderm. Most of the early signalling pathways are studied and validated. Starting from 
the lateral plate mesoderm, the heart is understood to give rise to two distinct fields which 
develop into different parts of the heart explained as primary heart field (PHF) and secondary 
heart field (SHF) (Duelen & Sampaolesi, 2017). PHF is also called the first heart field (FHF) 
(Vincent & Buckingham, 2010; Van Vliet et al., 2012). Both atrial valves and the left ventricles 
are products of the PHF or FHF, while the right ventricle and the outflow tract are developed 
from SHF (Duelen R & Sampaolesi M, 2017; Wu et al., 2006). Although both fields share 
the same progenitors, some transcription factors and signalling pathways are explicitly 
regulated to serve each field. 
 
1.1.1. Genetic factors involved 
One of the first genes to be activated is Mesp1, which encodes for the Mesp1 protein and is 
predicted as a marker of the cardiac progenitor (Vincent & Buckingham, 2010). There are 
150 reported mutations of genes involved in the development of cardiac lineage as reviewed 
by Brand in 2003. NKX 2.5, eHAND, dHAND, GATA-4, and other transcription factors are the 
leading key players to be targeted to evaluate cardiogenesis in transplanted or cultured cells 
(Figure 1.1). α-cardiac actin mRNA and β-myosin heavy chain proteins were also tested by 
Auda-Boucher et al. (2000) using tissues from mouse embryo transplanted into a 2-day old 
chick. The author’s work concluded that the presence of endoderm could stimulate the 
mesodermal cells to a cardiac lineage, unlike the ectoderm, which showed no influence on 
programming the mesoderm cells into cardiac fate. 
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The downregulation of some of the key pluripotency transcription factors resulted in the 
enhancement of the differentiation of the cells into cardiac cells as well as the 
overexpression of Gata4, Tbx5, BAF60c (Van Vliet et al., 2012) and Nkx2.5 (Wu et al., 
2006). Both PHF and SHF express KDR and Nkx 2.5, and selectively, ISL12 is expressed 
only by SHF (Wu et al., 2006). Over-expression of some of the cardiac-specific markers like 
GATA4, Tbx5, and BAF60c were able to differentiate multipotent mesodermal stem cells 
(SCs) into cardiac myocytes (Takeuchi JK, Bruneau BG, 2009). 
  
 
Figure 1.1: The time course of the early embryonic cardiogenesis. 
Illustration from mouse embryonic stem cells (Blastocyst) main transcription factors and genes 
involved in the formation of the cardiac myocytes. This time course end on day 12 for the mouse 
and day 16 for humans. Signalling pathways involved: Nodal, BMP2 (Bone morphogenetic 
proteins 2), FGFs (Fibroblast growth factor) (Van Vliet et al., 2012). 
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1.1.2. Cell signalling 
It is widely agreed that the role of some of the signalling cues is critical in the regulation of 
cell fate during gastrulation (Duelen & Sampaolesi M., 2017). The activation and inhibition 
of some of these signalling pathways also is the tool used in directing the germ layer to be 
formed in the process. In some cases, more than one signalling pathway is involved, for 
instance, BMP4, Activin/Nodal and Wnt are involved in the formation of the different germ 
layers (Gadue et al., 2005). TGFβ, BMP4, and Nodal are members of a family called 
Transforming Growth Factors (TGF) (Taha & Valojerdi, 2008). Wnt, Notch, and Hedgehog 
are other key signalling molecules which were extensively studied and linked to 
cardiogenesis (Marín- García, 2014; Liu, 2015; Fraineau et al., 2017). 
BMP 
Bone morphogenetic proteins (BMPs) are growth factors which play a role in the 
development of neurological and ophthalmic system, adipose tissue, urinary system, 
musculoskeletal system, gastrointestinal system, and more importantly cardiovascular and 
pulmonary system (Wang et al., 2014). Therefore, a lot of researchers have suggested that 
bone morphogenetic proteins should be called body morphogenetic proteins instead 
following the discovery of all its functions. Extracellularly it can act as an agonist or 
antagonist. BMPs generally crosstalk with other signalling pathways (Wang et al., 2014). 
Hence why it is linked to many of the earliest processes including various regulatory roles in 
adult tissue homeostasis and organs formation (Zhang & Bradley, 1996, Bragdon et al., 
2011, Kobayashi et al., 2005). Intracellularly BMP could be regulated by various factors like 
miRNAs, I-SMADs, Phosphatases and FKBP1A, and FKBP12. The last modulator is the 
membrane modulator of the BMP proteins (Wang et al., 2014). 
BMP acts through two types of signalling pathways, canonical and non-canonical (Yuan et 
al., 2015; Cho et al., 2010; Wang et al., 2014). The SMAD canonical signal transduction is 
initiated by binding to the receptors on the cell surface. It is formed of two dimers type 1 (TGF-
β family ligands, ALK1-7) and type 2 serine/threonine kinase receptor. The non- canonical 
pathway is a SMAD-independent BMP signalling pathway activates the serine-threonine 
kinase of the MAPK family by the activation of TAK-1 by BMP-4 (Derynck & Zhang, 2003). 
Other BMPs can also affect different signalling pathways, including PI3k/AKT, PKC, Rho- 
GTPase (Zhang, 2009). 
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Currently, there are 20 expressed BMP family member identified, by which only 8 of these 
expressed in heart and linked to the cardiovascular system (Bragdon et al., 2011). These 
are BMP-1, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8a, BMP-8b, BMP-10. BMP-2 is not 
expressed 
in the pharyngeal endoderm, where Csx is found to be expressed which along Nkx2.5 has 
shown to be critical in mutant Csx. Likewise, a mutation in BMP-2 in mice caused abnormal 
development of the heart (Zhang & Bradley, 1996) which raise questions on the role both 
BMP-2 and Csx/Nkx2.5 cluster plays and stress the need of extensive studies. BMP-2, 
according to Zhang & Bradley’s conclusion (1996), is also involved in the relationship 
between the ectodermal cells and the mesodermal cells during the early embryonic 
development. In the amnion and chorion according to Jones et al. (1991), BMP-4 could not 
rescue the loss of BMP-2 despite the 92% homology shared between both in their amino 
acids (Zhang & Bradley, 1996). This results in the development of the heart in the 
exocoelomic cavity or arrest in the development of the heart due to the closure of the pro-
amniotic canal. 
 
WNT 
Wnt signalling pathway is one of the main pathways widely linked to several activities. It is 
established that WNT signalling is required for the induction of the mesodermal stage (Naito 
et al., 2006) and primitive streak formation (Yamaguchi TP, 2001). WNT is understood to 
pursue its effect through two ways, canonical and non-canonical. The canonical is a β-
catenin dependent pathway and is characterised better compared to the non-canonical 
(Gomez-Orte et al., 2013). The canonical WNT ligands interact with the Frizzled (Fz) 
receptors and a lipoprotein receptor-related protein (LRP), specifically lipoprotein receptor-
related protein 5 and 6 (LRP5 & LRP6) (Gay & Towler, 2017). This pathway is also known 
to be a stage-based regulator, especially in cardiomyogenesis and hematopoiesis (Naito et 
al., 2006). Naito and his colleagues (2006) reported this developmental stage-specific 
(biphasic) by testing the expression of WNT genes in Drosophila, P19 cells, Chick, and 
Xenopus at different stages. In Drosophila cardiogenesis and the EB formation stage they 
found that WNT/Catenin activates the essential markers to induce the differentiation of ES 
into cardiomyocytes and at the same time act as an antagonist to the vascular marker genes 
(hematopoietic).  
6 
 
On the other hand, they found that the stage post-EB formation, it activates the 
hematopoietic/vascular genes and downregulates BMP, which, as a result, inhibits the 
cardiac genes. On the contrary, a negative role was reported in chick and Xenopus where 
WNT/catenin inhibited cardiomyogenesis at stages 5-6 and 8-9. However, the report 
discussed how the cells were already committed at this stage, and the fate was decided 
already in the gastrulation stage and SHF where the expression of WNT is high and 
activated (Gomez-Orte et al., 2013; Naito et al., 2006). 
The non-canonical signal transduction is β-catenin independent, and the most popular 
pathways are the planar cell polarity (PCP) and the WNT/Ca2+ pathway (Gomez-Orte et al., 
2013). The canonical WNT/PCP acts through the c-Jun N-terminal kinases (JNK) (Meyer et 
al., 2017). This pathway controls cytoskeletal activities and cellular orientation (Gay & 
Towler, 2017). Ras homolog A gene family (RHOA) and small GTPases RAC1 are also 
other downstream effectors of the Wnt/PCP signal transduction (Gomez-Orte et. Al., 2013). 
While the WNT/Ca2+ is predominantly linked with cardiovascular diseases due to its 
regulation of vascular smooth muscle cells (VSM) (Gay & Towler, 2017), it is also linked to 
inflammation (Kohn & Moon, 2005), cancer and neurodegenerative diseases (Gomez-Orte 
et al., 2013). The G-protein coupled receptors family (GPCR) also releases calcium, which 
is mediated by Fz independently from the LRP5/LRP6 (Slusarski et al., 1997; Kohn & Moon, 
2005). 
The role of Wnt and its functions specified in the cardiomyogenic stage is believed to be 
linked to BMP. WNT also promotes the development of PS cells by inducing the expression 
of brachyury from ES cells (Gadue et al., 2005). The secreted frizzled-related proteins 
(SFRPs) inhibits the WNT pathway, and it inhibits both the canonical and the non-canonical 
sclerostin and Dickkopf (Dkk) proteins also inhibit the WNT pathway by binding to LRP5 and 
LRP6 proteins (Gay & Towler, 2017). 
Nodal/Activin 
Nodal is a member of the TGF family and is one of the most critical growth factors in 
cardiogenesis (Gadue et al., 2005) and organogenesis in general. Nodal is found to be 
mediated by several transcription factors and proteins like Crypto (Brand, 2003), FoxH1 
(Lenhart et al., 2013), Smad (Gahr et al., 2012), Apelin (Deshwar et al., 2016), Nodal 
modulator 1 (NOMO1) (Zhang et al., 2015A) and other factors.  
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 The signalling pathways of Nodal and Activin are very similar, and the effect is sometimes 
indistinguishable to which one is responsible, hence why it is widely referred to as 
Nodal/Activin or Activin/Nodal complex (Pauklin & Vallier, 2015). 
It is understood that the Nodal/Activin ligands play an active role in the Inhibition of the 
neuroectoderm and the regulation of the pluripotent factors and most importantly drive the 
differentiation of the mesendoderm (Bertero et al., 2015). In work presented by Bertero and 
his colleagues (2015), they demonstrated the link between Nodal-SMAD2/3 and the 
pluripotency transcription factor NANOG in maintaining self-renewal and differentiation. 
Nodal also plays a role in the mesodermal germ layers specification in the early stage 
(Kattman et al., 2010). While in the later stage, Nodal is understood to inhibit and lower the 
expression of BMP on the left side of the cardiac field unilaterally (Veerkamp et al., 2013). 
This action of Nodal results in cellular migration of the tissues and lower expression of non-
muscular myosin which, overall, give rise to the cardiac left-right axis asymmetry of the heart 
(Veerkamp et al., 2013; Brennanet., 2002). 
The Nodal signal transduction binds to one of two Activin receptors through type I activin 
receptor through ALK4 or ALK7 and type II activin receptor ACTRIIA or ACTRIIB (Schier, 
2003; Pauklin & Vallier, 2015). This action results in the phosphorylation of SMAD2 and 
SMAD3, which further initiates the downstream effects (Schier, 2003; Pauklin & Vallier, 
2015). 
 
1.1.3. Post-transcriptional factors involved by Non-coding RNA 
sequences and RNA G-quadruplexes: 
Recently, the post-transcriptional regulation has been investigated as one of the cues into 
solving the mechanisms in several biological activities. Regarding the cardiac development, 
there are two major groups of regulators; Non-coding sequences and G-quadruplex. Both 
share the same role in the regulation of mRNA and the translation of proteins (Nie et al., 
2015; Choong et al., 2017). The non-coding sequences are of three types, a small non-
coding RNAs sequence (SncRNAs), a long non-coding RNAs sequence (LncRNAs) and a 
circular non-coding sequence (CircRNAs) (Ottaviani & Martins, 2017). SncRNAs are the 
most researched group, the LncRNAs comes next, and finally the recently reported group 
CircRNAs. The structural differences are illustrated in figure 1.2.  
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RNA non-coding sequences 
The short non-coding RNA sequences (SncRNA) or in other words, the microRNAs 
(miRNAs) are an endogenous single-stranded sequence in the non-coding RNA sequence. 
It has been extensively studied, and some key miRNAs have been identified as regulators 
of precisely the cell fate, differentiation, development, proliferation, and regeneration, and 
repair of cardiomyocytes (Katz et al., 2016; Choong et al., 2017). miRNAs are introduced in 
detail in section 1.4. 
LncRNAs similarly are another group of non-coding sequence which are longer than 
miRNAs (18-25 bp (Ying et al., 2013)) with a size larger than 200 bp (Ottaviani & Martins, 
2017). According to Nakagawa (2016), LncRNAs are key in the regulation of the epigenetic 
modifications as well as in genomic imprinting (allelic modulation) and the transcriptional 
and post-transcriptional genetic regulation. These set of regulators are found in both the 
nucleus and the cytoplasm, which explains the interaction with several molecules found in 
both either activated or inhibited (Ottaviani & Martins, 2017). LncRNAs Can perform RNA 
editing, polyadenylation, alternative splicing, and a 5’ terminal methylguanosine capping 
post-transcriptionally. These activities take place when LncRNAs are activated when key 
transcriptional factors bind to the transcriptional start site (TSS) in the lncRNA (Choong et 
al., 2017; Guttman et al., 2009; Derrien et al., 2012). These factors such as OCT4, SOX2, 
NANOG, NFκB, P53, and MYC regulates LncRNAs by binding to its TSS which is the place 
of the histone marks (Choong et al., 2017; Guttman et al., 2009; Derrien et al., 2012). These 
histone marks, such as H3K27, H3K4me3, H3K9ac, and H3K4me2, are also associated with 
the expression of lncRNA (Derrien et al., 2012). 
In mice, there are two significant examples of the role of lncRNA in the differentiation and 
development of cardiac myocytes. Foxf1 adjacent non-coding developmental regulatory 
RNA (FENDRR) is proven to be critical and essential when silenced or inhibited; it can cause 
a severe defect in cardiac development (Grote et al., 2013). FENDRR is also a vital regulator 
of some of the most important transcription factors in the development of cardiac fate (Grote 
et al., 2013). 
The other example is Braveheart (BVHT), which was identified by Klattenhoff and his 
colleagues (2013) to be crucial in initiating the cardiac lineage and in maintaining the cardiac 
fate during mammalian developments. They are linked to the progression of the mesodermal 
stage through the regulation of MesP1 and other cardiovascular gene networks. 
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Figure 1.2: Structural differences between the three non-coding RNA sequences. 
The last type of the non-coding sequences is circRNA. It is transcribed from intronic and 
exonic according to Hsiao et al. (2017), Qu et al. (2015) however, they could also originate 
from an anti-sense, intragenic and intergenic depending on the position of the gene and its 
adjacency. The role of circRNA and activities have been revealed and discussed (Qu et al., 
2015). Due to its circular configuration, circRNA contains no 5’ and 3’ ends, which concludes 
the reason for its stability (Hsiao et al., 2017). However, in the biogenesis of the CircRNA it 
is back spliced when the 5’ end moves towards the 3’ end, hence how it leads to a circular 
RNA structure with covalently a closed loop (Siede et al., 2017; Cheng & Joe, 2017). 
Siede et al., (2017) reported that a significant change in CircRNAs expression was found 
suggesting the critical role these set of non-coding sequences could possess. These were 
specifically regulated in the context of the cardiac β-adrenergic signalling and the cardiac 
myocyte differentiation state. They used a human induced pluripotent SCs derived from   
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cardiomyocytes. They also concluded that circRNAs are highly regulated in the case of the 
stress response as well as in the development of cardiac fate. 
On the other hand, another group (Chen et al., 2017) identified a circRNA which regulates 
vascular smooth muscle cells proliferation and migration. This finding elucidated by silencing 
the WDR77, which, as a result, suppressed VSMCs proliferation and migration by targeting 
its downstream regulators like FGF2 and mir-124. Another example of functions of circRNA 
in the heart is what is called heart-related circRNA (HRCR). It tends to play a role as an anti-
hypertrophic agent by targeting mir-223 acting as a sequester of the RNA-binding protein 
(Wang et al., 2016 B; Ottaviani & Martins, 2017). 
From these previous examples, the critical role of circRNAs could be summarised as a 
miRNA sponge (decoy) which results in the termination of the post-transcriptional regulation 
by miRNA (Hansen et al., 2013). They also manipulate and regulate mRNAs expression 
directly via imperfect base-pairing when attached to the mRNA (Hentze & Preiss, 2013). 
CircRNAs, moreover, could help in transporting miRNAs intracellularly to its targets as well 
as interacting with ribosomes and RNA-induced silencing complex (RISC) (Siede et al., 
2017). Altogether, suggest that circRNAs could be a key contributor into a lot of phenotypic 
diseases (Ottaviani & Martins, 2017) and other many processes like cancer, tissue 
developments and ageing (Qu et al., 2015). 
The importance of this non-coding sequences rest on the fact that they acquire almost 98% 
of the whole genome compared to 2% of the coding sequences (Carninci et al., 2005) which 
explains the increasing interest on these ncRNAs and the possible roles as therapeutic 
targets or as disease markers. 
 
RNA G-quadruplexes (G4s) 
G-quadruplex is formed of a tetrad-stranded structure rich in Guanine DNA and RNA 
sequence (Nie et al., 2015; Cammas & Millevoi, 2017). In the non-coding sequence or the 
untranslated regions (UTRs) G4Ss are found in both the 5’ and 3’ end, according to Huppert 
and his colleagues (2008). While in the coding sequences (exons), it is found only in the 5’ 
end (Eddy & Maizels, 2008). 
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RNA-G4S has recently been increasingly focused on compared to DNA-G4S. This is due to 
its regulatory roles in gene expression and translation (Agarwala et al., 2015). Besides, 
RNA- G4s is also more stable and compact due to its single-stranded structure compared 
to the double-stranded deoxyribose sugar and the increased intramolecular bonds 
(Agarwala et al., 2015). 
RNA-G4S biologically function as a translational regulator, specifically repression and 
augmentation. It also features like a 3’ end processing (alternative polyadenylation) as 
demonstrated within the downstream of P53s 3’end after a UV irradiation (Decorsière et al., 
2011). RNA-G4S has also been found to be like Rho in the mechanism of termination of 
transcriptions (Wanrooji et al., 2010). The functions of RNA-G4s also includes mRNA- 
localisation and alternative splicing (Agarwala et al., 2015). 
These RNA-G4S motifs have recently been linked to other post-transcriptional regulators and 
ncRNAs. This is illustrated with lncRNAs (Jayaraj et al., 2012) and miRNAs (Mirihana et al., 
2015) as well as the regulation of several gene expressions (Cammas & Millevoi, 2017) hence 
why this set of motifs attracted attention due to its competence in being a therapeutic target 
or markers. 
 
1.1.4. Cardiovascular diseases (CVDs) 
The cardiovascular system is one of the most studied systems in the body. Cardiovascular 
diseases (CVDs) are associated with high death rates (31%) in the world, according to the 
world health organisation (WHO). In 2015, 17.7 million were estimated to have died because 
of CVDs like coronary heart disease, strokes, atherosclerosis, and myocardial infarction (MI). 
Congenital heart defect (CHD) malformation is one of the primary defects that occur during 
the development of babies before birth. Heart defects affect 1 in 100 babies, hypertrophic 
cardiomyopathy (HCM) is another form of the disease which is diagnosed at infancy and is 
the second most common form of heart muscle disease. Rheumatic heart disease and 
Kawasaki disease are all other forms of diseases linked to the heart. All these are affecting 
not only the health of the people of the world but also have a significant financial impact 
worldwide, especially in low and middle-income countries (WHO). Although research is on-
going and emerging, there are still several issues that remain unresolved and unanswered. 
In most of the European countries, CVD is the first death causing factor in premature babies   
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(De Backer et al., 2003). Some risk factors that are involved in CVDs are high blood pressure 
(hypertension) (Forouzanfar et al., 2017; Lim et al., 2012), high cholesterol (Sinicato et al., 
2013), diabetes (Sinicato et al., 2013), smoking (De Backer et al., 2003), obesity (De Backer 
et al., 2003) and genetic (a family history with a CVD) (Padmanabhan et al., 2015; 
Kathiresan & Srivastava, 2012). All these factors, including others, could be interlinked and 
increase the susceptibility to a CVD which, as a result, could lead to mortality. 
 
1.1.5. Pathophysiology of CVDs: 
In atherosclerosis, the dysfunction of endothelial cells results in the elevation of reactive 
oxygen species (ROS) which promotes foam cells or atherosclerotic lesions and increase 
oxidative stress in the heart (Ooi et al., 2017). Oxidative stress joined with the inflammation 
developed as a result of the atherosclerotic lesions are also highly associated in causing 
CVDs (Sinicato et al., 2013; Ooi et al., 2017) and acute coronary syndromes (Ooi et al., 
2017). Similarly, MI is an outcome of cardiac cells death by ischaemic insult (Frangogiannis, 
2015). This cell death is widely reported as either apoptosis of the cells or necrosis. The 
most robust difference is that with apoptosis the dead cells are cleared without the induction 
of inflammation, while in necrosis, it triggers the inflammatory factors justifiably due to the 
swelling that occurs to the cells (Frangogiannis, 2015). MI is also mainly caused by coronary 
atherosclerotic disease in the heart, specifically by the rupture of the plaques, which also 
leads to thrombosis pathophysiologically (DeWood et al., 1980; Frangogiannis, 2015). The 
severe loss of these myocardial cells post-infarction could lead to hypertrophy and fibrosis 
because of the exhaustion of the non-infarcted cardiomyocytes (Frangogiannis, 2015; Tham 
et al., 2015). 
Cardiac hypertrophy, however, pathologically is associated with factors like epigenetic 
changes, cellular dysfunctions, over-production of pro-inflammatory cytokines, and fibrosis. 
These changes, also, are induced because of either hypertension or MI and further would 
cause prolonged and abnormal hemodynamic stress (Tham et al., 2015; Shimizu & 
Minamino, 2016). 
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1.1.6. Recent therapies linked to cardiovascular diseases 
Despite promising pre-clinical studies, some clinical trials on cardiovascular diseases have 
been less conclusive with slightly conflicting findings. However, currently, there are several 
pharmaceutical drugs and therapies used, like β-receptor blockers like acebutolol, 
angiotensin receptor blocker (ARB), angiotensin-converting enzyme inhibitor (ACE inhibitor) 
like enalapril and renin inhibitor and calcium channel blockers (CCB). 
There is also a lot of promising results and reports pre-clinically either on animal models or 
at the cellular level. This includes using non-coding regulators which have been shown to be 
able to contribute to the transcriptional changes in disease models as well as in clinical 
samples. Yang and his colleagues (2017) discussed how the CircRNA_081881 regulates 
miR-548, which is also a peroxisome proliferator-activated receptor gamma (PPARγ) 
regulator, which acts as a heart-protective factor. Several miRNAs are linked to many CVDs; 
this includes but not limited to mir-133, mir-21, mir-132, mir-208a, and mir-1 (Roma-
Rodrigues et al., 2015). Oligonucleotides modification is used to decrease the expression of 
these miRNAs (AntagomiRs) as well as using RNA mimics for overexpression (Roma-
Rodrigues et al., 2015). 
One of the most highly promising therapies is exploiting cell therapy or SCs therapy 
(Malliaras & Marban, 2011). This therapy includes the transplantation of SCs to the infarcted 
heart for the regeneration and repair of the damaged tissue. Induced pluripotent stem cell 
(iPSC)-derived cardiomyocytes are specifically under the spotlight. A group led by Shiba 
(2016) reached a conclusion based on their experiments on Monkeys. The Monkeys with 
matching MHC iPSC- derived cardiomyocytes showed no immune rejection up to week 12 
and showed no signs of tumours besides other downsides that were found soon after 
transplantation, however, this is a promising step in tackling two of the biggest problems that 
face cell therapies in the heart. Some of the limitations in using pluripotent embryonic SCs 
clinically are the risk of tumours, immunogenicity, and genetic instability, including ethical 
matters (Robertson 2001). In 2014, a damaged heart tissue in a primate myocardial 
infarction model was engrafted and repaired using embryonic SCs (Chong et al., 2014). This 
finding and others have given some hope to the possibility of using in vitro programmed cells 
without risks. Prof Mummary who is one of the first people to inject ESC to animal heart 
suggests that these findings and contributions will move this therapy forward to the clinical 
field sooner if future studies address the effect of larger grafts with longer follow up and   
14 
 
address any possible complications (Fernandez-Ruiz, 2016).  
SCs are essential in developing effective treatment strategies for most of these diseases by 
either repairing or regenerating the cells and tissues or using them as a mimic to the actual 
organ in-vitro by using a specific differentiation inducer to the cells using cell culture 
techniques. New novel opportunities are needed and to this end stem cell therapy is 
emerging as a potential therapy for regenerating the infarcted or failing myocardium 
especially with the little reported changes in the impaired cardiac functions from the clinical 
trials. 
 
1.2. Stem cells 
SCs are the foundation for all the different cells and tissues. These cells can self-renew by 
continuously dividing and growing through mitosis. SCs can be driven to differentiate into 
another specific kind of cells with a specialised function which, as a result, can form the 
different lineages and tissues in the body. 
This differentiation can be monitored by a set of genes which can be expressed or repressed 
in the cells (Potten & Loeffler, 1990) through any differentiation or specialisation inducer. In 
vivo, this can happen by the interaction of SCs with neighbouring specialised or 
differentiated cells, by chemicals secreted, or by signalling through growth factors. While in 
vitro, scientists can drive the SCs to specialise in the petri dish by inducing with growth 
factors (signalling pathways activation). Cell substrates are used as an extracellular matrix 
(ECM) constituent in plates, by which the SCs would be grown on top of this ECM, which 
will give rise to a specific lineage. A published example of these ECM with cell substrates is 
a matrigel which contained pancreatic cells. Pluripotent SCs were grown on top of the ECM 
in a plate, and the cells developed into an actual pancreatic cell (Zhang et al., 2009). Other 
ECM substrates include fibronectin, collagen, laminin, and hyaluronic acid (Cell and 
Molecular Biology and Imaging of SCs “book,” 2014). This co-culturing of existing 
differentiated and undifferentiated cells in the same culture would allow specific proteins to 
be secreted on the ECM and the three-dimensional structures of the cells form a spherical 
aggregate known as embryoid bodies (EB), which mimics the natural process of 
differentiation and the development of new cells. 
  
15 
 
1.2.1. Types of Stem cells 
There are different types and classifications of SCs according to the potential of each to be 
differentiated. Totipotent, pluripotent, and multipotent stem cells are the major types which 
can differentiate into various lineages. Other kinds of SCs are oligopotent or unipotent. 
These cells can only differentiate into limited cell types (Gülçin, and Erdal, 2012). Totipotent 
is the earliest stage of stem cell in the organism by which it can give rise to a whole living 
species with the identical specification to the mother cell. Pluripotent SCs are cells which can 
be differentiated into any other cell type unlimitedly by which after this stage, the cells cannot 
have the same specificity as pluripotent and the lineages of these cells will be limited. 
 
Multipotent cells are mainly found within organs, and they are limited to cells linked to their 
tissue type. For example, a multipotent blood stem cell can be differentiated into the different 
kinds of blood in the body, while the multipotent cardiac SCs can be driven to produce 
endothelial cells, myocytes, and smooth muscle cells (Beltrami et al., 2003). Unipotent SCs 
are cells which have the potential to be developed into one single cell type. Figure 1.3 
illustrates the different stages of SCs from an embryo to the differentiated cells. 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.3: Source of different types of stem cells through the development 
stages from an embryo to the formation of organs (Jones, 2006). 
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There are two classes of SCs; embryonic stem cell and adult stem cell (somatic). This 
classification depends on the source of these cells and the capability they hold to be 
differentiated into more varied kind of cells or the ability to self-renew. Embryonic stem (ES) 
cells are pluripotent cells which are found in the inner cell mass (ICM) of the blastocyst 
(Evans and Kaufman, 1981; Martin, 1981; Keller, 2005). ES can self-renew, and it serves 
as building blocks for the body. Adult SCs are multipotent cells and have limited ability to 
self- renew or to differentiate into various kinds of cells. This limitation is because these cells 
are produced in a specific tissue environment, which limits their differentiation into other cell 
types linked to other tissues. 
 
1.2.2. Embryonic Stem cells (ES) 
According to Smith (2001), ES cells give rise to three different germ layers, endoderm, 
mesoderm, and ectoderm-derived lineages. Each layer gives rise to distinct lineage and 
tissues (Figure 1.4). The endoderm gives rise to the liver, pancreas, and lung, while 
mesoderm develops into blood, heart and skeletal muscles and ectoderm develop into the 
central nervous system (CNS) and skin (Keller, 2005).  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.4: Embryonic stem cells lineages and stages (Keller, 2005). 
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1.2.3. Types of the embryonic pluripotent stem cells 
Embryonic SCs can be sub-grouped into embryonic carcinoma cells (EC) or embryonic germ 
cells (EGC) (Boheler et al., 2002). The difference is that ES cells are derived from the ICM 
and epiblast in the blastocyst stage in the embryo. However, EC is a tetracarcinoma isolated 
from the extra-uterine sites in mice which have been transferred initially from the (ES) cells 
in the epiblast in the ICM (Table 1.1). EG cell line is isolated from the genital ridge of 9.5-
12.5dpc embryos of a mouse by the ES transferred from the ICM and derived from primordial 
germ cells (PGCs). EC in comparison to ES and EG does not require feeder cells to be 
cultivated, while the other two groups (ES & EG) are feeder cell layers dependent (e.g., 
mouse embryonic fibroblast). A lack of this feeder layer, which contains differentiation 
inhibitors would result in the cells to lose the stability of the chromosomes karyotype and the 
function of being self-renewing cells (Boheler et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1.1: A comparison between sources of P19 embryonic carcinoma, embryonic stem 
cells, and embryonic germ cells (Boheler et al., 2002). 
Type of Stem 
cells 
Origin 
Feeder 
Layer 
Karyotype 
Development into 
lineages 
Embryonic stem 
cells (ES) 
Inner cell mass (ICM) Yes Euploid Multiple 
Embryonic 
carcinoma cells 
(EC-P19 cells) 
Extra uterine sites No Heteroploid Limited 
Embryonic germ 
cells (EG) 
Primordial germ cells Yes Euploid Limited 
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1.2.4. Induced Pluripotent Stem cells (iPSCs) 
iPSCs hold a potential source of a self-renewing and spontaneously growing cells with the 
ability to be derived from different cell types in the body. iPSCs were recently discovered by 
re-programing to pluripotent SCs from an adult differentiated cell. It was reported by 
Takahashi & Yamanaka, in 2006 and was examined on somatic cells by inducing four 
different transcription factors, which are Oct3/4, SOX2, c-Myc, and KLF4. These four 
transcription factors share the same objective, which is keeping the cells in their 
undifferentiated state and keeps the cells regenerated and renewed. Other successful 
combinations of the transcription factors which could generate iPS cells include Sox2, Oct4, 
Lin28, and Nanog (Yu et al., 2007). The process of producing these cells includes 
overexpressing several endogenous pluripotency inducers in the cells. These inducers have 
been recently found to help maintain and induce transcription factors like Oct3/4, SOX2, and 
KLF4. Xu et al. (2009) reported that mir-145 is at its lowest expression level in ESCs, which 
means the pluripotency transcription factors were at their highest level of expression as a 
result. On the other hand, they found that mir-145 was highly overexpressed during 
differentiation, which correlates with the decrease of the pluripotency markers of the 
transcription factors (Xu et al., 2009). What makes iPSC unique is that they are remarkably 
like ES cells in their morphology, proliferation, and gene expression (Yamanaka et al., 2012). 
 
1.2.5. Induction of embryonic stem cells differentiation  
One of the most popular ways of inducing differentiation of SCs is by forming embryoid bodies 
(EBs) in a suspension culture plate. The fate of these embryoid bodies could be monitored 
by either adding specific growth factors (GF), transcription factors, and drugs. Recently, 
another endogenous factor is being highlighted by researchers, and these are the non-
translated sequences (i.e., miRNAs), which proved to play a significant role in regulating the 
factors which keep the cells in their original undifferentiated state by renewing and 
regenerating those cells (Xu et al., 2009). Embryoid bodies could be formed in a 3-
dimensional culture using a technique called hanging drop technique. 3D cell culture is a 
technique which creates scaffold-free cells in three dimensional instead of the usual 2-
dimensional embryoid culture. Recent results showed that 3D spheroid cell culture formed 
in vitro mimics the in vivo development and growth of cells more than the 2D cell culture. 
Differentiation can be induced by using GF in the medium to drive the SCs to be differentiated 
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into their fate. An example of a successful growth factor transcription factors/signalling 
showing a significant difference in the expression between the control and the GF induced 
stem cell in a research done by Ayatollahi from Iran in a published paper in 2011. This paper 
illustrated that insulin-like growth factor (IGF) induced differentiation of mesenchymal SCs. 
Moreover, another research carried out by a group in 2000 led by Schuldiner demonstrated 
that eight different GFs could develop in cells derived from human embryonic SCs (hESCs). 
Besides these papers, many other research papers showed that using GF for inducing 
differentiation of SCs is a successful way of driving ESCs to develop into another type of 
cells. 
Another example of differentiation inducer is transcription factors or signalling molecules like 
BMPs, leukemic inhibitory factor (LIF), GATA family, and Nkx-2.5. All are linked to the 
process of the differentiation either positively or negatively. According to Monzen et al. 
(1999), BMPs exert their effect on the cells by inducing an antagonist which inhibits the 
differentiation of the cells into cardiomyocytes by stopping the transcription factors 
associated in their development into cardiac cells. This BMP antagonist is called Noggin. 
However, the differentiation could be reactivated either by overexpressing BMP-2 or adding 
the BMP protein to the culture. In the same research paper, GATA-4 and Nkx-2.5 were 
shown to be highly expressed during the differentiation process of SCs into a cardiomyocyte. 
This reaction to the differentiation has been confirmed by Grepin et al. (1997) who examined 
this zinc finger cardiac transcription factors and concluded that GATA-4 could cause 
embryonic stem cell markers to be down-regulated, while the cardiac transcription factors to 
be activated or over-expressed (Grepin et al., 1997; Boheler et al., 2002). LIF is understood 
to play a negative role in blocking the differentiation of the cells as well as the development 
of mesoderm cells (Boheler et al., 2002). 
Emerging models of organs in vitro that mimic naturally formed tissues or organs are one of 
the highly focused areas by scientists using ES cells in the last 20 years (Keller, 2005). 
Various ways of deriving the lineages of ES cells have been discovered and applied for the 
same reason for the best tissue model. These contribute in understanding the nature of the 
development of these tissues, and the kind of the disorders in the tissues by identifying defect 
markers or targeting the main reason behind the problem or using these in-vitro tissues for 
transplantation as replacement or regeneration to the defected organs.  
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The key player in this process could be the identification of a clinically relevant molecule for 
inducing the differentiation of SCs. One of the favourites used agents for the differentiation 
of the tetracarcinoma stem cell-like P19 cell line into cardiomyocytes is dimethyl sulfoxide 
(DMSO) (Abilez et al., 2006; Angello et al., 2006; Van der Heyden et al., 2003A; Boheler et 
al., 2002; Jasmin et al., 2010; Edwards et al., 1983; Arreola et al., 1993; Skerjanc, 1994). In 
this thesis, the agent that will be focused on is Lysophosphatidic acid (LPA) which is of more 
physiological relevance but has not been thoroughly investigated about the differentiation of 
SCs into cardiomyocytes nor has its potential underlying mechanisms been fully 
investigated. 
 
1.2.6. Induction of the differentiation of P19 cells into 
cardiomyocytes: 
P19 cells are pluripotent teratocarcinoma cells induced in the C3H/HeHa mouse (Jasmin et 
al., 2010). The uniqueness of the P19 cell line lies on that it can grow undifferentiated rapidly 
without the need of feeder layers like ES cells (Choi et al., 2004). They also have proven to 
be one of the excellent models to mimic the early stages of cardiogenesis and beyond 
(Paquin et al., 2002). These pluripotent like EC, P19 cells are established to being able to 
induce differentiation into multiple cell types that represent the three germ layers (McBurney, 
1993). The differentiation of P19 cells into the neuroectoderm derivatives like neurons, 
microglia, and astroglia has been shown by retinoic acid (RA) as one of the main lineages. 
Skeletal muscles, as well as cardiac, has also been widely developed to represent the 
endodermal and mesodermal stages by using DMSO in aggregates of P19 cells (McBurney, 
1993). The induction of differentiation into cardiomyocytes by DMSO is the most studied 
kind of induction using P19 cells (Angello et al., 2006; Jasmin et al., 2010). Comparing the 
efficiency of the differentiation of P19 cells showed that using a non-toxic or a physiological 
relevant agent to drive the differentiation is more effective than using other chemical agents 
like DMSO (McBurney, 1993; Skerjanc et al., 1999; Paquin et al., 2002). There are several 
reported agents for being able to induce the cardiac differentiation using P19 cells, oxytocin 
(Paquin et al., 2002), 5-azacytidine (Choi et al., 2004), cardiogenol C (Wu et al., 2004), and 
finally DMSO as mentioned earlier. Moreover, Lysophosphatidic acid has recently emerged 
as one of the cardiac lineage inducers in our group using P19 cells (Pramod, 2017).  
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1.3. Lysophosphatidic acid (LPA) 
Lysophosphatidic acid is a product of a blood clotting process and a serum-constituent that 
activates a G-protein coupled receptors found in different cell types to initiate the various 
processes (Moolenaar et al., 1997). It is revealed that LPA plays a similar role to hormones 
and growth factors (Eichholtz, 1993; Moolenaar et al., 1997). Some papers suggest that the 
purpose of LPA is stimulating platelet aggregation, smooth muscle contraction, neuronal cell 
rounding, and neurite retraction and initiate proliferation in fibroblasts (Eichholitz, 1993). Ishii 
et al., (2004) suggest, that LPA is involved in cellular processes, proliferation, apoptosis, 
inhibition, cell migration, secretion of chemokine and cytokines in addition to other roles not 
yet revealed (Figure 1.5). 
 
 
 
 
 
 
Previously, phospholipids were understood to be as building blocks for the cell membranes 
and tissues but, this hypothesis is no more recognised and recent publications have reported 
phospholipids could play a critical role in cell signalling and in mediating vascular physiology 
and pathophysiology due to their circulation in the blood (Moolenaar et al., 1999). LPA was 
first identified in 1978, then in 1989, the growth factor-like roles were discovered, and in 
1996, the LPA receptors were identified (Tigyi, 2001). 
 
1.3.1 Production and release of LPA 
LPA is a glycerophospholipid which consists of three different parts in its chemical structure: 
head group, linker group, and lipophilic tail which explains why LPA is one of the easily 
soluble phospholipids in water (Xu et al., 2001). LPA is mainly produced from phosphatidic 
acid (PA) processed into phospholipids (PLs) then hydrolysed by autotaxin (ATX), an 
enzyme secreted by phospholipase D (PLD) which is an ectonucleotide   
 
Figure 1.5: Chemical structure of LPA. 
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pyrophosphatase/phosphodiesterase-2 (ENPP2) (Perrakis & Moolenaar, 2014) and could 
be produced in the external cellular membrane by the hydrolysis of lysophosphatidylcholine 
(LPC) (van Dijk et al., 1998). Other mechanisms and production pathways have been 
reported depending on the site of release of LPA and the cell type. According to Pages et 
al. (2001), LPA could be produced intracellularly in mitochondria and the endoplasmic 
reticulum by the acylation of glycerol-3-phosphate by the glycerol-3-phosphate-
acyltransferase. Moreover, the active circulating LPA molecules are transformed by 
dephosphorylation to monoacylglycerol (MAG) (Figure 1.6). 
 
 
 
Ongoing research in our group has made significant progress in recognising LPA as an 
endogenous bio-lipid inducer of stem cell differentiation into cardiomyocytes, and from other 
reports, can also regulate proliferation, adhesion, migration, survival, and morphogenesis 
(P´ebay et al., 2007). LPA regulates the immune activation response by activating T cells 
and dendritic cells (DCs) (Chen R et al., 2006). As to its role in the immune system, LPA is 
increasingly found to play significant roles in the cardiovascular system, nervous system, 
reproductive system, respiratory system and in cancer (P´ebay et al., 2007). 
  
Figure 1.6: The synthesis process of LPA and the involvement of specific enzymes in 
the digestion: 
PLs, Phospholipids; PLD, Phospholipase D; PLA, Phospholipase A; PA, Phosphatidic 
acid; LPL, Lysophospholipid; ATX/LysoPLD, Autotaxin/Lysophospholipase D; LPA, 
Lysophosphatidic acid; LPAAT, LPA acyltransferase; LPP, Lipid phosphate 
phosphatase; MAG, monoacylglycerol (Ye & Chun, 2010; Rosen & Goetzl, 2005). 
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 This shows that LPA is involved in many biological processes by signal transduction and 
signalling molecules through the G protein-coupled receptors (GPCRs) primarily through 
LPA receptors 1, 2, 3, 4 and 5 (LPA1-LPA5) (P´ebay et al., 2007) and LPA6 which may be a 
new member of the GPCRs activated by LPS (Pasternack et al., 2008). Several papers now 
suggest that LPA regulate the differentiation of SCs, protect different types of cells, including 
cardiac myocytes from apoptosis, and enhance myocytes contractility (Lin et al., 2010). 
 
1.3.2 Lysophosphatidic acid receptors (GPCRs)  
As indicated above, LPA acts on potentially six different G-protein (Gi, Gq, G12/13 alpha 
subunits) coupled receptors (LPA1-LPA6). One more receptor is recently reported as an 
addition to the family (reviewed by Ye & Chun, 2010) and two other potential receptors are 
being validated. Each receptor mediates different and multiple roles and responses at the 
cellular level (Lin et al., 2010). Some of the roles of each receptor are not yet clearly 
established, but the downstream targets are suggested to be as follows in figure 1.7. 
LPA1 and LPA2 seem to be similar in their targets, and both have a high affinity towards 1- 
acyl- and 2-acyl-LPA, while LPA3 has a higher affinity for 2-acyl-LPA (reviewed by Ye & 
Chun, 2010). LPA1, LPA2, and LPA3 receptors are mainly found in the testis, according to 
Ye et al. (2008). LPA1 and LPA2 are two highly expressed receptors in human prostate 
cancer cells (Xie et al., 2002). While, LPA4, LPA5, and LPA6 are shown relatively less 
compared to LPA1-3. The LPA4 receptor is expressed in the ovary (Noguchi et al., 2003) 
and LPA5 expressed in ESCs, spleen, dorsal root ganglion, and small intestine (Kotarsky et 
al., 2006). Additionally, Pasternack et al. (2008) suggested that P2Y5 receptor (LPA6) is 
essential for hair growth and maintenance. They claim to be the first to indicate the link and 
the importance of a G-protein coupled receptor to human hair. Several LPA receptors are 
also found in the heart and involved in the overall mammalian development. LPA1 is 
expressed in tissues like the heart (Contos et al., 2000). LPA3 and S1p1, however, are found 
to be highly expressed in the developing heart specifically (Ohuchi et al., 2008). Although, 
LPA2, LPA4, and LPA5 are found to be expressed in the heart at a lower level compared to 
their presence in other tissues (as reviewed by Yung et al., 2014).  
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1.3.3 Role of LPA in diseases: 
LPA is understood to function pathologically and physiologically and tend to influence 
cellularly apoptosis, proliferation, and other processes (Sengupta et al., 2004). Hence, LPA 
is linked to several abnormalities and defects in human, animal, and cell lines. 
Neuropathic pain (NP) develop as a consequence of multiple sclerosis, cancers, diabetes, 
as well as other chronic diseases (Velasco et al., 2017). It occurs once lesions to the central 
nerve fibres advances or in the case of acute nerve injuries (Velasco et al., 2017). LPA 
expression was found to be over-expressed, which suggested a role in demyelination of the 
neurons as one of the core causes of NP (Yung et al., 2014). Also, Inoue’s group (2004) 
elaborated on the role of LPA in NP through Rho-kinase, ROCK, and Ras pathways via 
Gα12/13 and LPA could trigger and maintain NP. 
LPA could be one of the challenges in cancer patients treated with chemotherapy, as it 
activates AKT, which protects cells from induced apoptosis potentially caused by 
chemotherapy (Baudhuin et al., 2002). LPA is also linked to ovarian, prostate, breast, 
pancreatic, colon, lung, melanoma, and hepatoma cancers. It is, however, most extensively 
studied in ovarian cancer (OC) (Sengupta et al., 2004). LPA plays a crucial role in migration, 
invasion, and metastatic activities. Sengupta et al. (2004) reviewed that for successful 
metastasis, cells should: a) detach from the original area of cancer, b) be able to survive 
under adverse situations, c) migrate to any distant locations, d) adhere to and invade the 
basement membrane of new loci, and e) grow as secondary metastatic foci. 
In OC, LPA act as a growth factor (Xu et al., 1995). It is also highly elevated in OC patients 
compared to other cancers and control (disease-free patients) (Xu et al., 1998). Yu and his 
colleagues (2016) also showed that LPA is highly correlated to the metastatic capabilities in 
OC. LPA1, LPA2, and LPA3 were significantly higher in a patient with metastatic OC. 
Besides, the OC cell lines, which responded well to the LPA induced invasion, showed 
higher metastasis colonisation capabilities. Mitogen-activated protein kinase 1 (MEKK1) is 
one of the essential agents in the OC-linked migration of the cells, activated by G(i)-Ras-
dependent manner (Bian et al., 2004). The G(i)-Ras-MEKK1 pathway mediates LPA-
stimulated OC’s cell migration by facilitating focal adhesion kinase redistribution to focal 
contact (Bian et al., 2004). The heavy focus in OC is because it is the deadliest disease 
among the gynaecological types of cancers (Yu et al., 2016).   
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In prostate cancer, part of the roles played by LPA is activation of NFκB, which enhances 
the survival of prostate cancer (Kue et al., 2002). It also activates extracellular signal-
regulated kinase 1 & 2 (ERK) pathway and transactivates EGFR which induces the 
proliferation of androgen, which also stimulates prostate cancer (Kue et al., 2002; Sengupta 
et al., 2004). 
In CVDs, LPA could influence platelets, cardiomyocytes, blood cells, SMC, endothelial cells, 
and fibroblasts (Sengupta et al., 2004). Calcium is also, modulated by LPA receptors which in 
conjunction with WNT could regulate vascular smooth muscle cells and it is predominantly 
linked to diseases in the heart (An et al., 1998; Hunter et al., 1999; Dubin et al., 2010). LPA 
similarly regulate cell migration and vascular maturation in the cardiovascular system (Teo 
et al., 2009). 
Human CD34 in MI were rescued and survived better when treated with LPA in a 
concentration and time-dependent manner (Kostic et al., 2015). This group also confirmed 
experimentally the capability of LPA to induce cell proliferation and inhibit apoptosis. LPA is 
also reported to directly activate PPARγ, a known heart-protective factor (McIntyre et al., 
2003; Yang et al., 2017). This action may indicate that any defect linked to the PPARγ 
pathway could be because of lack of activation or the over-activation by LPA. 
Some GPCRs are shown to regulate other receptors indirectly through miRNA. In this 
regard, LPA3 mediated heart hypertrophy has been suggested to involve blockade of the 
expression of LPA1 using miRNA23a which was overexpressed after the signal transduction 
of LPA3 was activated (Ye et al., 2005; Yang et al., 2013). The involvement of miRNA in the 
broad activities of LPA within some of the complex mechanisms is yet to be fully established. 
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1.4. MicroRNA 
MicroRNAs are a tiny regulatory non-coding sequence in RNA; they range from 18-25 
nucleotides in length (Huang, 2010; Ying et al., 2013) and are first described and discussed 
by two research groups, Pasquinelli et al. (2000) and Reinhart et al. (2000). Both addressed 
the link between miRNA and let-7 and the regulation of cell functions. miRNAs are now widely 
known in terms of their structure, involved mechanisms, and roles. They are found in the 3' 
untranslated region (3' UTR) and may regulate 60% of mammalian and human genes 
(Friedman, 2009). These miRNAs were discovered when a group of researchers were 
studying a gene called lin-14 in C. elegans development in 1993 and found that a small non-
coding sequence regulated this gene. They found two sets of RNA of different sizes, the first 
one with 61nt and the other one was 22nt. The 61nt RNA was found to be the precursor of 
the 22nt, now referred to as microRNA (miRNA) (Bartel, 2004). miRNA can regulate targeted 
mRNA by either the cleavage of the mRNA if the miRNA perfectly complements the sequence 
on the mRNA or by repression, which is activated if the sequence does not complement 
perfectly. In this case, the mRNA is post-transcriptionally silenced (Bartel, 2009) (Figure 
1.9). 
miRNAs can be quantified either by qRT-PCR (Wilson et al.,2010, Pratt et al.,2013) or by 
using specific primers which can be studied by northern blot gel electrophoresis. Flow 
cytometry is another specific miRNA detection process that uses the beads-based 
technique. One of the differences between this technique and other is that it is analysed in 
a solution, unlike the different techniques examined in glass plates. Digital counting, Micro-
Arrays, and sequencing are different techniques that un-specifically detect all miRNAs in 
any sample, and they are ideal techniques for miRNA profiling. Northern blot is said to be a 
standard in the detection of miRNA with limitations which make it unfavourable because of 
its low sensitivity and is time-consuming (Cissell & Deo, 2009). However, qPCR is one of 
the most convenient techniques in quantifying miRNAs and is less costly compared to the 
mentioned techniques. The only downside is that the number of targets is limited and could 
be less specific depending on the primers and the sensitivity. 
Many investigators are discovering the significance of miRNAs in most of the diseases 
influenced by this small single-stranded RNA. However, it is not clear exactly how miRNAs 
influence and target critical proteins production. Potential targets could be predicted through 
a database website Called “TargetScan” (http://targetscan.org).  
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According to the latest version of update of the discovered miRNAs database, “miRBase” 
(http://mirbase.org) there are currently 3,5828 mature miRNAs identified (21), an increase 
of 5,441 mature miRNAs since last release (20). “HMDD” (the Human microRNA Disease 
Database) is a database website which reports all diseases which are validated to be 
regulated by miRNAs. Last released update suggests that the number reached 378 diseases 
linked to 572 miRNAs. 
 
1.4.1 Biogenesis of microRNA 
MicroRNAs are a non-coding RNAs that act at the post-transcriptional level to regulate gene 
expression (Tong & Nemunaitis, 2008). In the mature form, they exist as short (22 
nucleotides) single-stranded RNA molecules. These originate from a primary large 70 
nucleotides transcript called pri-microRNAs (Figure 1.8) (Broderick & Zamore, 2011). This 
pri-miRNA contains a multiple stem-loop known as a hairpin structure. RNase II enzyme 
Drosha initially processes it in the nucleus which changes it into pre-miRNA and then 
transported to the cytoplasm by an enzyme called exportin where they are converted to the 
mature form by a second RNase III enzyme called, DICER (Broderick & Zamore, 2011). Once 
produced, the mature microRNA subsequently incorporates into a ribonucleic particle, 
forming the RNA-induced silencing complex (RISC). The latter induce gene silencing, 
targeting mRNA for degradation to prevent protein expression (Tong & Nemunaitis, 2008). 
In doing so, microRNAs regulate a multitude of physiological processes and have also been 
implicated in several diseases. 
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1.4.2 The role of microRNA in development 
MicroRNAs control and regulate development in almost all mammals, plants, and insects by 
controlling the genes responsible for producing proteins, including growth factors which help 
in the development of the organisms. Lin-4, let-7, and mir-10 genes are found in the HOX 
cluster are examples of miRNAs that control development in the body of C. elegans and 
mammals in general (Bartel, 2004). miRNAs are also found to be involved in the 
development of cancers in cells highlighting the effect of miRNAs and their link to diseases 
in humans. The role for some miRNAs has been acknowledged. For instance, miRNAs-1 
and -133 are known to regulate the differentiation and the development of cardiac cells and 
the cardiovascular system (Wilson KD et al., 2010). 
  
Figure 1.7: Biogenesis and mechanism of miRNA in the inhibition 
process of the targeted mRNA (Tong & Nemunaitis, 2008). 
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1.4.3 The role of microRNA in diseases: 
There are more than 378 different diseases linked to 572 miRNAs (HMDD) including cancer 
(metastatic and non-metastatic), cardiovascular diseases, nervous system diseases, 
diabetes and all its complications including insulin dependent and non-insulin dependent. All 
these make miRNAs important to understand and to prioritise as they may be potential 
therapeutic targets in the treatment of most of the diseases (Figure 1.9). In addition, miRNAs 
could be targeted as markers to identify diseases in any organ or tissue, where the miRNAs 
may be linked to the disease or found to be upregulated. 
 
Insulin production intra-cellularly is regulated by miRNA by blocking two of the inhibitors of 
insulin (Tattikota & Poy, 2011). Mir-24, mir-26 and mir- 148 are reported to share the same 
mRNA targets, Bhlhe22 and Sox6, which in their active state inhibits the production of insulin. 
This inhibition was confirmed after the up-regulation of Bhlhe22 and Sox6 after the enzyme 
Dicer was knocked out (Tattikota & Poy, 2011). This outcome shows how a deficiency in a 
miRNA could develop into a life-threatening problem. Another form of miRNA mutation with 
a consequence is that associated with let-7 miRNA in C. elegans which caused a 
developmental, physical abnormality as shown on the figure below (Reinhart et al., 2000; 
Rougvie, 2001). Majority of animals with the loss of let-7 by mutation or knockout would 
result in ruptured vulvas, which, as a result, cause their death. 
 
 
 
 
 
 
 
 
 
  
Figure 1.8: Picture of wild-type C. elegans let-7 miRNA gene and a knocked-out 
let-7 miRNA gene which shows a developmental abnormality. 
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Depending on the organism, organ, tissue, and cell, miRNAs could vary in their functions 
and regulatory roles in all linked diseases. Various miRNAs play a role in heart diseases like 
miRNA-21, -195, and -208 which cause hypertrophy (Rooij et al., 2007), heart failure, and 
response to stress, while miRNAs-1 and miRNA-133 are found to regulate some aspects of 
cardiac diseases as well as monitoring the development and the differentiation of the 
cardiovascular system (Wilson KD et al., 2010). 
 
1.4.4 MicroRNA and Stem cells  
Recently miRNAs have been found to be able to re-program differentiated SCs and play a 
role in differentiating pluripotent cells (reviewed in Trevor et al., 2010) and de-differentiate 
somatic cells into induced pluripotent cells (Nakagawa et al., 2008). Other research 
suggests that miRNAs can repress pluripotency of human embryonic SCs (hESCs) (Xu et al., 
2009). Overall, researchers agreed that miRNAs are a vital regulator of differentiating cells 
and development of cells (Figure 1.10). Thus, miRNAs play a role in de-differentiating 
programmed cells by inducing pluripotency and reprogramming the cells. Some of the 
functions that are reported and published are illustrated in table 1.2. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.9: Role of specific miRNAs in the differentiation of human stem 
cells (Gangaraju & Lin., 2009). 
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# miRNA Reference Effect Main targets 
1 1 
(Rajala et al., 2011) 
(Callis & Wang., 2008) 
(Rooij et al., 2007) 
(Wilson et al., 2010) 
Overexpression increased the proportion 
of beating aggregates. 
CdK9 
(Ghanbarian et 
al., 2011) 
  (Care` et al., 2007) 
Decreased expression induced 
hypertrophy, while overexpression 
inhibited hypertrophy. 
RhoA, Cdc42, 
& Nelf-
A/WHSC2 
  (Thum et al., 2007) 
Expansion of cardiac and muscle 
progenitor cells & proliferation of the 
ventricular myocytes. 
Notch ligand 
delta 
2 133 (Rajala et al., 2011) Differentiation into cardiac cells  
 
(Care` et al., 2007) 
(Yang et al., 2013) 
Decreased expression induces 
hypertrophy, while overexpression 
inhibits hypertrophy in the heart. 
RhoA, Cdc42, 
& Nelf-
A/WHSC2 
3 208 
(Rooij et al., 2007) 
(Rajala et al., 2011) 
(Yang et al., 2013) 
Heart-specific and required for cardiac 
growth under stress. Highly up-regulated 
in cardiac- differentiated ESCs 
 
4 499 
(Wilson et al., 2010) 
(Sluijter et al., 2010) 
Expression would Induce cardiac 
differentiation 
SOX6 & Wnt/β 
5 145 
(Rajala et al., 2010) 
(Xu et al., 2009) 
Decreased in ESC, upregulated during 
EBs and differentiation 
Oct4, SOX2, 
KLF4 and 
pluripotency 
6 23a 
(Yang et al., 2013) 
(Wang et al., 2012) 
-Involved in the modulation of cardiac 
function. -Regulate (inhibit) hypertrophy 
in the heart when activated by LPA3 
through LPA ligands. 
-LPA1 receptor 
-Foxo3a 
7 206 (Rajala et al., 2011) Associated with cardiac remodelling  
 
 
Table 1.2: Summary of main miRNAs playing a role in the differentiation into 
cardiomyocytes: 
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1.4.5 MicroRNA and differentiation of Stem cells (P19) into 
cardiomyocytes regulated by LPA  
Unpublished observations from our group (Pramod 2017) have shown that LPA can induce 
cardiac cells differentiation from P19 SCs. Other researchers confirmed the role of LPA in 
the differentiation of SCs into cardiac cells (Pébay et al., 2007). The differentiation of p19 
cells can be assessed by observing the presence of the protein markers for cardiac lineage 
and by observing beating cell (Pébay et al., 2007, reviewed in Humphrey, 2009). Wilson and 
his team (2010) suggested using Flow cytometry for a cardiac marker called α-sarcomeric 
to confirm the differentiation of the hESCs and observing a pluripotency marker like OCT4 
which is believed to be significantly decreased in the case of the differentiation of the stem 
cells. miRNAs have been recently linked to the process of differentiation as well as 
reprogramming of cells (Ivey et al., 2008). Assessing the reciprocal role these post-
transcriptional regulators play is critical and vital to grasp the mechanism of this 
differentiation fully. The main miRNAs to be targeted are mir-1, mir-133 as cardiac markers, 
and mir-145 as pluripotency marker using qPCR.  
 
1.5. Aims and objectives 
This thesis aims to examine and possibly establish the role of miRNAs in the regulation of 
P19 SCs in the LPA induced stem cell differentiation into cardiomyocytes. Further to this, to 
investigate the involvement of the various LPA receptors and signalling pathways and study 
the relationship with these miRNAs.  
The achievement of this aim is to be accomplished through confirming the ability of LPA to 
induce the regulation of stem cell differentiation into cardiac cells regulation of LPA induced 
effects through specific transcription factors and markers. The first stage of the studies 
involves looking at the effect of LPA and establishing whether it is concentration and time-
dependent (long and short course). After which select LPA receptors and kinase inhibitors will 
be investigated to determine their role in differentiation. The involvement of miRNAs and the 
identification of the primary key miRNAs that are critical for differentiation will also be 
inspected. Furthermore, the inhibition and over-expression of these miRNAs will be 
evaluated in the presence and absence of LPA.  
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CHAPTER 2 
MATERIALS and METHODS 
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2.1. Routine cell culture 
The P19 stem cell line derived from a C3H/He strain mouse was ordered from the European 
Collection of Cell Cultures (ECACC; Salisbury, UK). 
The vial was thawed and then cultured in a T25 tissue culture flask containing complete 
medium (CM) which was α-minimal essential medium (α-MEM) consisting of 10% foetal 
bovine serum (FBS) and 1% of penicillin/streptomycin. When the cultures reached a 
confluency of around 70-80%, the cells were trypsinised and a density of 3.7x105 cells/ml 
was plated into non-tissue culture grade Petri dish for four days. During this period, the cells 
were treated with or without LPA (5-20µM) in the absence and presence of select drugs. 
Other experiments require following different steps. Inhibitor experiments require pre-
treatment for 30-60 minutes before adding LPA to the cells. Regarding the transfection 
experiments, cells were transfected prior to forming EBs, and these cells were then formed 
into EBs for four days and plated to be lysed at specified time points. 
All the P19 cells studies were performed in a cell culture lab to avoid contaminations, and 
all techniques were performed inside the biosafety cabinet following aseptic techniques and 
strict cell culture regulations. A brief of the routine cell culture process is illustrated in figure 
2.1. 
Cells were placed into a 25ml flask containing 6ml of CM. The media was changed the next 
day after washing with 5 ml of 1X phosphate buffer saline (PBS) twice. The media was 
changed every other day until the cells reached a confluency of 70-80% then they were 
trypsinised to be passaged and cultured in a new 75 ml flask with 13 ml of CM. Cells are 
routinely incubated in 5% CO2 incubator at 37˚C and 95% air. 
 
35 
 
 
 
Figure 2.1: Illustration of the major cell culture steps. 
 
2.1.1 Trypsinisation 
Confluent cells at T75 flask were trypsinised to be sub-cultured or form embryoid bodies. 
First, the medium in the flask was removed and cells rinsed with 1X PBS twice each with 10 
ml, then 4 ml of 1X trypsin incubated for 2-5 minutes with a gentle tapping on the side of the 
flask to make sure all cells were detached. The cells were re-suspended with 8-9 ml of CM 
and transferred into a 15 ml falcon tube to be centrifuged at 13,000 rpm for 5 minutes. After 
centrifugation, the supernatant was discarded, and the pellet was resuspended with 3-4 ml 
of CM and mixed thoroughly to be ready for forming embryoid bodies after performing cell 
and viability count. 
 
2.1.2 Cell count 
Cell counting was performed using a Countess® (Figure 2.2) from Invitrogen, Life 
technologies. This machine is an automated cell counter which counts the total number of 
cells (live and dead cell; Figure 2.3) allowing for the viability to be determined.
36 
 
 
Figure 2.2: Automated cell count trypsinised cultures using Countess® from Invitrogen 
Inc. 
(A) Countess® machine includes glass slides and trypan blue. (B) The user interface of 
the Countess® machine shows a sample picture of cells on the slide and a total 
number of cells, live and dead cell count and the viability percentage. 
 
A 10 µl aliquot from the sample of resuspended cells was transferred into an Eppendorf tube 
and mixed with 10µl of 0.08% of trypan blue. 10µl from the mix was added to the counting 
chamber of the slide, cells counted, and the numbers determined as follows (Figure 2.3): 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.3: Cell count result and calculations. 
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After this step, cells were ready to be transferred into a suspension culture to form embryoid 
bodies (EBs). 
 
2.2. Cryopreservation 
The freezing medium was prepared by mixing 10% of glycerol with 90% of FBS. Following 
washing and trypsinisation, cells were spun at 1000 RPM at 4°C for 5mins. The supernatant 
was discarded gently, and the cells re-suspended with 1ml of the freezing medium. This 
suspension was split into two cryovials (1:2 ratio) and left in a Mr Frosty container in a -80°C 
freezer overnight before being transferred into liquid nitrogen tank for long term storage, 
properly labelled with the type of cells, date and passage number. 
 
2.3. Embryoid body formation 
Embryoid bodies were formed in a non-adherent petri dish (6ml). The seeding density was 
3.5x105 to avoid the cells being overcrowded and to allow the EBs to have space to grow to 
the required size. 
 
2.3.1 Induction of stem cell differentiation using LPA 
Lyophilised LPA was ordered from Sigma Aldrich and dissolved in 0.1 (w/v) fatty acid-free 
bovine serum albumin mixed with 1X PBS (pH 7.2) with a final concentration of 5mM stock. 
5µM of LPA was used in the studies as this had previously been determined to induce 
significant differentiation without adverse effects on the cells (Pramod, 2015). 1% DMSO 
was also used as a positive control. The cells were left to grow over four days once treated 
with LPA or DMSO (Table 2.1). 
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O
. 
 Control 
DMSO 
(1%) 
LPA (5µM) 
1 
Volume of cell suspension (3.5X105 
cells/ml) 
247µl 247µl 247µl 
2 Volume of condition 0 60µl 6µl 
3 Volume of media 5,753µl 5,693µl 5,747µl 
4 Total volume 6000µl 6000µl 6000µl 
 
 
2.3.2 Embryoid body formation and treatment with different 
concentrations of LPA 
In these experiments, the concentration-dependent effect of LPA (0µM – 20µM) on the 
differentiation of P19 cells into cardiomyocytes was investigated. An example of the 
calculation is illustrated in the table below (Table 2.2). 
 
NO.  
LPA 
(0.5µM) 
LPA 
(2µM) 
LPA 
(5µM) 
LPA 
(10µM) 
LPA 
(20µM) 
1 
Volume of cell suspension  
(3.5X105 cells/ml) 
247µl 247µl 247µl 247µl 247µl 
2 Volume of LPA stock (5mM) 0.6µl 2.5µl 6µl 12µl 24µl 
3 Volume of media 5,753µl 5,750µl 5,747µl 5,741µl 5,729µl 
4 Total volume 6000µl 6000µl 6000µl 6000µl 6000µl 
 
  
Table 2.1: Set up experiments for the determination of the effects of control, DMSO 
and LPA. 
 
Table 2.2: Set up experiments for the determination of the concentration-dependent 
effect of LPA. 
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2.4. The use of inhibitors and blockers of signalling 
and receptors 
EBs were formed prior to adding LPA following the collection of the pellet and the 
resuspension with fresh media. The EBs are treated with the selected inhibitor for 1 hour 
before being treated with LPA (5uM) and then left to incubate for four days without changing 
the medium. This EBs were collected and plated for a defined time of period (Section 2.6). 
The inhibitors used are Suramin (Sigma Aldrich, UK), LY294002 (Tocris, UK), H2L5765834 
(Tocris, UK), H2L5186303 (Tocris, UK), TC LPA5 4 (Tocris, UK), and bisindolylmaleimide I 
(BIM I) (Merck Chemicals Ltd, UK). Most of the inhibitors were diluted or dissolved in DMSO 
but with no more than 0.08% of DMSO as a final concentration. 
 
2.5. Transfection of miRNAs 
Once a T75 flask reaches a confluence of around 70-80% it was trypsinised and plated in a 
6-well plate for transfection. 0.25X106 cells/ml were seeded in each well and left for 24 hours 
in a CO2 incubator. Wells were labelled as 1- control, 2- negative (Lipofectamine® RNAiMAX 
only), 3- (target A) inhibitor, 4- (target A) mimic, 5- (target B) inhibitor and 6- (target B) mimic 
(Figure 2.4). After 24 hours, cells were then treated with each condition mixed with FBS and 
free of P/S antibiotics medium following the protocol supplied by the company (Table 2.3). 
Plates are then incubated for another 24-48 hours and cells allowed to form EBs in the 
absence and presence of LPA for four days before being transferred into tissue culture grade 
6-well plates. Protein lysates and RNA were extracted on day 6. 
Figure 2.4: Setup of the plate for the transfection experiment. 
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The siRNAs for the inhibitor and mimic of mir-1 and mir-145 were used to study any possible 
effect on several proteins and mRNA targets using the suggested protocol by the supplier.  
 
2.6. Plating embryoid bodies for differentiation 
On the fourth day after forming the 3D aggregates of EBs, the EBs were transferred into a 
tissue culture grade plate. Plating started by transferring all the contents of the dish into a 
new falcon tube and left inside the safety cabinet until a clear aggregate of pellets collected 
at the bottom of the tube. The supernatant was discarded gently, and then resuspended with 
fresh CM and mixed before starting the process of plating. Based on the experimental 
design, EBs are then plated in 6 or 12 well plate or even in a single tissue culture plate 
according to the time point required. The plates were then incubated in a CO2 incubator at 
37˚C for 3-12 days, and the media was changed every second day. Day 0 was the only 
exception which was not plated because cells were lysed on the same day, and the samples 
kept for analysis. 
  
Table 2.3: Set up of steps and reagents for transfection experiments. 
 Steps 6-well 
1 Seeded cells 0.25X106 cells/ml 
2 Incubation 24 hours 
3 Dilute Lipofectamine RNA + αMedium 150µL + 9µL 
4 Dilute siRNA + αMedium 150µL + 3µL (30pmol) 
5 Mix diluted siRNA + diluted 
Lipofectamine RNAiMAX (1:1) 150µL + 150µL 
6 Incubation 5 minutes 
7 Add siRNA-lipofect.mix to cells 250µL (25pmol) 
8 Incubation 24-48 hours 
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2.6.1 Short time course experiment 
For Short time course experiments, cells were treated with LPA after the cells reach 60% 
confluency in a T25 flask on a monolayer. The time range from 5, 15, 30 minutes, and then 
1, 3, 6, 9, and 24 hours. Complete medium was mixed with 5µM or 20µM LPA and incubated 
with the cells for the time specified. Cells were then washed with PBS twice, trypsinised and 
set up to form EBs for four days. The EBs were subsequently plated in tissue culture grade 
plates and allowed to grow into monolayers, lysing cells at day 6 and day 12. 
2.7. Cell lysis and protein quantification 
The media in each plate was discarded, the wells washed with 1ml of 1X PBS twice. 
Following this, the cells were lysed with 1X of ice-cold lysis buffer (2mM of Tris-HCl (pH 7.4), 
1% Sodium dodecyl sulphate (SDS). The cells were scraped using the back of a yellow 
pipette tip and collected in an Eppendorf tube which was heated (95˚C) for 5 minutes and 
sonicated in an ultrasound water bath three times for 30 seconds each and then was 
centrifuged for 25 minutes. The upper phase was separated from the lower and used for the 
protein assay and western blotting.  
2.7.1 Protein quantification assay (BCA) 
The bicinchoninic acid assay (BCA assay) was used to determine the quantity of cell protein 
concentration. Standards were prepared by mixing 50 mg of bovine serum albumin (BSA) 
dissolved in 5ml of double distilled water (DDW), and a set of concentrations from 0-3µg/µl 
were prepared as follows (table 2.4): 
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Subsequently, 5μl of the standard concentrations were pipetted into 96-well plate, 5μl of 1X 
lysis buffer was added to each standard. Sample wells were prepared by adding 5μl of lysed 
sample proteins together with 5μl of DDW. Finally, 100μl of BCA reagent (Reagent A + reagent 
B, 1:50) was added to all wells. Each standard and sample were done in a triplet. The plate 
was left to incubate on a plate shaker for 45 minutes at room temperature before analysing 
the absorbance at 620nm wavelength. The quantity of protein in each well was determined 
from the standard curve (Figure 2.5).  
  
Table 2.4: Protein standard preparation 
No. 
Protein/well 
(μg) 
BSA (μl) 
DDW 
(μl) 
Protein concentration 
(μg/μl) 
1 0 0 1000 0 
2 1 20 980 0.2 
3 2 40 960 0.4 
4 3 60 940 0.6 
5 5 100 900 1 
6 10 200 800 2 
7 20 300 700 3 
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Figure 2.5: BCA protein standard curve. 
 
 
2.8. Cytotoxicity and cell viability assay 
The MTT (3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide) assay was 
used to determine the cytotoxicity that could be detected following treatment under different 
conditions. MTT (Sigma) is a yellow tetrazole which is enzymatically transformed into a 
crystallised purple formazan by metabolically active live cells. 
Cells were initially seeded in a 96-well plate and treated with drugs or conditions (in replicates) 
mixed with complete medium for 24 hours. Afterward, 200µl of a 5mg/ml stock of the MTT 
solution was added to each well for 4 hours with a final concentration of 0.5mg/ml per well. 
The medium was then discarded, formazan crystals were dissolved in 200μl of isopropanol. 
Absorbance was finally taken at 540nm on a Multiskan® plate reader (Ascent). Changes in 
cell viability were calculated relative to the 100% of controls.  
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2.9. Western Blotting 
Western blot was carried out using a polyacrylamide gel or SDS-PAGE on a Mini- 
PROTEAN® Tetra Cell from BIO-RAD. 
First, the casting frame and the glass plate sandwich were set on the casting stand and filled 
with DDW to check for any leakage. While observing the sandwich glass for any possible 
leakage resolving and stacking gels for two gels were prepared. 10ml of resolving gel (12%) 
was prepared by mixing 3.31ml of DW and 3.99ml of 30% acrylamide/bisacrylamide mixture 
beside 2.5ml of cold 1.5M of Tris-HCl (pH8.8) and 100µl of 10% SDS. 100µl of 10% 
ammonium persulphate (APS) and 60 µl of tetra-methyl-ethylene-diamine (TEMED) were 
added right before filling the glass plate sandwich with the resolving gel. Bubbles were 
removed using isobutanol layered on the top of the resolving gel. 
Next, 4ml of stacking buffer gel was prepared by adding 2.44ml of DW, 0.52ml (520µl) of 
30% acrylamide/bisacrylamide mixture along with 1ml of cold 0.5M Tris-HCl (pH6.8) and 
40µl of 10% SDS. Again, 20 µl of APS and 4 µl TEMED were added right before pouring the 
mixture on top of the resolving gel followed by placing the comp (for wells formation) in the 
stacking gel. The glass plate sandwich was separated from the casting frame and attached 
to the clamping frame (electrode assembly) face to face and placed in the electrophoresis 
tank which was filled with 1X tank buffer prepared by mixing 1X 0.025 M of Tris base, 0.192 
M glycine and 0.1% of SDS. Lysates were prepared by mixing a sample buffer (bromophenol 
blue) at a ratio of 1:5 for 5X loading buffer or 1:1 for the 2X loading buffer. These samples 
were prepared to be loaded on the gel by heating for 5 minutes alongside the biotinylated 
protein molecular ladder. The loaded concentration of each sample was calculated to give 
20µg/µl per well. The gel was run at 220V at 40mA (20mA/gel) and increased up to 50mA 
(25mA/gel) after the samples passed the stacking region of the gel. 
 
2.9.1 Protein transfer from the gel to polyvinylidene difluoride 
membrane (PVDF): 
PVDF membrane and six filter papers were cut into the gel size. Three filter papers were 
placed below the gel and the other three on top of the gel once placed on the membrane. 
The membrane was soaked for 5 minutes in methanol then washed with distilled water (DW) 
before placing it in the sandwich (Figure 2.6). 
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1X Transfer buffer (48mM Tris base pH7.5 + 39mM glycine + 0.0375% SDS and a 20% 
methanol) was poured to the sandwich on the semi-dry transfer cell that enclosed the gel 
and bubbles removed. The transfer was carried out at 50mA (25 mA/gel) for 15-20 minutes. 
 
2.9.2 Membrane blocking: 
After the transfer, the membrane was transferred into a plastic plate contained a blocking 
buffer which was a mixture of 200µl of tween20, 10g of fat-free milk and 90ml of DDW and 
membranes were blocked for at least 1 hour or more. 
 
2.9.3 Incubations with primary and secondary antibodies: 
5ml of the blocking buffer was used for the primary antibody, myosin light chain-1v (MLC-
1v; diluted 1:100) or the other antibodies diluted according to supplier’s instructions. Each 
membrane was placed in a plastic hybridisation bag together with the relevant antibody, 
ensuring air bubbles were eliminated. The bag was sealed and stuck tightly on a shaker at 
Figure 2.6: The order of placing the items for transferring protein. 
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4°C (cold room) overnight. The next day the membrane was removed from the hybridisation 
bag and washed with 1X washing buffer for 30 minutes on an orbital shaker, changing the 
wash buffer every 10 minutes. The process was repeated with the secondary antibody (β-
actin; diluted 1:5000) and with the anti-biotin antibody (diluted 1:1000) which were incubated 
with the membrane on a shaker for 1 hour at room temperature. After 1 hour the membrane 
was again transferred for washing using 1X washing buffer but this time washed 5 times, 
each for 10 minutes. 
 
2.9.4 Stripping and re-probing membranes: 
Western blot stripping buffer (Restore™) supplied by Thermo Scientific was used to strip 
membranes to allow re-probing a different target with a different antibody following the 
manufacturer's protocol. First, the chemiluminescent substrate was discarded, and the 
membrane washed with PBS until the substrate was washed away. Following the previous 
step, the membrane was soaked in the RestoreTM stripping buffer for 5 to 15 mins at room 
temperature then washed with TBST and blocked for 1 hour. The protocol for primary and 
secondary antibodies was next followed (as previously illustrated). The membrane is finally 
exposed for analysis and either stored for future re-probing or discarded. 
 
2.9.5 Protein bands visualisation: 
ECL western blotting substrate solution from Thermo Fisher was used and was prepared as 
described in the manufacturer’s protocol by mixing the two solutions before pouring on the 
membrane and incubated for 5 minutes. The membranes were imaged on my ECL Imager, 
which determines the most suitable exposure time and saves it to be analysed. Membranes 
post this step were kept for possible future re-probing for other targets. 
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2.10. Total RNA extraction and qRT-PCR: 
Cells were analysed either on day 6 or 12 after the EBs were plated in a six-well plate. Media 
was removed, and the plate was placed on an ice bucket to preserve cells from the 
degradation of the proteins. Washed with 1X PBS twice and then 300-600µl (according to 
the rate of the growth) of lysis/binding solution from the miRNA isolation kit from Ambion 
(miRVana™; Invitrogen™) was added. The lysates were then collected and mixed by 
pipetting and transferred into an Eppendorf tube and vortexed vigorously to completely lyse 
all the cells (Figure 2.8). 
The next step was adding a volume of 1/10 of the miRNA homogenate additive solution 
(included in the kit) to the lysate. The mixture was incubated for 10 minutes at 4oC in an ice 
bucket. Acid-phenol: chloroform equal to the volume of the lysate solution was then added. 
Acid-phenol: chloroform was not supplied with the kit, so was prepared using a dilution of 
125µl:25µl. The mixture was vortexed for 30-60 seconds and centrifuged at the highest 
speed. The aqueous layer (top phase) was carefully collected, and the volume was noted 
for the following steps. This kit gives the option of isolating a total RNA and small RNA 
(Fig. 2.7). 
 
2.10.1 Total RNA isolation using the miRVana™ kit 
For the isolation of total RNA, a 1:25 volume of absolute ethanol was added to the recovered 
aqueous phase, and the mixture was passed through a capillary tube provided in the kit with 
a filter and centrifuged at 10,000 rpm for 15 seconds. The liquid which passed through the 
filter was then discarded, washed with washing solution 1 (700µl) and centrifuged as in the 
previous step. The washing solution 2/3 was used twice (500µl) and centrifuged each time, 
and the liquid was removed. The empty tube with the filter was then centrifuged for 1 minute 
just to remove traces of fluid. The last step was applying a pre-heated (95˚C) 100 µl of elute 
solution (Supplied in the kit) to a fresh collecting tube and spun for 20-30 seconds. All the 
steps were following the suggestion of the supplier illustrated in figure 2.8 suggested by the 
supplier.
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2.10.2 Determination of RNA quality and quantity 
After extracting RNA from each sample, concentrations were determined by absorbance at 
260nM, and the purity was established by the absorbance ratio of 260/280 and 260/230 nm. 
NanoDrop™ ND-1000 UV-Vis Spectrophotometer was used to analyse samples. 
 
 
2.10.3 Agarose gel electrophoresis 
 Two types of gel analysis were performed due to the two different kind of RNA. Total RNA 
was examined on a 1% denaturing agarose gel, while the product of the qPCR (Amplicon) on 
1.5% denaturing agarose gel. 1µg per sample per lane was used. Agarose was mixed with 
1x Tris- Boric acid-EDTA (TBE buffer or TE) to prepare the gels (Table 2.5). 
 
 
Figure 2.7: Steps for isolation of total RNA and small RNA (miRVana™) 
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Concentration Component 
For 1L (dissolved and 
adjusted to 1L) 
0.9M Tris base 109g 
0.9M Boric acid 55g 
20mM 0.5M EDTA 40ml 
 
 
The mixture of agarose and TBE was heated in a microwave for 1-2 minutes until the 
agarose powder was dissolved. Gel Red stain was added to the beaker, left to cool down 
and then poured into the gel casting tray with the comb placed prior to pouring the agarose. 
The agarose gel was finally analysed using the MyECL™ imager machine. 
A miScript Reverse Transcriptase kit (Qiagen) was used to convert the total RNA to cDNA. 
Total volume per reaction was 20µl, and 2µg of total RNA per reaction was used and was 
calculated using the data from the spectrophotometer (table 2.6.). Samples were kept at -
80˚C to avoid any degradations. 
Component RT sample 
miScript Reverse Transcriptase Mix 2µl 
10x miScript Nucleics Mix 2µl 
RNA sample (Template) Up to 9µl 
5x miScript HiFlex Buffer* 4µl 
Nuclease-free water To make up to 20µl 
Total per reaction 20µl 
 
Table 2.5: Preparation recipe of 10X TBE buffer. 
 
Table 2.6: Reverse transcription of samples from total RNA to cDNA using the 
miScript PCR system. 
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2.10.4 Primers design and dilution 
 Custom primer assays for SYBR green were supplied by Qiagen. miScript Primer Assay for 
miRNAs and QuantiTect Primer Assay for the other genes were used. Primers used are 
illustrated in table 2.7. All miRNAs primers share a single universal reverse primer and were 
supplied as a lyophilised forward primer. Other mRNA targets are provided with a mix of 
lyophilised forward and reverse primers. 550µl for the miscript and 1.1ml of the QuantiTect 
primers were reconstituted according to the manufacturer’s protocol delivered with the 
assays. All miScript assays derived from mature sequences in the miRBase database 
(http://microrna.sanger.ac.uk). QuantiTect assays were also derived from gene sequences 
in the NCBI database (Table 2.7 & 2.8). (www.ncbi.nlm.nih.gov/RefSeq). Both groups were 
validated and showed to be highly efficient and sensitive by Qiagen (www.qiagen.com). 
miRNA Primer ID miRNA sequence (5'-3') 
miR-145 mmu-miR-145a-
5p 
5'GUCCAGUUUUCCCAGGAAUCCCU 
miR-1 mmu-miR-1a-3p 5'UGGAAUGUAAAGAAGUAUGUAU 
miR133 mmu-miR133a-
3p 5'UUUGGUCCCCUUCAACCAGCUG 
 
U6 
 
Hs_RNU6 
Forward: CGC TTC GGC AGC ACA TAT AC 
Reverse:  AAA  ATA  TGG  AAC GCT 
TCA CGA 
Universal 
Reverse 
Primer 
 ATCC AGT GCA GGG TCC GAG G 
 
 
Table 2.7: miRNA primer sequence details 
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miRNA Primer ID 
Detected 
transcript 
OCT4 Pou5f1 NM_013633 
Gata4 
GATA binding 
protein 4 
NM_008092 
NKx2.5 NK2 homeobox 5 NM_008700 
 
U6, a commonly used control house-keeping gene, was ordered with the primers and was 
included in the miScript PCR starter kit. 
 
2.10.5 Samples set up for qPCR 
The SYBR green dye was used to amplify and quantify the targets. The kit used was the 
miScript PCR starter kit. A reaction mix was first prepared according to the numbers of 
samples and repeats (as shown in table 2.9 and 2.10). The total reaction mix was 20-25µL 
per well. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.8: Primer binding details 
Table 2.9: Setup of qPCR reactions (mRNA) 
Component 
 
Volume/reaction 
(20µL) 
Volume/reaction 
(25µL) 
QuantiTect SYBR green 
PCR master mix 
10µL 12.5μl 
QuantiTect Primer 
Assay 
2µL 2.5μl 
RNase-free water Makeup to 20 µL  Makeup to 25µL 
Template cDNA ≤2μl ≤2.5μl 
Total volume 20µL 25µL 
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Once all master mixes were prepared, plates were sealed with an adhesive seal and 
centrifuged briefly for 1 minute. The machine used was the QuantStudio™ 7 Flex Real-Time 
PCR System (96-well). And the cycling conditions are set as per the supplier’s instructions 
for 40 cycles (Table 2.11). Normalisation for some house-keeping genes and the primers 
took place first, and a standard curve was acquired to compare stability and efficiency of 
each primer. Samples were set up in duplicates with negative control (No template) and 
positive control genes (U6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.10: Setup of qPCR reactions (miRNA) 
Component 
Volume/reaction 
(20µL) 
Volume/reaction 
(25µL) 
QuantiTect SYBR green 
PCR master mix 
10µL 12.5μl 
miScript Primer 
(Universal Reverse 
Primer) 
2µL 2.5 μl 
miScript Primer Assay 2µL 2.5μl 
RNase-free water Makeup to 20µL Makeup to 25µL 
Template cDNA ≤2μl ≤2.5μl 
Total volume 20µL 25µL 
 
Table 2.11: Cycling conditions for qPCR 
Step Time Temperature Comment 
 
Activation step 15 min 95oC 
HotStarTaq DNA 
Polymerase gets activated 
in this step. 
3-step cycling:    
1- Denaturation 15 sec 94oC  
2- Annealing 30 sec 55oC  
3- Extension 
30 sec 70oC 
Perform fluorescence data 
collection 
Cycle number 
40 
Cycles 
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Normalisation for some house-keeping genes and the primers took place first, and a 
standard curve was acquired to compare stability and efficiency of each primer. Samples 
were set up in duplicates with negative control (No template) and positive control genes (U6). 
2.10.6 Analysis of relative gene expression:  
Experiments were performed following the Comparative CT (ΔΔCT) method. In this method, 
the CT for control and the other conditions were noted for targeted genes and the 
housekeeping gene. The fold difference was then calculated based on the data produced. 
 
2.11. Confocal microscopy and Immunofluorescence 
Adherent cultures of P19 cells were grown to reach up to 50-60% of confluence under the 
regular conditions mentioned earlier. Cells are then fixed and stained by removing the media 
from the plate and washed with PBS twice. The following step was to fix the cells with Ice-
cold methanol for 20 minutes prior to rinsing the plates briefly with PBS after the excess 
fixative is discarded. The cells were then incubated in a blocking buffer containing 5% of 
BSA dissolved in PBS for 30 minutes to block any non-specific bindings. Next, the primary 
antibodies OCT4 (Abcam®; ab19857) and Troponin I (Abcam®; ab47003) were then diluted 
in the used blocking buffer at 1µg/ml for an hour. The cells are then rinsed with PBS for 3 
times considering a 5 minutes gap in between. The incubation with a secondary antibody 
using a mixture of a green goat anti-rabbit IgG called Alexa fluor® 488 (2µg/ml), and a drop 
of a blue DAPI as a nuclear stain was used for an hour in 5% BSA. The plate from this step 
was covered with aluminium foil to protect it from light. Finally, the cells are again rinsed 
briefly three times with five minutes of the gap before the visualisation with Nikon Confocal 
Microscope (TE-2000U) at a magnification of 100x immersion oil. 
 
2.12. Statistical data analysis 
Statistics and calculation were performed with GraphPad Prism software. All the results are 
the mean SEM of at least 3 separate experiments. Statistical difference was calculated by 
ANOVA (one and two way) and T-test with post hoc studies based on the need of each 
independent experiments. The software used for all statistical analysis studies was 
GraphPad Prism version 5. 
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CHAPTER 3 
 RESULTS 
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3.1. Regulation of P19 stem cells (SCs) differentiation 
P19 cells were seeded and maintained undifferentiated. Furthermore, its fate was driven 
with different concentrations and different inducers following the routine cell culture 
techniques. 
 
3.1.1 Maintenance of monolayers of semi-confluent P19 cells 
Figure 3.1 shows a primary culture of P19 cells growing normally with no unexpected 
differentiation or changes in confluence. The cells from day 4 were ready to be resuspended 
to form embryoid bodies (EBs) for further experimentation and analysis. Inverted 
microscopes were routinely used to examine any morphological or growth pattern changes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Routine growth pattern of P19 stem cell line in culture. 
Cells maintained under routine culture as monolayers in a T75 flask with complete media. 
The figures are representative of the growth on days 0, 1, 3 and 4 (A and B at 10X and 
20x Magnification, respectively). Photographs were taken at 10X and 20X magnification 
under an inverted Microscope (Olympus microscope CKX41). 
Day 3 Day 4A 
Day 0 Day 1 
Day 4B 
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3.1.2 Formation of embryoid bodies 
P19 cells formed an aggregation of a three-dimensional structure of cells or EBs. The EBs 
were non-adherent, appeared spherical, and ultimately big, depending on the cells mass. 
The formation of EBs was not altered in the presence of Lysophosphatidic acid (LPA). Plated 
cells still aggregated, forming spherical 3D EBs, which was similar both in size and structure 
to the controls (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Formation of embryoid bodies in culture. 
P19 cells were trypsinised and plated in a non-tissue culture grade Petri dishes at a 
seeding density of 3.7 X 105 cells per dish (6 ml) and allowed to aggregate over four days. 
All pictures were taken at a magnification of 20X on Days 1 (A), 2 (B) and 4 (C) using an 
Olympus (CKX41) microscope. 
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3.1.3 Growth of plated embryoid bodies into monolayers 
Embryoid bodies were plated in a 6-well tissue culture grade plates on the fourth day. As 
shown in Figure 3.3, EBs attached as soon as they were plated, and cells grew into monolayers 
from the mass of EBs. This growth pattern was also consistent and established when treated 
with LPA. 
 
 
 
 
 
 
 
 
Figure 3.3: Growth of plated EB in a monolayer. 
Embryoid bodies were transferred into tissue culture grade plates four days after being formed in 
Petri dishes. Cells grew from EBs to form monolayers. The pictures shown were taken at a 
magnification of 20X under an inverted Olympus (CKX41) microscope on day 3 and 6. 
 
Day 3 Day 6 
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3.1.4 Confocal microscopy 
Isolated P19 cells were cultured and immune-stained with protein markers like octamer-
binding transcription factor 4 (POU5F1 (OCT4)) as a pluripotency marker to assess 
differentiation. The second antibody that was used is Troponin I, which is a cardiac lineage 
marker. Cells were either Control (untreated or undifferentiated) or LPA and DMSO pre-
treated (Figure 3.4). This experiment aimed to give an insight into the possible behaviours 
of the cells in response to the treatment with any of the mentioned inducers compared to 
control. 
 
  
 
Figure 3.4: Stained P19 cells treated with LPA and DMSO monolayers compared to 
control. 
P19 cells were plated in 6-well plates and allowed to grow for two days, then incubated with a 
primary antibody (OCT4 and Troponin I antibodies (Green)) for one hour. This was followed by 
incubation with the goat anti-rabbit IgG secondary antibody (Alexa Fluor 488) for an hour beside 
a DAPI dye (Blue) to stain the nucleus. Nikon Confocal Microscope (TE-2000U) was used at a 
magnification of 100x immersion oil. The photograph is representative and suggest an effect of 
treatment with different conditions on the expression of OCT4 and Troponin I, compared to 
control (untreated). 
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OCT4 is more intensely stained in control cells. This also contrasts with LPA and DMSO 
treated cells, which shows a decreased stain and expression of OCT4. On the other hand, 
the green stain of troponin I show a high intensity and expression in LPA and DMSO 
incubated cells (Figure 3.4). Although the control is missed for cells stained by troponin I, 
however, it still gives a hint on the high expression of the Troponin I in comparison to the 
expression of OCT4 in both cells.  
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3.2 Cell viability in the presence of various 
pharmacological inhibitors  
(MTT assay) 
 
To confirm whether responses to various drugs were specific and indeed related to their 
pharmacological actions, the MTT cytotoxicity assay was carried out to establish cell viability 
under the different experimental conditions. Effect of DMSO, BIM-1, LY294002, Suramin, 
H2L5765834, H2L5186303, and TC-LPA5-4 was assessed. Bisindolylmaleimide 1 (BIM-1) 
a chemical compound with a selective and potent with inhibitory roles for PKC isoforms, PKA, 
PKG and myosin-light-chain-kinase (MLCK) with an IC50 of 10nM. LY294002 also, which is 
a PI3-kinase inhibitor (PI3-Kβ, PI3-Kα, PI3-Kσ, and PI3-Kγ) have an IC50 for PI3-Kβ, PI3-
Kα, PI3-Kσ and PI3-Kγ respectively at 0.31, 0.73, 1.06 and 6.60µM. Suramin on the other 
side blocks binding sites of GPCRs specifically LPA receptor 4 and calmodulin including 
acting as an antagonist for the P2 purinergic with an IC50 of 43µM. H2L5765834 binds to 
LPA receptor 1, 5, and 3 with IC50 of 94, 463, and 752nM. With H2L5186303, LPA receptor 
2, 3, and 1 are targeted with IC50 of 8.9, 1230, and 27354nM. TC-LPA5-4 is a selective 
antagonist of LPA receptor 5 with an IC50 of 0.8µM 
The toxicity of LPA was tested by incubating cells 24 hours with 1- 80µM of LPA and 
conducting the MTT assay at the end of the relevant incubation period. The results show a 
significant change in cell viability as measured by MTT. Turkey test showed that only cells 
treated with 40µM are significantly less viable than the control (Figure 3.5).  
With DMSO, used as a positive control for induction, the cytotoxic effect was statistically 
significant and started to show at 5% and was significant at 10 and 20% (Figure 3.6). Well 
above the 1% used for inducing differentiation. In parallel studies, LY294002 was 
investigated at 0.5, 1, 10, 20, and 40µM and was also statistically significant, but was found 
to only be cytotoxic at 40µM which again was much higher than the actual concentrations to 
be used in the following studies (Figure 3.7). 
H2L5765834 (0.5-30µM; Figure 3.8), H2L5186303 (0.5-30µM; Figure 3.9), TC-LPA5-4 (0.5-
40µM; Figure 3.10), and Suramin (5-500µM; Figure 3.12) showed no statistically significant 
change in cell viability. BIM-1, on the other hand, was statistically significant, although it was 
well tolerated up to 10µM, showing some degree of reduced cell viability at 20µM but this 
was not significant until 40µM (Figure 3.11).    
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Figure 3.5: Cellular viability of P19 cells when treated with different concentration of 
LPA by MTT assay. 
Cells were incubated with LPA concentration 1-80µM, for 24 hours followed by incubation for 
4 hours with MTT as illustrated in the previous chapter. The data represents a % change in 
cell viability with the control taken as 100%. The bars represent the densitometric mean ± SEM 
from 5 independent experiments. One-way analysis of variance (ANOVA) followed by Turkey 
comparison method was used to determine statistical significance. * denotes p<0.05 
compared to control. 
Figure 3.6:  Cellular viability of P19 cells when treated with different concentration of 
DMSO by MTT assay. 
Cells were incubated with DMSO 0.5-20µM, for 24 hours followed by incubation for 4 hours 
with MTT as illustrated in the previous chapter. The data represents a % change in cell 
viability with the control taken as 100%. The data represent the means ± S.E.M from 3 
individual experiments. One-way analysis of variance (ANOVA) was used to determine 
statistical significance. * denotes p<0.05 compared to control cells. 
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Figure 3.7: Cellular viability of P19 cells when treated with different concentration of 
LY294002 by MTT assay. 
Cells were incubated with LY294002 0.5-40µM, for 24 hours followed by incubation for 4 
hours with MTT as illustrated in the previous chapter. The data represents a % change in cell 
viability with the control taken as 100%. The data represent the means ± S.E.M from 3 
individual experiments. One-way analysis of variance (ANOVA) was used to determine 
statistical significance. ** denotes p<0.01 compared to control cells. 
Figure 3.8: Cellular viability of P19 cells when treated with different concentration of 
H2L5765834 by MTT assay. 
 Cells were incubated with H2L5765834 0.5-30µM, for 24 hours followed by incubation for 4 
hours with MTT as illustrated in the previous chapter. The data represents a % change in cell 
viability with the control taken as 100%. The data represent the means ± S.E.M from 3 
individual experiments.  
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Figure 3.9: Cellular viability of P19 cells when treated with different concentration of 
H2L5186303 by MTT assay.  
Cells were incubated with H2L5186303 0.5-30µM, for 24 hours followed by incubation for 4 
hours with MTT as illustrated in the previous chapter. The data represents a % change in cell 
viability with the control taken as 100%. The data represent the means ± S.E.M from 3 
individual experiments. 
 
Figure 3.10: Cellular viability of P19 cells when treated with different concentration of 
TC-LPA5-4 by MTT assay. 
 Cells were incubated with TC-LPA5-4 0.5-40µM, for 24 hours followed by incubation for 4 
hours with MTT as illustrated in the previous chapter. The data represents a % change in cell 
viability with the control taken as 100%. The data represent the means ± S.E.M from 3 
individual experiments.  
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Figure 3.11: Cellular viability of P19 cells when treated with different concentration 
of BIM-1 by MTT assay. 
Cells were incubated with BIM-1 0.5-40µM, for 24 hours followed by incubation for 4 
hours with MTT as illustrated in the previous chapter. The data represents a % change in 
cell viability with the control taken as 100%. The data represent the means ± S.E.M from 
3 individual experiments. One-way analysis of variance (ANOVA) was used to determine 
statistical significance. * denotes p<0.05 compared to control cells 
Figure 3.12: Cellular viability of P19 cells when treated with different concentration of 
Suramin by MTT assay. 
 Cells were incubated with Suramin 5-500µM, for 24 hours followed by incubation for 4 hours 
with MTT as illustrated in the previous chapter. The data represents a % change in cell 
viability with the control taken as 100%. The data represent the means ± S.E.M from 3 
individual experiments.  
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3.3 Establishment and development of cardiac cells 
model and examination of the effects of LPA on 
differentiation 
In this section, establishing the capability of LPA to regulate the differentiation P19 SCs into 
cardiomyocytes was crucial to confirm previous data from our group. It was also essential 
to understand this regulation in terms of sensitivity to concentration and time course of the 
induction of effects, especially immediately after exposure to LPA. Currently, it is not clear 
how early SCs commit to a cardiac lineage when exposed to LPA, and this has been 
investigated in this thesis. 
3.3.1  Expression of MLC-1V protein induced by different LPA 
Concentrations 
Differentiation into cardiomyocytes was determined by monitoring changes in ventricular 
myosin light chain (MLC-1v) protein expression. In these studies, MLC-1v has increased in 
response to the increasing concentrations of LPA (µM). The increase to the latter was 
statistically significant at 5µM 10µM as well as at 20µM, which induced the maximum 
expression of MLC-1v as shown by western blotting (Figure 3.13B). This concentration also 
induced spontaneously beating clusters of the cells, which is one of the characteristics of 
the presence of cardiomyocytes (Figure 3.15). 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.13: Protein expression of MLC-1v 
(%) induced by increasing concentrations of 
LPA. 
Monolayers of P19 cells at confluency (4 days) 
were trypsinised and seeded in petri-dishes to 
form EBs. During this stage, cells were either 
incubated with medium alone (Controls) or with 
increasing concentrations of LPA (0.5 - 20µM). 
Formed EBs were subsequently plated in tissue 
culture grade plates after four days and allowed 
to grow into monolayers. Lysates were 
generated on day six after plating EBs in cell 
culture dishes and probed for the protein 
expression of MLC-1v by western blotting as 
described in the previous chapter. Protein 
expression of β-actin (Figure 3.5A) was used as 
a loading control. Figure 3.5B shows changes 
in MLC-1v expression in response to LPA treatment. The bars represent the densitometric mean 
± SEM from 4 independent experiments. One-way analysis of variance (ANOVA) followed by 
Dunnett comparison method was used in statistical analysis to determine significant differences. 
* p<0.05 and ** p<0.01 when compared to control. 
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3.3.2 Expression of OCT4 protein induced by different LPA 
Concentrations 
In parallel with MLC-1v, changes in OCT4 were also investigated in lysates generated from 
P19 SCs treated with increasing concentrations of LPA. Figure 3.14 shows a decrease in 
the expression of OCT4 as the concentration of LPA increased. At LPA 20µM, the expression 
of OCT4 was the lowest, which parallels with the increase in the number of beating clusters 
found after observing the monolayer from day three onwards (Figure 3.14). OCT4 
expression was significantly different compared to the control at 5µM (and this was more 
evident in 10µM and 20µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
   
Figure 3.14: Expression of OCT4 (%) 
induced by increasing concentrations 
of LPA. 
Monolayers of P19 cells were trypsinised 
and seeded in petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) 
or with increasing concentrations of LPA. 
Formed EBs were subsequently plated in 
tissue culture grade plates after four days 
and allowed to grow into monolayers. 
Lysates were generated on day six after 
plating EBs in cell culture dishes and 
probed for the expression of OCT4 
(43kDa) by western blotting as described 
in the previous chapter. Expression of β-
actin (Figure 3.6A) was used as a loading 
control in the blot. Figure 3.6B shows 
changes in OCT4 expression in response to LPA treatment. The bars represent the densitometric 
mean ± SEM from 4 independent experiments. One-way analysis of variance (ANOVA) followed 
by Dunnett comparison method was used in statistical analysis to determine significant 
differences. ** p<0.01 and *** p<0.001 all compared to control. 
 
Figure 3.15: Morphological 
structure of beating clusters of 
induced P19 stem cells. 
 
P19 SCs were treated with 20µM LPA 
while forming EBs. The black circles 
are the regions of the beating clusters 
formed after day 6. This image was 
taken from videos which were 
recorded at magnification 20X by 
Olympus (CKX41) microscope. 
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3.3.3 Time-dependent induction of MLC-1v protein expression by 
LPA 
Treatment of cells with LPA (5µM) caused a time-dependent increase in MLC-1v expression, 
which was at a maximum in lysates generated at day 6 and maintained up to day 9 but declining 
by day 12. Levels of MLC even at day 12 were, however, still higher than controls where MLC 
expression remained relatively unaltered throughout the 12 days incubation period (Figure 
3.16). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.16: Time-dependent 
induction of MLC-1v protein 
expression by LPA. 
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either 
incubated with medium alone 
(Controls) or with 5µM LPA. 
Formed EBs were 
subsequently plated in tissue 
culture grade plates after four 
days and allowed to grow into 
monolayers. Lysates were 
generated on the days shown 
on the graph after plating EBs 
in cell culture dishes and 
probed for the protein 
expression of MLC-1v (25kDa) 
by western blotting as described in the previous chapter. Protein expression of β-actin (Figure 
3.8A) was used as a loading control in the blot. Figure 3.8B shows changes in MLC-1v 
expression in response to LPA treatment. The bars represent the densitometric mean ± SEM 
from 5 independent experiments.T-test analysis was used to extract statistical analysis to 
determine significant differences and ** p<0.01 compared to control. 
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3.3.4 Protein expression of Troponin I in controls and LPA 
treated P19 cells 
To further confirm that LPA induced differentiation of P19 SCs into cardiomyocytes, lysates 
were also analysed for another cardiac specific marker, Troponin I. As shown in Figure 3.17, 
the controls had less induction or expression of Troponin I than the LPA treated cells which 
illustrated a significant induction (Figure 3.17). 
 
Figure 3.17: Protein expression of 
cardiac Troponin I in controls and 
LPA treated P19 cells. 
Monolayers of P19 cells were 
trypsinised and seeded in Petri-dishes 
to form EBs. During this stage, cells 
were either incubated with medium 
alone (Controls) or with 5µM LPA. 
Formed EBs were subsequently plated 
in tissue culture grade plates after four 
days and allowed to grow into 
monolayers. Lysates were generated 
on the days shown on the graph after 
plating EBs in cell culture dishes and 
probed for the expression of Troponin 
I (cTnI; 26kDa) by western blotting as 
described in the previous chapter. 
Expression of β-actin (Figure 3.9A) 
was used as a loading control in the 
blot. Figure 3.9B shows changes in 
MLC-1v expression in response to 
LPA treatment. The bars represent the 
densitometric mean ± SEM from 3 
independent experiments. T-test analysis was used to extract statistical analysis to 
determine significant differences, and * p<0.05 compared to control. 
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3.3.5 Expression of MLC-1v following short incubations with 
LPA 
In these studies, the aim was to determine whether MLC-1v expression can be induced by 
LPA when incubated for shorter time points, ranging from 5 min to 24 hours. This was done 
to determine whether LPA induces the expression of MLC-1v at an early time-point. DMSO 
was used in parallel studies for comparison. LPA was used at two different concentrations, 
5µM and 20µM. Lysates were generated on day 6 and day 12 for analysis of MLC-1v 
expression by western blotting. 
Earlier time points up to 9 hours did not appear to be enough for significant induction of MLC- 
1v in lysates generated six days after plating EBs in cell culture dishes. There was, however, 
an increase in MLC-1v expression following 24h incubation with LPA before plating EBs in 
the cell culture plates (Figures 3.18., 3.19. and 3.20.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.18: Protein expression of MLC-1v induced in Short time points by LPA on day 6. 
Monolayers of P19 cells were trypsinised and seeded in petri-dishes to form EB. During this 
stage, cells were treated medium alone (Controls) or with LPA (5µM & 20µM) for 5 min to 24 
hours. P19 cells were also treated with DMSO in a monolayer (as a positive control). Formed 
EBs were subsequently plated in tissue culture grade plates after four days and allowed to 
grow into monolayers. Lysates were generated on day six after plating EBs in cell culture 
dishes and probed for the expression of MLC-1v by western blotting as described in the 
previous chapter. Expression of β-actin was used as a loading control in the blot, and the bars 
represent the densitometric mean ± SEM from 3 independent experiments (B). 
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Figure 3.19: Protein 
expression of MLC-1v 
induced in Short time 
points by 5µM LPA 
Short time-dependent (5 
min to 24 hours) protein 
expression of MLC-1v at 
5µM lysates collected at 
day six compared with % 
of LPA 5µM treated for 
four days. The 
densitometric represents 
mean ± SEM from 3 
independent experiments. 
One-way analysis of 
variance (ANOVA) method 
was used to extract 
statistical information. The 
P value * p<0.5 and ***p<0.001 compared to LPA 5µM. 
Figure 3.20: Protein expression of MLC-1v induced in Short time points by 20µM LPA. 
Short time-dependent expression (5 min to 24 hours) of MLC-1v at 20µM lysates collected at 
day 6 compared with % of LPA 5µM treated for four days. The densitometric represents mean 
± SEM from 3 independent experiments. One-way analysis of variance (ANOVA) method was 
used to extract statistical information. The P value * p<0.5 and ** p<0.01 compared to LPA 
20µM. 
%
 E
x
p
re
s
s
io
n
 o
f 
1
v
-M
L
C
C
on
tr
ol M
 

LP
A
 5 5 
M
in
15
 M
in
30
 M
in
1 
H
r
3 
H
r
6 
H
r
9 
H
r
24
 H
r
0
20
40
60
80
100
120
***
***
*
Treatment duration of LPA 5M
Treatment duration of LPA 20µM LPA 
71 
 
By comparison, in lysates generated on day 12, MLC-1v expression was significantly higher 
at all time points from 5 min to 24 hours (Figure 3.21). However, the expressions trend was 
higher, specifically at 9 and 24 hours treated cells with 20µM of LPA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.21.: Protein expression of MLC-1v induced in Short time points by LPA at day 
12. 
Monolayers of P19 cells were trypsinised and seeded in petri-dishes to form EB. During this 
stage, cells were treated medium alone (Controls) or with LPA (5µM & 20µM) for 5 min to 24 
hours. Formed EBs were subsequently plated in tissue culture grade plates after four days and 
allowed to grow into monolayers. Lysates were generated on day 12 after plating EBs in cell 
culture dishes and probed for the expression of MLC-1v by western blotting as described in the 
previous chapter (A). Expression of β-actin was used as a loading control in the blot, and the 
bars represent the densitometric mean ± SEM from 5 independent experiments (B). 
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3.4 PCR normalisation and quantification: 
 
3.4.1 The purity of isolated RNA  
Table 3.1 shows the purity and concentration of RNA in the samples generated from P19 cells 
from BIM-1 inhibitor experiment. The absorbance at 260/280 was between 1.99-2.04 with an 
average of 2.01, while, the 260/230 was 2.05. The concentrations of RNA isolated was high 
and averaged 616 ng/µl. 
 
Table 3.1: Concentration and purity for isolated total RNA using 
Nanodrop. 
Experiment Condition 
Concentration 
(ng/µl) 260/280 260/230  
N1 
Control 720 2 2.15  
LPA 648 2.04 2.16  
BIM-1 551 2.03 2.12  
BIM-1+LPA 600 2.04 2  
N2 
Control 623 2.04 2.15  
LPA 624 2.01 1.85  
BIM-1 611 2.02 2.10  
BIM-1+LPA 715 2.02 2.11  
N3 
Control 718 2.02 1.92  
LPA 598 2 2.05  
BIM-1 466 1.99 1.95  
BIM-1+LPA 518 2.02 1.92  
In addition to the spectrophotometric analysis, the purity of the RNA isolated was also 
established by gel electrophoresis. Figure 3.22 below illustrates how pure the RNA samples 
isolated were. 28s and 18s rRNA are seen with no smears that may indicate genomic DNA, 
other contaminants or RNA degradation. Figure 3.23 also shows identified single band which 
represents the primer amplified in qPCR with no smears or multiple amplification of non- 
specific mRNAs.  
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Figure 3.23: 1.5% 
denaturing agarose gel 
electrophoresis for 
amplicon (Products of 
qPCR). 
Lysates collected on day 
6 EBs were plated in cell 
culture dishes for total 
RNA extraction using the 
miRVana™ kit from 
Ambion. Samples were 
reverse transcribed to get 
cDNA samples, probed 
for the targets, and 
amplified using real-time 
PCR. 1µg/ml of each 
sample was used in each 
well. Agarose gel was 
pre-stained with GelRed. 
Lanes represents, L1= 
ladder 1 kb, L2= ladder 
100 bp, L3= mir-15a, L4= 
mir-145, L5=mir-1, L6= 
mir-133, L7= U6, L8= 
OCT4, L9= NKX2.5, L10= 
GATA4, L11= Total RNA 
sample A, L12= Total 
RNA sample B, L14= ladder 1 kb. This gel was visualised using the MyECL imager. 
  
Figure 3.22: 1% 
denaturing agarose gel 
electrophoresis for total 
RNA samples. 
Lysates were collected on 
day six from EBs plated in 
cell culture dishes for total 
RNA extraction using the 
miRVana™ kit from 
Ambion. 1µg/ml of each 
sample obtained was used 
in each well. This agarose 
gel was pre-stained with 
GelRed. Lanes represent, 
L1= ladder 1 kb, L2= 
ladder 100 bp, L3= Control 
P19 cells, L4-L8= LPA 
treated P19 cells. This gel 
was visualised using the 
MyECL imager. 
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3.4.2 Real-time/Reverse-transcription polymerase chain reaction 
(qRT-PCR). 
Two genes were tested for their stability and efficiency to be used as a control with the 
samples, U6 and mir-15a. In addition to these, mir-145, mir-1, mir-133, OCT4, Nkx2.5, and 
GATA4 were also screened. A standard curve using 10-fold serial dilutions was prepared 
for 6 points. Each dilution was repeated in duplicate. Some of the points were flagged 
(excluded) to get a better slope and efficiency (Figures 3.24- 3.31). For normalisation of any 
gene or primer, it is essential to get a single unique peak temperature in the melting curve 
plot (Figures 3.24B-3.31B) as this suggests that the primer is specific. Secondly, it gives 
information about the amplification blot relative fluorescence against the cycle number for 
each dilution (Figures 3.24C-3.31C). Lowest dilution in which the cycle threshold (CT) range 
between 20-30 cycles is an ideal concentration to be used in further qRT-PCR reactions for 
the same primer detected by SYBR-green. Efficiency and the slope equation help in getting 
reproducible and validated data (Figures 3.24A-3.31A). The R2 value represents the linearity 
of the data or how well the experimental data fit the regression line. In addition, this can 
suggest how good the pipetting techniques were and how reproducible the results are. The 
ideal linear standard curve should be R2 > 0.980 and efficiency % closer to 100%. Figures 
3.24-3.31 show the standard curves melting curves and amplification plots for U6-
housekeeping gene, mir-15a, mir145, mir-1, mir-133, OCT4, Nkx2.5, and GATA4, 
respectively. 
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Figure 3.24: Generating a standard curve to assess reaction optimisation for U6-
housekeeping gene. 
A standard curve was generated using a 10-fold dilution of the U6 gene using SYBR-green 
analysed by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was 
assayed in duplicates in three separate times. (A) A standard curve with the CT plotted against 
the log of the starting copy numbers. The regression line, R2 value, and efficiency are at the 
bottom of the graph. (B) The melting curve which shows how specific the primer is by looking at 
the number of peaks. (C) Amplification plot, relative fluorescence against cycle number. 
Figure 3.25: Generating a standard curve to assess reaction optimisation for mir-15a. 
A standard curve was generated using a 10-fold dilution of mir-15a using SYBR-green dye 
analysed by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was 
assayed in duplicates in three separate times. (A) A standard curve with the CT plotted against 
the log of the starting copy numbers. The regression line, R2 value, and efficiency are at the 
bottom of the graph. (B) The melting curve which shows how specific the primer is by looking at 
the number of peaks. (C) Amplification plot, relative fluorescence against cycle number. 
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Figure 3.26: Generating a standard curve to assess reaction optimisation for mir-145. 
A standard curve was generated using a 10-fold dilution of mir-145 using SYBR-green 
analysed by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was 
assayed in duplicates in three separate times. (A) A standard curve with the CT plotted against 
the log of the starting copy numbers. The regression line, R2
 
value, and efficiency are at the 
bottom of the graph. (B) The melting curve which shows how specific the primer is by looking at 
the number of peaks. (C) Amplification plot, relative fluorescence against cycle number. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: Generating a standard curve to assess reaction optimisation for mir-1. 
A standard curve was generated using a 10-fold dilution of mir-1 using SYBR-green analysed 
by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was assayed in 
duplicates in three separate times. (A) A standard curve with the CT plotted against the log of 
the starting copy numbers. The regression line, R2 value, and efficiency are at the bottom of the 
graph. (B) The melting curve which shows how specific the primer is by looking at the number 
of peaks. (C) Amplification plot, relative fluorescence against cycle number. 
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Figure 3.28: Generating a standard curve to assess reaction optimisation for mir-133. 
A standard curve was generated using a 10-fold dilution of mir-133 using SYBR-green 
analysed by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was 
assayed in duplicates in three separate times. (A) A standard curve with the CT plotted against 
the log of the starting copy numbers. The regression line, R2 value, and efficiency are at the 
bottom of the graph. (B) The melting curve which shows how specific the primer is by looking at 
the number of peaks. (C) Amplification plot, relative fluorescence against cycle number. 
Figure 3.29: Generating a standard curve to assess reaction optimisation for OCT4. 
A standard curve was generated using a 10-fold dilution of the OCT4 gene using SYBR-green 
analysed by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was 
assayed in duplicates in three separate times. (A) A standard curve with the CT plotted against 
the log of the starting copy numbers. The regression line, R2 value, and efficiency are at the 
bottom of the graph. (B) The melting curve which shows how specific the primer is by looking at 
the number of peaks. (C) Amplification plot, relative fluorescence against cycle number. 
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Figure 3.30: Generating a standard curve to assess reaction optimisation for NKX 2.5. 
A standard curve was generated using a 10-fold dilution of the OCT4 gene using SYBR-green 
analysed by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was 
assayed in duplicates in three separate times. (A) A standard curve with the CT plotted against 
the log of the starting copy numbers. The regression line, R2 value, and efficiency are at the 
bottom of the graph. (B) The melting curve which shows how specific the primer is by looking 
at the number of peaks. (C) Amplification plot, relative fluorescence against cycle number. 
Figure 3.31: Generating a standard curve to assess reaction optimisation for GATA4. 
A standard curve was generated using a 10-fold dilution of the GATA4 gene using SYBR-
green analysed by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). Each dilution was 
assayed in duplicates in three separate times. (A) A standard curve with the CT plotted 
against the log of the starting copy numbers. The regression line, R2 value, and efficiency are 
at the bottom of the graph. (B) The melting curve which shows how specific the primer is by 
looking at the number of peaks. (C) Amplification plot, relative fluorescence against cycle 
number. 
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3.5 Concentration-dependent effects of LPA on the 
expression of transcription factors and key miRNAs 
targeted 
In this section, the focus is on the results obtained by qPCR targeting several genes and 
miRNAs over 3, 6, & 12 days using varying concentrations of LPA (0.5-20µM). 
3.5.1 OCT4 
The expression of OCT4 at days 3, 6, and 12 showed no statistically significant changes 
when compared to controls. Although OCT4 expression appeared to increase at day 3 (1.461 
± 1.053 to 1.705 ± 0.9930 folds) in cells treated with LPA (5µM to 20µM) the increases were 
not significant compared to control (Figure 3.32). Figure 3.33 is a summary of the data 
obtained for LPA at 5µM over three days (1.461 ± 1.05 folds), six days (0.799 ± 0.147 
folds) and 12 days (0.8077 ± 0.244 folds). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.32: Expression of OCT4 induced by LPA at different time points and 
concentrations. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium alone (Controls) or treated with LPA at 0.5-
20µM. Formed EBs were subsequently plated in tissue culture grade plates after four days 
and allowed to grow into monolayers. Lysates were generated on day 3 (A), 6 (B), 12 (C). 
RNA was then extracted and transcribed into a cDNA, and OCT4 gene was amplified and 
analysed using SYBR-green dye by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). 
U6 (housekeeping gene) was used as an endogenous control for RNA input and 
normalisation. The bars represent the densitometric mean ± SEM from 3 independent 
experiments. 
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3.5.2 NKX2.5 
An increasing trend in the expression of the NKX2.5 gene was clear at days 3 (Figure 3.34A) 
and 12 (Figure 3.34C). The lowest expression was in cells treated with 0.5µM (0.56 ± 0.21-
fold change on day 3 and 1.3 ± 0.41-fold change on day 12) and highest at 20µM (2.33 ± 1.45-
fold change on day 3 and 4.09 ± 2.67-fold change on day 12). These differences did not 
show statistical significance partly because of the limited n values and to variations in the 
expression levels. In contrast to the data from days 3 and 12, there was no obvious trend in 
NKX2.5 expression on day six at any of the concentrations of LPA used (figure 3.34B). 
These observations, although preliminary, suggest a potential biphasic response in NKX 2.5 
expression following LPA treatment. Expression of NKX 2.5 in LPA 5µM treated cells over 
the days 3, 6, and 12 were compared, and it was highest at day 12 with 2.77 ± 1.65 (Figure 
3.35). 
  
Figure 3.33: Expression of OCT4 
induced by 5µM of LPA at different 
time points. 
Monolayers of P19 cells were 
trypsinised and seeded in Petri-dishes 
to form EB. During this stage, cells were 
either incubated with medium alone 
(Controls) or treated with 5µM of LPA. 
Formed EBs were subsequently plated 
in tissue culture grade plates after four 
days and allowed to grow into 
monolayers. Lysates were generated on 
day 3, 6, & 12. RNA was then extracted 
and transcribed into a cDNA, and OCT4 
gene was amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 
Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as an endogenous 
control for RNA input and normalisation. The bars represent the densitometric mean ± SEM 
from 3 independent experiments. 
5 M LPA Day 3,6,12 OCT4
F
o
ld
 d
if
fe
re
n
c
e
 i
n
 O
C
T
4
 e
x
p
re
s
s
io
n
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l
C
on
tr
ol
D
ay
 3
D
ay
 6
D
ay
12
0
1
2
3
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.34: Expression of NKX2.5 induced by LPA at different time points and concentrations. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this stage, cells 
were either incubated with medium alone (Controls) or treated with LPA at 0.5µM 
- 20µM. Formed EBs were subsequently plated in tissue culture grade plates after four days and allowed 
to grow into monolayers. Lysates were generated on day 3 (A), 6 (B), 12 (C). RNA was then extracted 
and transcribed into a cDNA and gene was amplified and analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as an 
endogenous control for RNA input and normalisation. The bars represent the densitometric mean ± SEM 
from 3 independent experiments. 
Figure 3.35:  Expression of 
NKX2.5 induced by 5µM of LPA at 
different time points. 
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EB. During this 
stage, cells were either incubated 
with medium alone (Controls) or 
treated with 5µM of LPA. Formed 
EBs were subsequently plated in 
tissue culture grade plates after four 
days and allowed to grow into 
monolayers. Lysates were 
generated on day 3, 6, & 12. RNA 
was then extracted and transcribed 
into a cDNA, and NKX2.5 gene was 
amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping 
gene) was used as an endogenous control for RNA input and normalisation. The bars represent the 
densitometric mean ± SEM from 3 independent experiments. 
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3.5.3  mir-145 
Lysates collected at day three from cells treated with increasing concentration of LPA showed 
an increase in mir-145 expression, which was highest at 20µM (1.96 ± 0.91 folds; Figure 
3.36A). At day 6, mir-145 expression was maximal with 5µM LPA (P<0.5) but declined back 
to near basal levels at 10µM and 20µM (Figure 3.36B). There was also a significant variation 
between 2 and 5µM of LPA (P<0.01) (Figure 3.36B). The trend at day 12 (Figure 3.36C) 
reflect a decrease in mir-145with concentrations of LPA up to 10µM. There were, however, 
variations in the data as reflected by the standard errors and there was, therefore, no 
statistical difference when compared to controls. Expression of mir-145 in LPA 5µM treated 
cells over the days 3, 6, and 12 were compared, and it was the highest at day 6 with 
statistical significance (Figure 3.37). 
 
 
Figure 3.36: Expression of mir-145 induced by LPA at different time points and 
concentrations. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EB. During this stage, 
cells were either incubated with medium alone (Controls) or treated with LPA at 0.5µM 
- 20µM. Formed EBs were subsequently plated in tissue culture grade plates after four days and 
allowed to grow into monolayers. Lysates were generated on day 3 (A), 6 (B), 12 (C). RNA was 
then extracted and transcribed into a cDNA, and mir-145 gene was amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping 
gene) was used as an endogenous control for RNA input and normalisation. The densitometric 
represents mean ± SEM from 3 independent experiments. One-way analysis of variance (ANOVA) 
method was used to extract statistical information. * P value of <0.5 and ** p<0.01. 
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Figure 3.37:  
Expression of mir-
145 induced by 
5µM of LPA at 
different time 
points. 
Monolayers of P19 
cells were 
trypsinised and 
seeded in Petri-
dishes to form EBs. 
During this stage, 
cells were either 
incubated with 
medium alone 
(Controls) or treated 
with 5µM of LPA. 
Formed EBs were subsequently plated in tissue culture grade plates after four days and 
allowed to grow into monolayers. Lysates were generated on day 3, 6, & 12. RNA was then 
extracted and transcribed into a cDNA, and mir-145 gene was amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 
(housekeeping gene) was used as an endogenous control for RNA input and normalisation.   
The bars represent the densitometric mean ± SEM from 3 independent experiments. One-
way analysis of variance (ANOVA) method was used to extract statistical information. The * 
denotes a P value of p<0.5 compared to control. 
5 M LPA Day 3,6,12 mir-145
Fo
ld
 d
iff
er
en
ce
 in
 m
ir-
14
5 
ex
pr
es
si
on
 r
el
at
iv
e 
to
 c
on
tr
ol
Co
nt
ro
l
Da
y 3
Da
y 6
Da
y1
2
0.0
0.5
1.0
1.5
2.0
2.5
*
84 
 
 
3.5.4  mir-1 
mir-1 gene was found to increase in response to increasing concentrations of LPA at days 
three and six but not at day 12 where levels of mir-1 gene were not significantly different to 
controls. The increases at day 3 were evident with 2-10µM LPA (p<0.5) (Figure 3.38A). At 
day six, the increase with 20µM was just below statistical significance while responses to 
5µM appeared to be significant when compared to controls and the latter was statistically 
variant between 2 and 20µM of LPA treated cells (Figure 3.38B). At day 12, mir-1 showed 
no variation in comparison to control contrary to day 3 and 6 (Figure 3.38C). Additionally, 
expression of mir-1 in LPA 5µM treated cells over the days 3, 6, and 12 were compared, 
and it was the highest at day 6 with statistical significance (Figure 3.39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38: Expression of mir-1 induced by LPA at different time points and 
concentrations. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During 
this stage, cells were either incubated with medium alone (Controls) or treated with LPA at 
0.5µM- 20µM. Formed EBs were subsequently plated in tissue culture grade plates after 
four days and allowed to grow into monolayers. Lysates were generated on day 3 (A), 6 (B), 
12 (C). RNA was then extracted and transcribed into a cDNA, and mir-1 gene was amplified 
and analysed using SYBR-green dye by QuantStudio™ 7 Flex Real-Time PCR System 
(Qiagen). U6 (housekeeping gene) was used as an endogenous control for RNA input and 
normalisation. The bars represent the densitometric mean ± SEM from 3 independent 
experiments. One-way analysis of variance (ANOVA) method was used to extract statistical 
information. The * denotes a P value of p<0.5 compared to control. 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39: Expression of mir-1 
induced by 5µM of LPA at different 
time points. 
Monolayers of P19 cells were 
trypsinised and seeded in Petri-dishes 
to form EBs. During this stage, cells 
were either incubated with medium 
alone (Controls) or treated with LPA 
at 0.5µM- 20µM. Formed EBs were 
subsequently plated in tissue culture 
grade plates after four days and 
allowed to grow into monolayers. 
Lysates were generated on day 3 (A), 
6 (B), 12 (C). RNA was then extracted 
and transcribed into a cDNA, and mir-
1 gene was amplified and analysed 
using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR 
System (Qiagen). U6 (housekeeping 
gene) was used as an endogenous control for RNA input and normalisation. The bars represent 
the densitometric mean ± SEM from 3 independent experiments. One-way analysis of variance 
(ANOVA) method was used to extract statistical information. The * denotes a P value of p<0.5 
compared to control. 
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3.6 Effects of pharmacological inhibitors of LPA 
receptors on the induction of differentiation: effects 
on protein and mRNA expression 
In this section, results are focused on the impact of Suramin, H2L5765834, H2L5186303, 
and TC-LPA5-4 to target specific binding sites of LPA receptors to block activation of 
differentiation induced by 5µM. Suramin using 50µg/ml to target LPA receptor 4, 
H2L5765834 using 0.5µM to target LPA receptor 1 & 5, 0.8µM to target LPA receptor 3 in 
addition to LPA receptors 2 & 3 to be antagonised by H2L5186303 with a concentration of 
1.25µM. Finally, a 1.6µM of TC-LPA5-4 was to antagonise LPA receptor 5. The effects of 
these compounds on the yield of specific antibodies and mRNA/miRNA were determined by 
either western blotting or qPCR, followed by a statistical analysis via a one-way analysis of 
variance (ANOVA). 
3.6.1 Effects of LPA receptors antagonists on protein expression 
Experiments were carried out to investigate whether the LPA receptor antagonists altered 
the protein expression of MLC-1v, OCT4, and GATA4. This was assessed by western blot 
analysis and compared qualitatively and quantitatively in graphs and statistical analysis. 
 
Effect of LPA receptors inhibitors on MLC-1v expression 
Suramin significantly inhibited the expression of MLC-1v in cells treated with LPA (5µM). 
Interestingly suramin also appeared to suppress the basal expression of MLC-1v in controls 
(Figure 3.40). In contrast to suramin, Cells treated with H2L5765834 by itself showed a slight 
increase in expression of MLC-1v compared to control but had no significant effect on LPA 
induced MLC-1v protein expression (Figures 3.41 and 3.42). Similarly, H2L5186303 
(1.25µM) did not affect either the basal nor LPA induced MLC-1v expression (Figures 3.41 
and 3.43). TC-LPA5-4 (1.6µM) on the other hand, did not affect basal levels of MLC-1v but 
suppressed LPA-induced expression of MLC. Thus, it was marginal but significant when 
compared to the LPA response (Figures 3.41 and 3.44). 
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Figure 3.40: Effect of suramin on 
the expression of ventricular 
myosin light chain (MLC-1v).  
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either incubated 
with medium alone (Controls) or 
treated with 5µM of LPA. While the 
cells treated with suramin (50µg/ml) 
were incubated for 1 hour before 
LPA was added (S+L). Formed EBs 
were subsequently plated in tissue 
culture grade plates after four days 
and allowed to grow into 
monolayers. Lysates were 
generated on day six after plating 
EBs in cell culture dishes and 
probed for the expression of MLC-1v 
by western blotting as described in 
the previous chapter. Expression of 
β-actin (Figure 3.40A) was used as 
a loading control in the blot. The 
bars represent the densitometric 
mean ± SEM from 3 independent 
experiments (Figure 3.40B). One-
way analysis of variance (ANOVA) method was used to extract statistical information. The * 
denotes a P value of p<0.5 compared to control. ** p<0.01 and *** p<0.001 compared to LPA 
treated or control. 
Figure 3.41: Effect of LPA receptor inhibitors on the protein expression of MLC-1v.  
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium alone (Controls) or treated with 5µM of LPA. 
While the cells treated with inhibitors were incubated for 1 hour before LPA was added. Formed 
EBs were subsequently plated in tissue culture grade plates after four days and allowed to 
grow into monolayers. Lysates were generated on day six after plating EBs in cell culture 
dishes and probed for the protein expression of MLC-1v (26kDa) by western blotting as 
described in the previous chapter. Protein expression of β-actin (43kDa) was used as a loading 
control in the blot. 
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Figure 3.42: Effect of 
H2L5765834 on the 
protein expression of 
MLC-1v.  
Monolayers of P19 
cells were trypsinised 
and seeded in Petri-
dishes to form EBs. 
During this stage, cells 
were either incubated 
with medium alone 
(Controls) or treated 
with 5µM of LPA. While 
the cells treated with 
H2L5765834 (0.5 & 
0.8µM) were incubated 
for 1 hour before LPA 
was added. Formed 
EBs were subsequently 
plated in tissue culture grade plates after four days and allowed to grow into monolayers. 
Lysates were generated on day six after plating EBs in cell culture dishes and probed for the 
expression of MLC-1v by western blotting as described in the previous chapter. Expression of 
β-actin (Figure 3.41) was used as a loading control in the blot. The bars represent the 
densitometric mean ± SEM from 3 independent experiments. 
Figure 3.43: Effect of 
H2L5186303 on the 
protein expression of 
MLC-1v. 
Monolayers of P19 
cells were trypsinised 
and seeded in Petri-
dishes to form EBs. 
During this stage, cells 
were either incubated 
with medium alone 
(Controls) or treated 
with 5µM of LPA. 
While the cells treated 
with H2L5186303 
(1.25µM) were 
incubated for 1 hour 
before LPA was 
added. Formed EBs 
were subsequently 
plated in tissue culture grade plates after four days and allowed to grow into monolayers. 
Lysates were generated on day six after plating EBs in cell culture dishes and probed for the 
expression of MLC-1v by western blotting as described in the previous chapter. Expression of 
β-actin (Figure 3.41) was used as a loading control in the blot. The bars represent the 
densitometric mean ± SEM from 3 independent experiments One-way analysis of variance 
(ANOVA) method was used to extract statistical information, and the * denotes p<0.05 
compared to LPA treated bar. 
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Effect of LPA receptors inhibitors on OCT4 expression 
In these studies, changes in OCT4 expression was investigated. The data in Figure 3.45 
shows that OCT4 expression was enhanced in controls and suppressed following LPA 
treatment. The next sets of results are from cells treated with or without H2L5765834, 
H2L5186303, or TC-LPA5-4. Of these three compounds, H2L5765834 partially reversed the 
suppression of OCT4 caused by LPA (Figures 3.45 and 3.46), but this was not statistically 
significant due to some degree of variability in the mean data except for LPA, presumably 
due to the small n numbers. H2L5186303 (Figures 3.45 and 3.47) and TC-LPA5-4 (Figures 
3.45 and 3.48) on the other hand reversed the suppression of OCT4 caused by LPA, 
bringing levels back to those seen in controls, and this was statistically significant. Neither 
inhibitor had any effect on control OCT4 levels when applied on their own.  
  
Figure 3.44: Effect of TC-LPA5-4 on the 
protein expression of ventricular myosin 
light chain.  
Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) or 
treated with 5µM of LPA. While the cells 
treated with TC-LPA5-4 (1.6µM) were 
incubated for 1 hour before LPA was added 
(LPA+ TC-LPA5-4). Formed EBs were 
subsequently plated in tissue culture grade 
plates after four days and allowed to grow 
into monolayers. Lysates were generated 
on day six after plating EBs in cell culture 
dishes and probed for the expression of 
MLC-1v by western blotting as described in 
the previous chapter. Expression of β-actin 
(Figure 3.41) was used as a loading control in the blot. The bars represent the densitometric 
mean ± SEM from 3 independent experiments. One-way analysis of variance (ANOVA) was 
used to determine statistical significance and * denotes p<0.05 and *** denotes p<0.001. 
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Figure 3.45: Effect of LPAR inhibitors on the expression of OCT4.  
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium alone (Controls) or treated with 5µM of LPA. 
While the cells treated with inhibitors were incubated for 1 hour before LPA was added. Formed 
EBs were subsequently plated in tissue culture grade plates after four days and allowed to 
grow into monolayers. Lysates were generated on day six after plating EBs in cell culture 
dishes and probed for the protein expression of OCT4 (43kDa) by western blotting as 
described in the previous chapter. Protein expression of β-actin (43kDa) was used as a loading 
control in the blot. 
Figure 3.46: Effect of 
H2L5765834 on the protein 
expression of OCT4.  
Monolayers of P19 cells 
were trypsinised and seeded 
in Petri-dishes to form EBs. 
During this stage, cells were 
either incubated with 
medium alone (Controls) or 
treated with 5µM of LPA. 
While the cells treated with 
H2L5765834 (0.5 & 0.8µM) 
were incubated for 1 hour 
before LPA was added. 
Formed EBs were 
subsequently plated in tissue 
culture grade plates after 
four days and allowed to grow into monolayers. Lysates were generated on day six after plating 
EBs in cell culture dishes and probed for the protein expression of OCT4 (43kDa) by western 
blotting as described in the previous chapter. Protein expression of β-actin (Figure 3.45) was 
used as a loading control in the blot. The bars represent the densitometric mean ± SEM from 3 
independent experiments.  One-way analysis of variance (ANOVA) was used to determine 
statistical significance, and ** denotes p<0.01 compared to control. 
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Figure 3.47: Effect of 
H2L5186303 on the protein 
expression of OCT4. 
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either 
incubated with medium alone 
(Controls) or treated with 5µM of 
LPA. While the cells treated with 
H2L5186303 (1.25µM) were 
incubated for 1 hour before LPA 
was added. Formed EBs were 
subsequently plated in tissue 
culture grade plates after four 
days and allowed to grow into 
monolayers. Lysates were generated on day six after plating EBs in cell culture dishes and 
probed for the protein expression of OCT4 (43kDa) by western blotting as described in the 
previous chapter. Expression of β-actin (Figure 3.45) was used as a loading control in the blot. 
The bars represent the densitometric mean ± SEM from 3 independent experiments. One-way 
analysis of variance (ANOVA) was used to determine statistical significance and * denotes 
p<0.05 and ** denote p<0.01 compared to control. 
 Figure 3.48: Effect of TC-LPA5-
4 on the protein expression of 
OCT4.   
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either incubated 
with medium alone (Controls) or 
treated with 5µM of LPA. While 
the cells treated with TC-LPA5-4 
(1.6µM) were incubated for 1 hour 
before LPA was added. Formed 
EBs were subsequently plated in 
tissue culture grade plates after 
four days and allowed to grow into 
monolayers. Lysates were 
generated on day six after plating 
EBs in cell culture dishes and 
probed for the protein expression 
of OCT4 (43kDa) by western blotting as described in the previous chapter. Protein expression 
of β-actin (Figure 3.45) was used as a loading control in the blot. The bars represent the 
densitometric mean ± SEM from 3 independent experiments. One-way analysis of variance 
(ANOVA) was used to determine statistical significance, and * denotes p<0.05 compared to 
control. 
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Effect of LPA receptors inhibitors on GATA4 expression  
In parallel with the studies above, changes in GATA4 expression was also investigated. In 
contrast to OCT4, GATA4 expression was relatively low under control conditions but 
enhanced in the presence of LPA (5µM) as demonstrated on the blot (Figure 3.49). Similar 
trends were also observed with H2L5765834 (Figure 3.50), H2L5186303 (Figure 3.51) and 
TC-LPA5-4 (Figure 3.52) which on their own appeared to enhance GATA4 expression but 
also suppressed that induced by LPA, with a statistical significance only for TC-LPA5-4 
respectively. There was, however, significant variability in the data for each compound when 
applied alone, making it necessary to increase the n values in future studies to confirm 
statistical significance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.49: Effect of LPAR inhibitors on the protein expression of GATA4.  
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium alone (Controls) or treated with 5µM of LPA. 
While the cells treated with inhibitors were incubated for 1 hour before LPA was added. Formed 
EBs were subsequently plated in tissue culture grade plates after four days and allowed to 
grow into monolayers. Lysates were generated on day six after plating EBs in cell culture 
dishes and probed for the protein expression of GATA4 (54kDa) by western blotting as 
described in the previous chapter. Protein expression of β-actin (43kDa) was used as a loading 
control in the blot. 
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Figure 3.50: Effect of H2L5765834 
on the protein expression of 
GATA4.  
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either incubated 
with medium alone (Controls) or 
treated with 5µM of LPA. While the 
cells treated with H2L5765834 (0.5 
& 0.8µM) were incubated for 1 hour 
before LPA was added. Formed 
EBs were subsequently plated in 
tissue culture grade plates after four 
days and allowed to grow into 
monolayers. Lysates were 
generated on day six after plating 
EBs in cell culture dishes and 
probed for the protein expression of 
GATA4 by western blotting as 
described in the previous chapter. 
Protein expression of β-actin (Figure 3.49) was used as a loading control in the blot. The bars 
represent the densitometric mean ± SEM from 3 independent experiments. One-way analysis 
of variance (ANOVA) was used to determine statistical significance, and ** denote p<0.01 
compared to LPA treated bar. 
Figure 3.51: Effect of H2L5186303 
on the protein expression of 
GATA4.  
Monolayers of P19 cells were 
trypsinised and seeded in Petri-dishes 
to form EBs. During this stage, cells 
were either incubated with medium 
alone (Controls) or treated with 5µM of 
LPA. While the cells treated with 
H2L5186303 (1.25µM) were incubated 
for 1 hour before LPA was added. 
Formed EBs were subsequently 
plated in tissue culture grade plates 
after four days and allowed to grow 
into monolayers. Lysates were 
generated on day six after plating EBs 
in cell culture dishes and probed for 
the protein expression of GATA4 by 
western blotting as described in the 
previous chapter. Protein expression 
of β-actin (Figure 3.49) was used as a loading control in the blot. The bars represent the 
densitometric mean ± SEM from 3 independent experiments. One-way analysis of variance 
(ANOVA) was used to determine statistical significance, and ** denote p<0.01 compared to 
LPA treated bar. 
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Figure 3.52: Effect of TC-LPA5-
4 on the Protein expression of 
GATA4.  
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either incubated 
with medium alone (Controls) or 
treated with 5µM of LPA. While 
the cells treated TC-LPA5-4 
(1.6µM) were incubated for 1 hour 
before LPA was added. Formed 
EBs were subsequently plated in 
tissue culture grade plates after 
four days and allowed to grow into 
monolayers. Lysates were 
generated on day six after plating 
EBs in cell culture dishes and 
probed for the protein expression 
of GATA4 by western blotting as 
described in the previous chapter. 
Protein expression of β-actin (Figure 3.49) was used as a loading control in the blot. The bars 
represent the densitometric mean ± SEM from 3 independent experiments. 
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3.6.2 Effects of LPA receptors antagonists on mRNA expression: 
Additional to the studies above, parallel experiments were carried out to investigate whether 
the LPA receptor antagonists altered the expression of miR-145, miR-1, miR-133, OCT4, 
and NKX2.5 at the mRNA level. Mir-145 and OCT4 were targeted due to their roles in 
stemness and pluripotency. While mir-1, mir-133, and NKX2.5 were targeted for their 
reported activities in cardiomyocytes.  
 
Effect of LPA receptor antagonist on the mir-145 expression 
As shown previously, the expression of mir-145 is statistically significantly higher in LPA-
treated cells when compared to controls (Section 3.5.3.). Treatment with 1.25µM of 
H2L5186303 caused a marginal decrease in mir-145 expression, which was not statistically 
significant and had no obvious effect on the induction caused by LPA (Figure 3.53). This 
was also the case for H2L5765834 (0.5 & 0.8µM; Figure 3.54) and for TC LPA5 4 (1.6µM; 
Figure 3.55) which had little or no effect on basal and LPA-induced expression of mir-145 
suggesting that this effect of LPA is independent of LPA receptors 1, 3 and 5. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.53: Effect of H2L5186303 on the 
expression of mir-145 mRNA. 
Monolayers of P19 cells were trypsinised and 
seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium 
alone (Controls) or treated with 5µM of LPA. 
While the cells treated H2L5186303 (1.25µM) 
were incubated for 1 hour before LPA was 
added. Formed EBs were subsequently plated 
in tissue culture grade plates after four days and 
allowed to grow into monolayers. Lysates were 
generated on day 6, and RNA was then 
extracted and transcribed into a cDNA, and mir-
145 gene was amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 Flex Real-
Time PCR System (Qiagen). U6 (housekeeping 
gene) was used as an endogenous control for 
RNA input and normalisation. The bars 
represent the densitometric mean ± SEM from 3 
independent experiments. One-way analysis of 
variance (ANOVA) was used to determine statistical significance, and * denotes p<0.05 
compared to LPA treated bar. 
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Figure 3.54: Effect of H2L5765834 on the 
expression of mir-145.  
Monolayers of P19 cells were trypsinised and 
seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium 
alone (Controls) or treated with 5µM of LPA. 
While the cells treated H2L5765834 (0.5 & 
0.8µM) were incubated for 1 hour before LPA 
was added. Formed EBs were subsequently 
plated in tissue culture grade plates after four 
days and allowed to grow into monolayers. 
Lysates were generated on day 6 and RNA 
was then extracted and transcribed into a 
cDNA, and mir-145 gene was amplified and 
analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System 
(Qiagen). U6 (housekeeping gene) was used 
as an endogenous control for RNA input and 
normalisation. The bars represent the 
densitometric mean ± SEM from 3 independent 
experiments. 
Figure 3.55: Effect of TC-LPA5-4 on 
the expression of mir-145. 
Monolayers of P19 cells were 
trypsinised and seeded in Petri-dishes 
to form EBs. During this stage, cells 
were either incubated with medium 
alone (Controls) or treated with 5µM of 
LPA. While the cells treated TC-LPA5-4 
(1.6µM) were incubated for 1 hour 
before LPA was added. Formed EBs 
were subsequently plated in tissue 
culture grade plates after four days and 
allowed to grow into monolayers. 
Lysates were generated on day 6 and 
RNA was then extracted and 
transcribed into a cDNA and mir-145 
was amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 
Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as an endogenous 
control for RNA input and normalisation. The bars represent the densitometric mean ± SEM 
from 3 independent experiments.  
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Effect of LPA receptor antagonist on the mir-1 expression 
Consistent with the data presented earlier (Section 3.5.4), the expression mir-1 was also 
higher compared to control, induced by LPA (5µM), but, with the exception that in the current 
experiment it was not significant (Figure 3.56). Additionally, all the inhibitors including 
H2L5186303 (1.25µM; Figure 3.56A), H2L5765834 (0.5 & 0.8µM; Figure 3.56B) and TC-
LPA5-4 (1.6µM; Figure 3.56C) did not significantly alter or affect the basal levels of mir-1 but 
shows a partial decrease compared to LPA with the inhibitor 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.56: Effect of LPA receptor antagonist on the expression of mir-1. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium alone (Controls) or treated with 5µM of LPA. 
While the cells treated H2L5186303 (1.25µM) (A), H2L5765834 (0.5 & 0.8µM) (B) and TC-
LPA5-4 (1.6µM) (C) were incubated for 1 hour before LPA was added. Formed EBs were 
subsequently plated in tissue culture grade plates after four days and allowed to grow into 
monolayers. Lysates were generated on day 6 and RNA was then extracted and transcribed 
into a cDNA, and mir-1 gene was amplified and analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as 
an endogenous control for RNA input and normalisation. The bars represent the densitometric 
mean ± SEM from 3 independent experiments. 
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Effect of LPA receptor antagonist on OCT4 expression 
The basal expression of OCT4 was marginally significantly downregulated when P19 cells 
were treated with LPA (5µM) in this experiment. This expression of OCT4 was also 
suppressed by H2L5765834 (0.8µM) when added in the absence of LPA, but, the antagonist 
did not change or further enhance the inhibition caused by LPA (Figure 3.57). Similarly, 
H2L5186303 (1.25µM; Figure 3.58) and TC-LPA5-4 (1.6µm; Figure 3.59) slightly 
suppressed basal OCT4 protein expression, respectively but not statistically. Furthermore, 
H2L5186303 and TC-LPA5-4 did reverse the inhibition of OCT4 expression caused by LPA, 
but evidently by TC-LPA5-4 only compared to LPA treated cells. This reaction of the 
antagonist on the LPA receptor was not observed with H2L5765834. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.57: Effect of H2L5765834 on the  
expression of OCT4.  
Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) or 
treated with 5µM of LPA. While the cells 
treated with H2L5765834 (0.5 & 0.8µM) 
were incubated for 1 hour before LPA was 
added. Formed EBs were subsequently 
plated in tissue culture grade plates after 
four days and allowed to grow into 
monolayers. Lysates were generated on 
day 6 and RNA was then extracted and 
transcribed into a cDNA, and OCT4 gene 
(Qiagen) was amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 Flex 
Real-Time PCR System. U6 (housekeeping 
gene) was used as an endogenous control 
for RNA input and normalisation. The bars 
represent the densitometric mean ± SEM 
from 3 independent experiments. One-way analysis of variance (ANOVA) was used to 
determine statistical significance, and * denotes p<0.05 compared to control. 
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Figure 3.58: Effect of H2L5186303 on the 
expression of OCT4.  
Monolayers of P19 cells were trypsinised and 
seeded in Petri-dishes to form EBs. During 
this stage, cells were either incubated with 
medium alone (Controls) or treated with 5µM 
of LPA. While the cells treated H2L5186303 
(1.25µM) were incubated for 1 hour before 
LPA was added. Formed EBs were 
subsequently plated in tissue culture grade 
plates after four days and allowed to grow into 
monolayers. Lysates were generated on day 6 
and RNA was then extracted and transcribed 
into a cDNA, and OCT4 gene was amplified 
and analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System 
(Qiagen). U6 (housekeeping gene) was used 
as an endogenous control for RNA input and 
normalisation. The bars represent the 
densitometric mean ± SEM from 3 independent experiments. One-way analysis of variance 
(ANOVA) was used to determine statistical significance, and * denotes p<0.05 compared to 
control. 
Figure 3.59: Effect of TC-LPA5-4 
on the expression of OCT4.  
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either incubated 
with medium alone (Controls) or 
treated with 5µM of LPA. While the 
cells treated with TC-LPA5-4 (1.6µM) 
were incubated for 1 hour before 
LPA was added. Formed EBs were 
subsequently plated in tissue culture 
grade plates after four days and 
allowed to grow into monolayers. 
Lysates were generated on day 6 
and RNA was then extracted and 
transcribed into a cDNA, and OCT4 
gene was amplified and analysed 
using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time 
PCR System (Qiagen). U6 
(housekeeping gene) was used as 
an endogenous control for RNA input and normalisation. The bars represent the 
densitometric mean ± SEM from 3 independent experiments. One-way analysis of variance 
(ANOVA) was used to determine statistical significance, and * denotes p<0.05 compared to 
LPA treated bar. 
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Effect of LPA receptor antagonist on NKX 2.5 expression 
LPA-treatment marginally enhanced the expression of NKX2.5 when compared to control 
(Figure 3.60). Treatment with H2L5765834 (0.5 & 0.8µM; Figure 3.60A) downregulated 
basal NKX2.5 expression, but this appeared to be statistically non-significant and marginal. 
H2L5765834 also had no significant effect on the LPA induced response (Figure 3.60A). 
H2L5186303 (1.25µM) on the other hand, seems to be decreasing the elevation in NKX 2.5 
caused by LPA but did not affect basal levels when applied on its own (Figure 3.60B). When 
used, TC-LPA5-4 (1.6µM) had little or no effect on either basal or LPA-induced changes in 
NKX2.5 expression (Figure 3.60C).  
 
 
Figure 3.60: Effect of LPA receptor antagonist on the expression of NKX2.5.   
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium alone (Controls) or treated with 5µM of LPA. 
While the cells treated with H2L5765834 (0.5 & 0.8µM) (A), H2L5186303 (1.25µM) (B) and TC-
LPA5-4 (1.6µM) (C) were incubated for 1 hour before LPA was added. Formed EBs were 
subsequently plated in tissue culture grade plates after four days and allowed to grow into 
monolayers. Lysates were generated on day 6 and RNA was then extracted and transcribed into 
a cDNA, and NKX2.5 gene was amplified and analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as 
an endogenous control for RNA input and normalisation. The bars represent the densitometric 
mean ± SEM from 3 independent experiments. 
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Effect of LPA receptor antagonist on the mir-133 expression 
The basal expression of mir-133 was not as significantly enhanced by LPA when compared 
to the others investigated above (Section 3.5.5). Although the trend, in this case, showed an 
increase, it was not found to be statistically significant when compared to control levels. 
Furthermore, neither basal not changes induced by LPA were altered by either H2L5186303 
(1.25µM; Figure 3.61A), H2L5765834 (0.5µM; Figure 3.61B) or TC-LPA5-4 (1.6µM; Figure 
3.61C). 
 
 
Figure 3.61: Effect of LPA receptor antagonist on the expression of mir-133.   
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium alone (Controls) or treated with 5µM of LPA. 
While the cells treated with H2L5186303 (1.25µM) (A), H2L5765834 (0.5 & 0.8µM) (B), and TC-
LPA5-4 (1.6µM) (C) were incubated for 1 hour before LPA was added. Formed EBs were 
subsequently plated in tissue culture grade plates after four days and allowed to grow into 
monolayers. Lysates were generated on day 6 and RNA was then extracted and transcribed into 
a cDNA, and mir-133 gene was amplified and analysed using SYBR-green dye by QuantStudio™ 
7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as an endogenous 
control for RNA input and normalisation. The bars represent the densitometric mean ± SEM from 
3 independent experiments. 
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3.7 Effects of kinase inhibition on the induction of 
differentiation: effects on protein and mRNA 
expression 
The Inhibitors in these studies focused on the inhibition of specific kinases which previous 
studies in our group had indicated may be associated with the induction of differentiation by 
LPA. The inhibitors used includes BIM-1 (bisindolylmaleimide 1) a selective and potent 
inhibitor of PKC isoforms, PKA, PKG and myosin-light-chain-kinase (MLCK), and LY294002 
which is a PI3-kinase inhibitor (PI3-Kβ, PI3-Kα, PI3-Kσ and PI3-Kγ). The IC50 for PI3-Kβ, 
PI3-Kα, PI3-Kσ and PI3-Kγ is respectively 0.31, 0.73, 1.06 and 6.60µM. These effects of 
these compounds on targeted antibodies and mRNA/miRNA expression were also analysed 
and investigated. 
 
3.7.1 Effects of BIM-1 inhibition on protein expression 
The impacts of BIM-1 (10µM) on MLC (24kDa), OCT4 (43kDa) and GATA4 (54kDa) were 
investigated at the protein level using western blotting (Figure 3.62). Consistent with data 
shown earlier on the development of the model, expression of MLC was significantly 
enhanced following treatment of P19 cells with LPA (5µM). This induction of MLC was 
inhibited back to control levels in cells pre-treated with BIM-1 (10µM; Figure 3.63). 
Interestingly, basal OCT4 expression was not significantly altered by LPA, which contrasts 
with the inhibitions reported above (Figure 3.64). The reason for this discrepancy is unclear 
and could potentially reflect a lack of response of cells to LPA. BIM-1 appears to enhance 
OCT4s protein expression, but this was not significant when compared to control and may, 
therefore, be due to experimental variation rather than an actual change in expression 
levels. BIM-1, however, suppressed LPA induced GATA4s protein expression but on its own 
did not affect basal expression levels (Figure 3.65). 
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Figure 3.62: Blots for the effect of BIM-1 
inhibitor on protein expressions. 
Monolayers of P19 cells were trypsinised and 
seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium 
alone (Controls) or treated with 5µM of LPA. 
While the cells treated with BIM-1 inhibitor 
(10µM) were incubated for 1 hour before LPA 
was added. Formed EBs were subsequently 
plated in tissue culture grade plates after four 
days and allowed to grow into monolayers. 
Lysates were generated on day six after 
plating EBs in cell culture dishes and probed 
for the protein expression of MLC-1v (24kDa), 
OCT4 (43kDa) and GATA4 (54kDa) by 
western blotting as described in the previous 
chapter. Expression of β-actin (43kDa) was 
used as a loading control in the blot. 
Figure 3.63: Effect of BIM-1 
on the protein expression 
of ventricular myosin light 
chain.  
Monolayers of P19 cells were 
trypsinised and seeded in 
Petri-dishes to form EBs. 
During this stage, cells were 
either incubated with medium 
alone (Controls) or treated 
with 5µM of LPA. While the 
cells treated BIM-1 (10µM) 
were incubated for 1 hour 
before LPA was added (BIM 
1 & BIM+LPA). Formed EBs 
were subsequently plated in 
tissue culture grade plates after four days and allowed to grow into monolayers. Lysates were 
generated on day six after plating EBs in cell culture dishes and probed for the protein 
expression of MLC-1v (24kDa) by western blotting as described in the previous chapter. 
Protein expression of β-actin (Figure 3.62) was used as a loading control in the blot. The bars 
represent the densitometric mean ± SEM from 3 independent experiments. One-way analysis 
of variance (ANOVA) was used to determine statistical significance, and *** denotes p<0.001 
compared to LPA treated bar. 
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Figure 3.64: Effect of BIM-1 
on protein expression of 
OCT4.  
Monolayers of P19 cells were 
trypsinised and seeded in 
Petri-dishes to form EBs. 
During this stage, cells were 
either incubated with medium 
alone (Controls) or treated 
with 5µM of LPA. While the 
cells treated BIM-1 (10µM) 
were incubated for 1 hour 
before LPA was added (BIM 
1 & BIM+LPA). Formed EBs 
were subsequently plated in 
tissue culture grade plates 
after four days and allowed to grow into monolayers. Lysates were generated on day six after 
plating EBs in cell culture dishes and probed for the protein expression of OCT4 (43kDa) by 
western blotting as described in the previous chapter. Protein expression of β-actin (Figure 
3.62) was used as a loading control in the blot. The bars represent the densitometric mean ± 
SEM from 3 independent experiments. 
Figure 3.65: Effect of BIM-1 
on protein expression of 
GATA4.  
Monolayers of P19 cells were 
trypsinised and seeded in 
Petri-dishes to form EBs. 
During this stage, cells were 
either incubated with medium 
alone (Controls) or treated 
with 5µM of LPA. While the 
cells treated BIM-1 (10µM) 
were incubated for 1 hour 
before LPA was added (BIM 1 
& BIM+LPA). Formed EBs 
were subsequently plated in 
tissue culture grade plates after four days and allowed to grow into monolayers. Lysates were 
generated on day six after plating EBs in cell culture dishes and probed for the protein 
expression of GATA4 (54kDa) by western blotting as described in the previous chapter. Protein 
expression of β-actin (Figure 3.62) was used as a loading control in the blot. The bars 
represent the densitometric mean ± SEM from 3 independent experiments. 
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3.7.2 Effects of BIM-1 on mRNA/miRNA expression 
The effects of BM-1 were additionally investigated on expression of the various miRNAs and 
genes investigated previously. In these studies, LPA (5µM) enhanced mir-145 expression, 
which was still statistically significant when compared to control. More importantly, BIM-1 
(10µM) significantly inhibited both basal and LPA-induced expression of mir-145 (Figure 
3.66). Similarly, BIM-1 (10µM) also suppressed mir-1 (Figure 3.67) and mir-133 (Figure 
3.68) expression in both controls and in LPA-treated cells where both miRNAs were 
significantly enhanced by LPA when compared to controls respectively.  
In contrast to the miRNAs, expression of OCT4 mRNA was only marginally suppressed by 
LPA but this and indeed levels in controls were enhanced by BIM-1. The enhancements in 
both instances were significantly higher than levels in controls, and LPA treated cells for mir-
133; and for BIM-1, respectively (Figure 3.69). NKX2.5, on the other hand, was enhanced 
by LPA and BIM-1 partially inhibited this although this response did not appear to be 
statistically significant due to large variabilities in the experiments which were limited to an 
n of 3 because of time constraints. BIM-1 did not significantly alter basal NKX2.5 expression 
(Figure 3.70).  By comparison, BIM-1 significantly inhibited GATA4 expression in controls 
and LPA treated cells where GATA4 levels were markedly enhanced above controls by LPA, 
respectively (Figure 3.77). 
Figure 3.66: Effect of BIM-1 on 
the expression of mir-145.  
Monolayers of P19 cells were 
trypsinised and seeded in Petri-
dishes to form EBs. During this 
stage, cells were either incubated 
with medium alone (Controls) or 
treated with 5µM of LPA. While the 
cells treated BIM-1 (10µM) were 
incubated for 1 hour before LPA 
was added. Formed EBs were 
subsequently plated in tissue 
culture grade plates after four days 
and allowed to grow into monolayers. Lysates were generated on day 6 and RNA was then 
extracted and transcribed into a cDNA, and mir-145 gene was amplified and analysed using 
SYBR-green dye by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 
(housekeeping gene) was used as an endogenous control for RNA input and normalisation. 
The bars represent the densitometric mean ± SEM from 3 independent experiments. One-way 
analysis of variance (ANOVA) was used to determine statistical significance. * denotes p<0.05 
and ** indicates p<0.01 compared to control. 
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Figure 3.68: Effect of BIM-1 
on the expression of mir-
133.  
Monolayers of P19 cells were 
trypsinised and seeded in 
Petri-dishes to form EBs. 
During this stage, cells were 
either incubated with medium 
alone (Controls) or treated 
with 5µM of LPA. While the 
cells treated BIM-1 (10µM) 
were incubated for 1 hour 
before LPA was added. 
Formed EBs were 
subsequently plated in tissue 
culture grade plates after four 
days and allowed to grow into 
monolayers. Lysates were generated on day 6 and RNA was then extracted and transcribed 
into a cDNA, and mir-133 gene was amplified and analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as 
an endogenous control for RNA input and normalisation. The bars represent the densitometric 
mean ± SEM from 3 independent experiments. One-way analysis of variance (ANOVA) was 
used to determine statistical significance. * denotes p<0.05, ** denotes p<0.01 and *** denotes 
p<0.001 compared to control. 
  
Figure 3.67: Effect of BIM-
1 on the expression of 
mir-1.  
Monolayers of P19 cells 
were trypsinised and 
seeded in Petri-dishes to 
form EBs. During this stage, 
cells were either incubated 
with medium alone 
(Controls) or treated with 
5µM of LPA. While the cells 
treated BIM-1 (10µM) were 
incubated for 1 hour before 
LPA was added. Formed 
EBs were subsequently 
plated in tissue culture grade plates after four days and allowed to grow into monolayers. 
Lysates were generated on day 6 and RNA was then extracted and transcribed into a cDNA, 
and mir-1 gene was amplified and analysed using SYBR-green dye by QuantStudio™ 7 Flex 
Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as an endogenous 
control for RNA input and normalisation. The bars represent the densitometric mean ± SEM 
from 3 independent experiments. One-way analysis of variance (ANOVA) was used to 
determine statistical significance. * denotes p<0.05, ** denotes p<0.01 and *** denotes p<0.001 
compared to control. 
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Figure 3.69: Effect of BIM-1 
on the expression of OCT4.  
Monolayers of P19 cells were 
trypsinised and seeded in 
Petri-dishes to form EBs. 
During this stage, cells were 
either incubated with medium 
alone (Controls) or treated with 
5µM of LPA. While the cells 
treated BIM-1 (10µM) were 
incubated for 1 hour before 
LPA was added. Formed EBs 
were subsequently plated in tissue culture grade plates after four days and allowed to grow into 
monolayers. Lysates were generated on day 6 and RNA was then extracted and transcribed 
into a cDNA, and OCT4 gene was amplified and analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as 
an endogenous control for RNA input and normalisation. The bars represent the densitometric 
mean ± SEM from 3 independent experiments. 
Figure 3.70: Effect of BIM-1 
on the expression of 
NKX2.5. 
Monolayers of P19 cells were 
trypsinised and seeded in 
Petri-dishes to form EBs. 
During this stage, cells were 
either incubated with medium 
alone (Controls) or treated 
with 5µM of LPA. While the 
cells treated BIM-1 (10µM) 
were incubated for 1 hour 
before LPA was added. 
Formed EBs were 
subsequently plated in tissue culture grade plates after four days and allowed to grow into 
monolayers. Lysates were generated on day 6 and RNA was then extracted and transcribed 
into a cDNA, and NKX2.5 gene was amplified and analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). U6 (housekeeping gene) was used as 
an endogenous control for RNA input and normalisation. The bars represent the densitometric 
mean ± SEM from 3 independent experiments. 
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Figure 3.71: Effect 
of BIM-1 on the 
expression of 
GATA4. 
 Monolayers of P19 
cells were 
trypsinised and 
seeded in Petri-
dishes to form EBs. 
During this stage, 
cells were either 
incubated with 
medium alone 
(Controls) or treated with 5µM of LPA. While the cells treated BIM-1 (10µM) were incubated for 
1 hour before LPA was added. Formed EBs were subsequently plated in tissue culture grade 
plates after four days and allowed to grow into monolayers. Lysates were generated on day 6 
and RNA was then extracted and transcribed into a cDNA, and GATA4 gene was amplified and 
analysed using SYBR-green dye by QuantStudio™ 7 Flex Real-Time PCR System (Qiagen). 
U6 (housekeeping gene) was used as an endogenous control for RNA input and normalisation. 
The bars represent the densitometric mean ± SEM from 3 independent experiments. One-way 
analysis of variance (ANOVA) was used to determine statistical significance. * denotes p<0.05 
compared to control and LPA treated cells. 
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3.7.3 Effects of LY294002 (PI3 kinase) inhibition on protein 
expression 
The result of LY294002 antagonist (7µM) in this sub-section was examined on MLC (24kDa), 
OCT4 (43kDa) and GATA4 (54kDa) at the protein level using western blotting. Consistently, 
with the previously shown results on the development of the model, expression of MLC-1v in 
control was significantly lower following treatment of P19 cells with LPA (5µM). This induction 
was, however, inhibited back to control levels in cells pre-treated with LY294002 (7µM; 
Figure 3.72). While the expression of OCT4 was remarkably downregulated in all the 
conditions except in control (Figure 3.73). Cells incubated with LPA alone or LY294002 were 
both downregulated with a p-value of <0.001 compared to the basal levels. In contrast, the 
protein expression of GATA4 showed no evident impact when treated with either LPA or with 
LY294002 (Figure 3.74). 
 
Figure 3.72: Effect of LY294002 on the 
protein expression of MLC-1v.  
Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) or 
treated with 5µM of LPA. While the cells 
treated LY294002 (7µM) were incubated for 
1 hour before LPA was added (LPA+LY-7). 
Formed EBs were subsequently plated in 
tissue culture grade plates after four days 
and allowed to grow into monolayers. 
Lysates were generated on day six after 
plating EBs in cell culture dishes and 
probed for the protein expression of MLC-1v 
(24kDa) by western blotting as described in 
the previous chapter. Protein expression of 
β-actin (Figure 3.72A) was used as a 
loading control in the blot. The bars 
represent the densitometric mean ± SEM 
from 3 independent experiments (Figure 
3.72B). One-way analysis of variance 
(ANOVA) was used to determine statistical 
significance, and * denotes p<0.05 
compared to LPA treated bar. 
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Figure 3.74: Effect of LY294002 on the protein 
expression of GATA4. 
Monolayers of P19 cells were trypsinised and 
seeded in Petri-dishes to form EBs. During this 
stage, cells were either incubated with medium 
alone (Controls) or treated with 5µM of LPA. 
While the cells treated LY294002 (7µM) were 
incubated for 1 hour before LPA was added 
(LPA+LY-7). Formed EBs were subsequently 
plated in tissue culture grade plates after four 
days and allowed to grow into monolayers. 
Lysates were generated on day six after plating 
EBs in cell culture dishes and probed for the 
protein expression of GATA4 (54kDa) by 
western blotting as described in the previous 
chapter. Protein expression of β-actin (Figure 
3.74A) was used as a loading control in the 
blot. The bars represent the densitometric 
mean ± SEM from 3 independent experiments 
(Figure 3.74B). 
  
Figure 3.73: Effect of LY294002 on the 
protein expression of OCT4.  
Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) or 
treated with 5µM of LPA. While the cells 
treated LY294002 (7µM) were incubated for 
1 hour before LPA was added (LPA+LY-7). 
Formed EBs were subsequently plated in 
tissue culture grade plates after four days 
and allowed to grow into monolayers. 
Lysates were generated on day six after 
plating EBs in cell culture dishes and 
probed for the protein expression of OCT4 
(42kDa) by western blotting as described in 
the previous chapter. Protein expression of 
β-actin (Figure 3.73A) was used as a 
loading control in the blot. The bars 
represent the densitometric mean ± SEM 
from 3 independent experiments (Figure 
3.73B). One-way analysis of variance 
(ANOVA) was used to determine statistical 
significance, and *** denote p<0.001 
compared to control bar. 
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3.7.4 Effects of LY294002 (PI3 kinase) inhibition on mRNA 
expression 
In the current sub-section, mir-145, mir-1, mir-133, OCT4 and NKX2.5 expressions are 
investigated in response to the inhibition by LY294002 (7µM). The expression of mir-145, 
mir-1, mir-133 and NKX2.5 (Figure 3.75-3.77 and 3.79), did not result in any significant 
enhancement or decrease. LY294002 was marginally significant in LPA-induced cells 
expression of mir-145 and mir-1. Interestingly, expression of mir-133 was not enhanced 
either affected by LPA or LY294002 (Figure 3.83). 
In contrast to the miRNAs, the mRNA expression of OCT4 was significantly suppressed and 
even further inhibited by LY294002 in basal and LPA-induced expression (Figure 3.78). 
LY294002 pre-incubated LPA-induced cells were also significantly lower compared to LPA-
induced cells. NKX2.5, on the other hand, was enhanced by LPA while the basal was also 
partially inhibited by LY294002 but, not significant. LY294002 likewise did not significantly 
alter the LPA-induced cells of the expression of NKX2.5 (Figure 3.79). 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.75: Effect of LY294002 on the 
expression of mir-145.  
 Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either incubated 
with medium alone (Controls) or treated with 
5µM of LPA. While the cells treated 
LY294002 (7µM) were incubated for 1 hour 
before LPA was added. Formed EBs were 
subsequently plated in tissue culture grade 
plates after four days and allowed to grow 
into monolayers. Lysates were generated on 
day 6 and RNA was then extracted and 
transcribed into a cDNA, and mir-145 gene 
was amplified and analysed using SYBR-
green dye by QuantStudio™ 7 Flex Real-
Time PCR System (Qiagen). U6 
(housekeeping gene) was used as an 
endogenous control for RNA input and 
normalisation. The bars represent the densitometric mean ± SEM from 3 independent 
experiments. 
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Figure 3.77: Effect of LY294002 on the 
expression of mir-133. 
Monolayers of P19 cells were trypsinised and 
seeded in Petri-dishes to form EBs. During 
this stage, cells were either incubated with 
medium alone (Controls) or treated with 5µM 
of LPA. While the cells treated LY294002 
(7µM) were incubated for 1 hour before LPA 
was added. Formed EBs were subsequently 
plated in tissue culture grade plates after four 
days and allowed to grow into monolayers. 
Lysates were generated on day 6 and RNA 
was then extracted and transcribed into a 
cDNA, and mir-133 gene was amplified and 
analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR System 
(Qiagen). U6 (housekeeping gene) was used 
as an endogenous control for RNA input and normalisation. The bars represent the 
densitometric mean ± SEM from 3 independent experiments. 
 
  
Figure 3.76: Effect of LY294002 on the 
expression of mir-1.  
Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) or 
treated with 5µM of LPA. While the cells 
treated LY294002 (7µM) were incubated for 
1 hour before LPA was added. Formed EBs 
were subsequently plated in tissue culture 
grade plates after four days and allowed to 
grow into monolayers. Lysates were 
generated on day 6 and RNA was then 
extracted and transcribed into a cDNA, and 
mir-1 gene was amplified and analysed 
using SYBR-green dye by QuantStudio™ 7 
Flex Real-Time PCR System (Qiagen). U6 
(housekeeping gene) was used as an 
endogenous control for RNA input and 
normalisation. The bars represent the densitometric mean ± SEM from 3 independent 
experiments. 
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Figure 3.78: Effect of LY294002 on the 
expression of OCT4. 
Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) or 
treated with 5µM of LPA. While the cells 
treated LY294002 (7µM) were incubated 
for 1 hour before LPA was added. Formed 
EBs were subsequently plated in tissue 
culture grade plates after four days and 
allowed to grow into monolayers. Lysates 
were generated on day 6 and RNA was 
then extracted and transcribed into a 
cDNA, and OCT4 gene was amplified and 
analysed using SYBR-green dye by 
QuantStudio™ 7 Flex Real-Time PCR 
System (Qiagen). U6 (housekeeping gene) 
was used as an endogenous control for 
RNA input and normalisation. The bars represent the densitometric mean ± SEM from 3 
independent experiments.  The bars represent the densitometric mean ± SEM from 3 
independent experiments. One-way analysis of variance (ANOVA) was used to determine 
statistical significance and * denotes p<0.05 and *** denote p<0.001 compared to control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.79: Effect of LY294002 on the expression of NKX2.5. 
Monolayers of P19 cells were trypsinised 
and seeded in Petri-dishes to form EBs. 
During this stage, cells were either 
incubated with medium alone (Controls) or 
treated with 5µM of LPA. While the cells 
treated LY294002 (7µM) were incubated for 
1 hour before LPA was added. Formed EBs 
were subsequently plated in tissue culture 
grade plates after four days and allowed to 
grow into monolayers. Lysates were 
generated on day 6 and RNA was then 
extracted and transcribed into a cDNA, and 
NKX2.5 gene was amplified and analysed 
using SYBR-green dye by QuantStudio™ 7 
Flex Real-Time PCR System (Qiagen). U6 
(housekeeping gene) was used as an 
endogenous control for RNA input and 
normalisation. The bars represent the 
densitometric mean ± SEM from 3 
independent experiments. 
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3.8 Effects of knockdown and overexpression of 
mir-145 and mir-1 on differentiation 
In the current section, cells were treated according to the protocol illustrated in chapter 2 to 
either knockdown or overexpress mir-145 and mir-1. These studies were carried out to 
determine whether depletion or overexpression of either mir-145 or mir-1 regulated 
differentiation of P19 SCs into cardiomyocytes. siRNA for the inhibitors and a mimic of each 
target were used categorically. 
Additionally, a negative sample was used as a signal for the efficiency of the transfection 
process. Thus, changes in MLC-1v and OCT4 protein expression were investigated by 
western blot while expression of mir-145, mir-1, mir-133, OCT4, NKX2.5 and GATA4 by 
qPCR. Differentiation was also induced using 20µM of LPA to examine the maximum 
possible effect. 
 
3.8.1 Effect of transfection on Protein expression 
 
Effect of transfection on MLC-1v protein expression 
MLC-1v was first targeted to analyse any changes in differentiation that could occur as a 
result of the transfection, including when activated with LPA. This is to test the possible 
relationship between the actions of these miRNAs and LPA in the differentiation. The blot in 
Figure 3.80 is representative of the western blots generated with lysates from cells treated 
with LPA alone (20µM), cells with the master mix but no siRNA (negative/-ve), LPA- induced 
cells premixed with negative (-ve + LPA), cells treated with the inhibitor siRNA (inhib- mir-
145/inhib-mir1), cells treated with overexpression siRNA (mim-mir-145/mim-mir-1) and cells 
with overexpressed or inhibited mir-145/mir-1 induced by LPA (inhib-mir145+LPA/inhib- mir-
1+LPA and mim-mir145+LPA/mim-mir-1+LPA). β-actin was used as a loading control and a 
normaliser.  
Although marginally high, cells treated with LPA (20µM) showed similar levels of protein 
expression of MLC-1v statistically when compared to control. This is also what is observed 
when cells treated with the mimic of mir-145 and LPA was activated also showed a 
marginally higher trend but non-significantly. It did not, however, alter the effects of LPA when  
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applied together (Figure 3.81).  
Cells treated with mir-145 inhibitor alone did not show any statistically significant change even 
with the decrease in expression of up to 50% in MLC-1v levels when compared to LPA 
treated cells. Inducement of cells with LPA when applied together with a mir-145 inhibitor 
also did not increase the latter, suggesting a possible suppression of the LPA effect 
marginally (Figure 3.81).   
Different trends as those described for mir-145 were seen when mir-1 was used compared 
to LPA treated cells. Inhibitor-1 did not significantly suppress the LPA responses, but the 
mimic mir-1 enhanced MLC-1v protein expression on its own and more with the inducement 
of LPA (Figure 3.82). Moreover, MLC-1v marker potentiated the response to LPA every time 
it was added to the negative cells and cells with mir-1 inhibitor but not statistically (Figure 
3.82). Table 3.2 is a summary of the outcome from the statistical analysis for the MLC-1v 
protein expression, which shows the statistical difference to be between the different 
conditions. 
 
 
 
 
 
 
 
 
 
  
Table 3.2: One-way analysis of variance (ANOVA) table analysed for the 
antibodies MLC-1v and OCT4. 
ANOVA 
Variable 
Source of 
variation 
Sum of 
Square 
Squares 
Df 
Mean 
Square 
F Sig. 
WBMLC 
Between 
Groups 
181801.9 11 16527.448 2.435 
0.033 
* 
Within 
Groups 162916.6 24 6788.193   
Total 344718.556 35    
WBOCT4 
Between 
Groups 141409.3 11 12855.394 2.782 
0.017 
* 
Within 
Groups 110911.0 24 4621.291   
Total 252320.3 35    
“*” is Significant (p < 0.05): 
“ns” is non-significant (p > 0.05)  
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Figure 3.80: Blots for the effect of knockdown and overexpression of mir-145 and mir-1 
on MLC-1v. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. Before 
forming EBs cells were transfected with either over-expression (mimic) or the inhibition mixture 
(siRNA) for 24 hours following the manufacturer’s protocol (as detailed in chapter 2). During 
this stage, cells were either incubated with medium alone (Controls) or treated with 20µM of 
LPA. Formed EBs were subsequently plated in tissue culture grade plates after four days and 
allowed to grow into monolayers. Lysates were generated on day six after plating EBs in cell 
culture dishes and probed for the protein expression of MLC-1v (24kDa) by western blotting as 
described in the previous chapter. Protein expression of β-actin (43kDa) was used as a loading 
control in the blot. 
Figure 3.81: Effect of knockdown and overexpression of mir-145 on MLC-1v. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. Before 
forming EBs cells were transfected with either the mir-145 over-expression (mimic) or the 
inhibition mixture (siRNA) for 24 hours following the manufacturer’s protocol (as detailed in 
chapter 2). During this stage, cells were either incubated with medium alone (Controls) or 
treated with 20µM of LPA. The negative bar represents cells with the master-mixture without the 
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siRNA or mimic. EBs were subsequently plated in tissue culture grade plates after four days and 
allowed to grow into monolayers. Lysates were generated on day six after plating EBs in cell 
culture dishes and probed for the protein expression of MLC-1v (24kDa) by western blotting as 
described in the previous chapter. Protein expression of β-actin (43kDa; figure 3.80) was used 
as a loading control in the blot. The bars represent the densitometric mean ± SEM from 3 
independent experiments. ANOVA and Least Significant Differences (LSD) test were used in 
statistical analysis to determine significant differences. Similar letters indicate similar means, 
according to LSD. 
Figure 3.82: Effect of 
knockdown and 
overexpression of mir-1 
on MLC-1v. 
Monolayers of P19 cells 
were trypsinised and 
seeded in Petri-dishes to 
form EBs. Before forming 
EBs cells were transfected 
with either the mir-1 over-
expression (mimic) or the 
inhibition mixture (siRNA) 
for 24 hours following the 
manufacturer’s protocol (as 
detailed in chapter 2). 
During this stage, cells were 
either incubated with 
medium alone (Controls) or 
treated with 20µM of LPA. The negative bar represents cells with the master-mixture without 
the siRNA or mimic. EBs were subsequently plated in tissue culture grade plates after four 
days and allowed to grow into monolayers. Lysates were generated on day six after plating 
EBs in cell culture dishes and probed for the protein expression of MLC-1v (24kDa) by western 
blotting as described in the previous chapter. Protein expression of β-actin (43kDa; figure 3.80) 
was used as a loading control in the blot. The bars represent the densitometric mean ± SEM 
from 3 independent experiments. ANOVA and Least Significant Differences (LSD) test were 
used in statistical analysis to determine significant differences. Similar letters indicate similar 
means, according to LSD. 
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Effect of transfection on OCT4 protein expression 
Figure 3.83 is another representative of the western blots to investigate the impact on protein 
expression of OCT4 (43kDa). OCT4 was targeted as a marker for the pluripotency to test the 
response to the transfection of both mir-1 and mir-145. Generated lysates on day 6 are from 
cells treated with LPA alone (20µM), cells with the master mix but no siRNA (negative/-ve), 
LPA-induced cells premixed with negative (-ve + LPA), cells treated with the inhibitor siRNA 
(inhib-mir-145/inhib- mir1), cells treated with overexpression siRNA (mim-mir-145/mim-mir-1) 
and cells with overexpressed or inhibited mir-145/mir-1 induced by LPA (inhib-
mir145+LPA/inhib-mir-1+LPA and mim-mir145+LPA/mim-mir-1+LPA). β-actin was used as a 
loading control and a normaliser. 
Similar to the previous sub-section, the expression of OCT4 was as expected considerably 
low. However, that effect was not significant compared to Control. This was also the case 
with all the other conditions which did not show any influence by the overexpression or 
inhibition of mir-145 statistically (Figure 3.84). The expression of the protein OCT4 again is 
influenced by mir-1 transfection. Although not statistically significant, the % expression of 
LPA treated cells are visibly lower. Overall, LPA and mimic mir-1 showed a more evident 
responsibility in altering the latter in OCT4 (Figure 3.85). Cells transfected with a mir-1 
inhibitor which treated with LPA showed another evident reaction on the marker of OCT4 
compared to LPA only treated cells. Likewise, cells with mimic-mir-1 and mimic-mir-1 with 
LPA added (Figure 3.85). A very comparable reaction also was apparent compared to cells 
objected with the negative solution with LPA mixed. 
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Figure 3.83: Blot for the effect of knockdown and overexpression of mir-145 and mir-1 on 
OCT4. 
Monolayers of P19 cells were trypsinised and seeded in Petri-dishes to form EBs. Before 
forming EBs cells were transfected with either over-expression (mimic) or the inhibition mixture 
(siRNA) for 24 hours following the manufacturer’s protocol (as detailed in chapter 2). During 
this stage, cells were either incubated with medium alone (Controls) or treated with 20µM of 
LPA. Formed EBs were subsequently plated in tissue culture grade plates after four days and 
allowed to grow into monolayers. Lysates were generated on day six after plating EBs in cell 
culture dishes and probed for the protein expression of OCT4 (43kDa) by western blotting as 
described in the previous chapter. Protein expression of β-actin (43kDa) was used as a loading 
control in the blot. 
 
Figure 3.84: Effect 
of knockdown and 
overexpression of 
mir-145 on OCT4. 
Monolayers of P19 
cells were trypsinised 
and seeded in Petri-
dishes to form EBs. 
Before forming EBs 
cells were transfected 
with either the mir-
145 over-expression 
(mimic) or the 
inhibition mixture 
(siRNA) for 24 hours 
following the manufacturer’s protocol (as detailed in chapter 2). During this stage, cells were 
either incubated with medium alone (Controls) or treated with 20µM of LPA. The negative bar 
represents cells with the master-mixture without the siRNA. EBs were subsequently plated in 
tissue culture grade plates after four days and allowed to grow into monolayers. Lysates were 
generated on day six after plating EBs in cell culture dishes and probed for the protein 
expression of OCT4 (43kDa) by western blotting as described in the previous chapter. Protein 
expression of β-actin (43kDa; figure 3.83) was used as a loading control in the blot. The bars 
represent the densitometric mean ± SEM from 3 independent experiments. ANOVA and Least 
Significant Differences (LSD) test were used in statistical analysis to determine significant 
differences. Similar letters indicate similar means, according to LSD. 
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Figure 3.85: Effect of 
knockdown and 
overexpression of mir-1 
on OCT4. 
Monolayers of P19 cells 
were trypsinised and 
seeded in Petri-dishes to 
form EBs. Prior to forming 
EBs cells were transfected 
with either the mir-1 over-
expression (mimic) or the 
inhibition mixture (siRNA) 
for 24 hours following the 
manufacturer’s protocol (as 
detailed in chapter 2). During this stage, cells were either incubated with medium alone 
(Controls) or treated with 20µM of LPA. Negative bar represents cells with the master-mixture 
without the siRNA. EBs were subsequently plated in tissue culture grade plates after four days 
and allowed to grow into monolayers. Lysates were generated on day six after plating EBs in 
cell culture dishes and probed for the protein expression of OCT4 (43kDa) by western blotting 
as described in the previous chapter. Protein expression of β-actin (43kDa; figure 3.83) was 
used as a loading control in the blot. The bars represent the densitometric mean ± SEM from 3 
independent experiments. ANOVA and Least Significant Differences (LSD) test were used in 
statistical analysis to determine significant differences. Similar letters indicate similar means, 
according to LSD. 
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3.8.2 mRNA/miRNA expression 
This sub-section highlights the results from the qPCR experiments which targeted mir-145, 
mir-1, mir-133, OCT4, NKX2.5 and GATA4 in response to the inhibition of mir-145/mir-1 and 
overexpression of mir-145/mir-1. 
LPA-treated cells showed similar mir-145 and mir-1 expression compared to control. This 
was not affected by the negative, inhib-145 and not enhanced by mim-145. The latter also 
did not improve the basal expression of mir-145 and mir-1 when treated with inhib-1 and 
mim-1. The same was also true for, all the other targets examined including mir-133, OCT4, 
NKX2.5 and GATA4 which did not appear to be altered in any statistically significant manner 
under any of the conditions examined as summarised in table 3.3. 
Table 3.3: One-way analysis of variance (ANOVA) table analysed for the 
antibodies MLC-1v and OCT4. 
ANOVA 
Variable Source of 
variation 
Sum of 
Square 
Squares 
Df Mean 
Square 
F Sig. 
PCRmir145 
Betwee  
Groups 
0.865 11 0.079 1.336 0.265 ns 
Within 
Groups 
1.412 24 0.059   
Total 2.277 35    
PCRmir1 
Between 
Groups 0.850 11 0.077 0.602 0.809 ns 
Within 
Groups 
3.080 24 0.128   
Total 3.930 35    
PCRmir133 
Between 
Groups 0.225 11 0.020 0.776 0.660 ns 
Within 
Groups 
0.633 24 0.026   
Total 0.858 35    
PCROCT4 
Between 
Groups 5.288 11 0.481 0.698 0.728 ns 
Within 
Groups 
16.521 24 0.688   
Total 21.809 35    
PCRNKY 
Between 
Groups 16.829 11 1.530 0.484 0.895 ns 
Within 
Groups 
75.861 24 3.161   
Total 92.690 35    
PCRGATA4 
Between 
Groups 1.989 11 0.181 0.902 0.553 ns 
Within 
Groups 
4.813 24 0.201   
Total 6.802 35    
“ns” is non-significant (p > 0.05) 
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CHAPTER 4 
 DISCUSSION 
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Many diseases of the heart are linked to the loss of cardiomyocytes (Chiong et al., 2011; 
Nakano et al., 2012; Kumar et al., 2005). The cardiomyocytes could be lost through necrosis, 
apoptosis, or autophagy (Kumar et al., 2005; Chiong et al., 2011). Year by year, the mortality 
caused by this loss of cardiomyocytes increase and CVD remains the number one cause of 
death globally (American heart association update, 2014; World Health Organisation). 
Despite considerable advances in understanding some of the mechanisms of CVD at the 
cellular level, and the early diagnosis, surgical and pharmacological interventions in these 
diseases, there is no robust consensus on the best approach for its management. 
Transplantation of mature cardiomyocytes is one approach that has been developed 
recently and although it has been shown to improve the structure and the function of the 
heart after a myocardial infarction (MI) in several clinical trials, it is limited by poor cellular 
survival (Smits et al., 2009; Murry et al., 2005; Beltrami et al., 2001). The positive effect 
depends on the actual cell type transplanted (Hughes, 2002 & Hodgson et al., 2004). 
Embryonic SCs and many other cell types were transplanted to the region of damage post-
MI (Hodgson et al., 2004 & Kumar et al., 2005). However, the best efficient donor cell type 
and technique to perform this process are still not identified. Potential donor cells need to 
be studied thoroughly through differentiation in vivo or in vitro. Differentiation into 
cardiomyocyte using a clinically relevant differentiation inducer is a crucial requirement in 
understanding the different pathways involved in this process. 
The involvement of endogenous non-coding small RNAs which affect protein production 
post-transcriptionally holds an ability to change gene expression and would advance our 
understanding of CVD in health and disease (Kumar et al., 2005). To address this, an 
embryonic carcinoma stem cell line (P19) was used in this thesis. They are multipotent cells 
which may develop into all three germ layers (Hu et al., 2011 & Van Der Heyden et al., 
2003B). P19 cells are an established cardiomyocyte model which are used to investigate 
the early transcription factors involved in the signalling pathways (Hu et al., 2011). It is one 
of the first to be described as a successful cardiac muscle model (Van Der Heyden et al., 
2003A). 
One of the main advantages of P19 cell line differentiation to cardiac cells over human SCs 
or other types of SCs is that P19 do not require a feeder layer or a differentiation inhibitor 
like LIF to maintain the growth and differentiation into different lineages (Hu et al., 2011 &   
124 
 
Van Der Heyden et al., 2003A). This use of P19 cells contributes to lowering the cost and 
the complications that occur when using other types of cells. These advantages, as well as 
being able to self-renew and grow indefinitely undifferentiated (Martin & Evans, 1975; Van 
Der Heyden et al., 2003A), show that P19 stem cell line is the best choice to investigate 
cardiovascular cellular mechanisms over other types of SCs. 
P19 cells were maintained to develop a cardiac lineage using a bio-phospholipid molecule 
(LPA) as an agent. LPA is present endogenously in the heart and circulates in the blood and 
is released from activated platelets (Moolenaar et al., 1997). Although the role of LPA has 
not been fully established, however, it is known that it plays a role in proliferation, apoptosis 
inhibition, cell migration, and many other functions that are not fully elucidated (Ishii et al., 
2004). Recently, LPA has been found to play essential roles in wound healing, maintenance 
of vascular tone, vascular integrity and reproduction (Tyagi, 2014). 
LPA is an important component in the pathophysiology of the cardiovascular system. This 
importance is shown by the increase in serum LPA levels in post-acute MI which increased 
two-fold (10.43 mg/L) within 48-72 h, as compared with the control level of LPA 1.66 mg/L 
after 7 days (Chen et al., 2003). This outcome is consistent with LPA being antiapoptotic 
and protecting the myocytes from hypoxia, which requires an elevated level of LPA (Chen 
et al., 2008). However, the antiapoptotic role was mainly seen at concentrations between 2 
and 20µM (Chen et al., 2006; 2008). This range is the physiological concentration in serum, 
but it could be elevated and released in plasma in response to injury or thrombosis and MI 
in the pathological conditions (Chen et al., 2006). This correlates with other findings of how 
LPA plays a role in smooth muscle contraction, platelet aggregation and vasoactive effects 
to improve the myocytes in the heart (Gaits et al., 1997). This suggests a critical role of LPA 
in regenerating new cardiac cells from SCs, thus inhibiting apoptosis. Yang et al. (2013) 
observed that LPA receptor 1 knock-out enhanced LPA- induced cardiac hypertrophy. While 
LPA receptor 3 when over-expressed, repressed the cardiac hypertrophy and silenced LPA 
receptor 1. Accordingly, it is suggested that LPA receptors could have opposing roles that 
need further clarification by investigating possible targets and pathways that might explain 
these events.  
To investigate further, the signalling pathway and the potential role of other endogenous 
factors that may mediate and affect the regulation of P19 SCs differentiation into  
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cardiomyocytes induced by LPA; miRNAs were explored. These non-coding single-stranded 
RNA are known to be involved in cell proliferation, apoptosis, migration and differentiation 
(Crone et al., 2012), and LPA independently shares some of these roles. Growing evidence 
is establishing the involvement of miRNA in differentiation into several lineages, the 
development of diseases and cancer progression (Crone et al., 2012; Wilson KD et al., 
2010). Yang et al. (2013) recently suggested how mir-23a and 2 linked to the LPA receptors 
could reciprocally regulate each other. It has also been suggested that mir-146a could inhibit 
the G protein-coupled receptors (Crone et al., 2012), which are mainly activated by LPA in 
several systems (Moolenaar et al., 1997). 
Additionally, mir-30c-2 is expressed in ovarian cancer cells, and down-regulated an 
oncogene called BCL9. It also suppressed growth factor-induced cell proliferation, a role 
that LPA plays in the ovarian tumour microenvironment (Jia et al., 2011). 
Another example is, mir-24, which targets LPA acyltransferase (LPAATβ), and inhibits cell 
proliferation in osteosarcoma, one of the most commonly found tumours in the bones of 
adolescents and children (Song et al., 2013). Physiologically, LPA is converted into 
phosphatidic acid (PA) by LPAAT (Rastegar et al., 2010). This association of LPA with 
several cellular pathways suggests that miRNA may be involved in the differentiation of 
cardiomyocytes. The specific miRNAs involved, and their effects are essential in 
understanding their modes of action on how this translates into pathology in the 
cardiovascular system. 
Initially, this report looked at the effect of LPA on P19 SCs differentiation into 
cardiomyocytes, investigating the time and concentration-dependent actions. Also, as 
miRNAs are attracting increasing interest as a possible therapeutic target and as 
biomarkers, their role in LPA differentiation was investigated. The focus of this thesis, 
therefore, centred around two of the promising primary therapies, SCs and miRNA. This aim 
would significantly enhance the rationale in the treatment of cardiac hypertrophy and cardiac 
failure, as well as myocardial infarction and other heart problems. The induction of 
differentiation into cardiomyocytes by LPA, the endogenous phospholipid, would be of 
benefit as a biomarker, and as a potential advancement to the repair and regeneration of 
damaged hearts. 
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4.1. Primary cultures and model establishment 
The primary cultures of P19 cells were demonstrated to be rapidly growing cells, reaching 
70- 80% confluence within two days. We found that over-confluent cultures could cause 
unexpected and non-specific differentiation leading to inconsistent results in the protein level 
and elevated expression of cardiac biomarkers. This result observed in areas with dark 
plaques and growth of multiple layers of cells in the culture. Super-confluency of cells was 
avoided by continuous monitoring of cells and regular trypsinisation of cultures. Cultures 
were also maintained with media changes every second day and monitored daily under an 
inverted microscope for any unexpected changes. 
 
 
4.2. Cardiac cells model and effects of LPA 
Cells treated with LPA were examined using a confocal microscope and treated with either 
OCT4 or Troponin I. The pictures suggest a high expression of OCT4 in control unlike the 
cells treated with LPA and DMSO which shows diminished expression (Green). Troponin-I 
was also highly expressed in LPA, and DMSO treated cells (Figure 3.4). Velasquez-Mao et 
al. (2017) used amniotic fluid-derived SCs (AFSC) iPSC and differentiated cardiac myocytes 
and demonstrated the expression of a range of pluripotency markers, which indicated 
downregulation of OCT4 when differentiated into cardiac myocytes with functional cardiac 
genes. Czysz et al., (2015) showed that DMSO also rapidly downregulated the expression 
of OCT4 and NANOG using, immunohistochemistry, flow cytometry and RT-PCR. Lian et 
al., (2012) used GSK3 inhibitor to initiate the differentiation which did not result in the 
expression of OCT4 but expressed heart ISL1 and Nkx2.5 from human pluripotent SCs. 
Tasmin (2010), showed the role of the chemical induction into CM from P19 cells. They 
demonstrated the downregulation of OCT4 and the expression of Troponin I as explained in 
our data. All these confirm that downregulation of OCT4 is consistent with induction of 
differentiation into a cardiac lineage. 
In terms of the cardiomyocyte development, LPA triggered significant signalling to induce 
differentiation of the P19 cells as assessed by the differential expression of key protein 
markers. Initial experiments were designed to look at whether exerted its effect in a  
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concentration and time-dependent manner and if so, which concentration exerted the 
maximal effect and at which time point. The endpoint target was to monitor the significant 
expression of cardiac markers like MLC-1v and Troponin I as well as looking for lower 
expression in pluripotency markers like OCT4 protein reciprocally. Cells were aggregated 
into EB (as explained in the methods section) in the presence of LPA at concentrations of 
0, 0.5, 1, 5, 10, & 20µM. These cultures were lysed at day 6 after plating the aggregated 
EBs and western blot results were generated. MLC-1v expression was induced significantly 
at 5 (p<0.05), 10 (p<0.05) and 20µM (p<0.01) compared to control. While LPA 0.5 and 1µM 
concentration did not significantly induce MLC-1v, as shown in Figure 3.4. Correspondingly, 
beating clumps were observed at a 20µM concentration of LPA starting from day 3 until day 
6. In addition to MLC-1v, troponin-I was also enhanced following LPA treatment further 
confirming the ability of LPA to induce the differentiation of P19 SCs to differentiate. 
This data suggests that the regulation of differentiation by LPA is concentration dependent 
and the higher the concentration, the higher the expression of MLC-1v. This conclusion 
comes hand in hand with what our colleague Pramod (2017) found in her work. According 
to many reports on cardiac development, one of the main findings is observing beating 
clusters under the microscope (Van Der Heyden et al., 2003B; Kehat et al., 2001; Boheler 
et al., 2002; Maltsev et al., 1994; Kumar et al., 2005). These beating cells were elongated 
and increased in size as well as forming cell-cell junctions (Figure 3.7). These beating cells 
that are discussed in the mentioned reports were shadowed in our case when cells were 
clustered with LPA. However, this was apparent and constant at 20µM of LPA compared to 
the lesser concentrations. Even though Pramod (2017) discussed this finding but, the 
difference and the relevance of the beating clusters between the different concentrations 
were not disclosed.  
Other than LPA, oxytocin has also been reported to stimulate the production of beating cells 
by other researchers (Paquin et al., 2002). This report suggested that oxytocin could be a 
serum-borne factor which might be activated by DMSO. Whether oxytocin mediates the 
effect of LPA in our model remains to be established. Others have suggested that LPA and 
oxytocin share a similar role which includes inducing stress-fiber formation which is vital for 
the maintenance and the initiation of contractions in smooth muscle cells (Gogarten et al., 
2001). However, LPA is found to upregulate oxytocin receptors in vitro in the myometrial  
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cells (uterine myocytes) (Jeng et al., 2003). Clinically, labour in pregnancies is led by 
contractions, which are induced by oxytocin in the uterine (reviewed in Wocławek-Potocka 
et al., 2014). Therefore, LPA possesses the ability to enhance the stress-fiber in the uterine 
for contraction (reviewed in Wocławek-Potocka et al., 2014). LPA also could act similarly in 
regulating contraction of cardiomyocytes.  
The pluripotency marker, OCT4, was investigated to establish whether differentiation 
coincided with the loss or decrease in stemness. The expression of OCT4 decreased 
significantly as the concentration of LPA increased. However, a significant difference was 
found starting from a concentration of 1µM of LPA in contrast with MLC-1v, which showed 
a significant difference starting from 5µM. This reaction could be because the differentiation 
of the P19 SCs depends on the decrease in the factors that moderate their self-repair and 
regeneration that keeps the cells in their undifferentiated state through different transcription 
factors that hold the responsibility of these roles. Thus, as soon as the cells lose these 
characteristics, the cells start to differentiate and respond to the differentiation inducers 
(Wilson et al., 2010; Xu et al., 2009). While at 5, 10 & 20µM LPA suppressed the expression 
of OCT4, the difference between these three concentrations was not significant. The main 
pluripotency transcription factors were silenced or were downregulated, from 5µM LPA. This 
suggests that at a 5µM concentration of LPA, the pluripotency markers reduced, and the 
cells are expressing markers of differentiation or committed to differentiation. 
Having established our model showing that LPA regulates P19 stem cell differentiation in a 
concentration-dependent manner, the next step was to focus on determining the mechanism 
by which LPA establishes whether this differentiation is time-dependent. Long-time course 
and short-time course experiments were designed. In the long-time course experiment with 
5µM of LPA was used because of the ability to regulate P19 into myocytes. This 
concentration is in the lower range of the physiological concentration. 5µM of LPA and 
untreated P19 cell (negative control) from the same batch were lysed on day 0 (before 
plating), day 3, day 6, day 9 and day 12. The results obtained showed an apparent increase 
in the expression of MLC-1v in LPA treated cells in a time-dependent manner, except for 
day 12. At day 12, the expression slightly decreased as compared to day 6 and day 9. This 
was only significant in cells from day 6 compared to the untreated cells (p<0.01). This could 
suggest that the numbers of cells in the culture could affect the constant monolayer  
  
129 
 
formation. This also indicates that commitment occurs even after three days and that it is a 
time-dependent process. 
The second part of this time-course experiment was to investigate the expression of MLC-
1v from 5 minutes up to 24 hours. In this experiment, 5 & 20µM of LPA were used, and 
lysates were collected at day 6 and day 12. The results revealed that LPAs effect was both 
concentration and time-dependent. In these experiments, cells were treated with LPA before 
forming EBs, unlike the previous experiment, to investigate the capability of LPA to induce 
differentiation when treating the cells on a monolayer. 
The differences between cells treated with LPA 5µM for 4 days compared to cells incubated 
with the same concentration for shorter times (5 mins-24 hrs) were analysed and the least 
significance compared to LPA induced cells is shown in cells incubated for 24-hours 
(p<0.05), in contrast to all the other times which matched the basal levels (p<0.001). This 
suggests that 24 hours is the lowest time to show a difference in comparison to their peers. 
Furthermore, at 20µM LPA shows a clear difference compared to 5µM. The current outcome 
clarifies the variance seen at 6 hours and higher, including the 30 minutes incubation. These 
data suggest that while commitment may be initiated at a much earlier time point, sustained 
induction of differentiation requires longer incubation times, which gave rise to an enhanced 
commitment into the cardiac lineage. The cell viability was assessed in response to 
increasing concentration of LPA of 1-80µM. The different concentrations did not induce any 
significant changes in cell viability except on cells treated with 40µM, a non-physiological 
concentration which ranges between 5-20µM. 
In addition to LPA, DMSO was used as a positive control and was shown to regulate the 
differentiation showing high expression of MLC-1v. DMSO has been established as a 
differentiation inducer of P19 cells to cardiomyocytes (Abilez et al., 2006; Angello et al., 
2006; Van der Heyden et al., 2003A; Boheler et al., 2002; Jasmin et al., 2010; Edwards et 
al., 1983; Arreola et al., 1993; Skerjanc, 1994). The differentiation of the cardiac cells is 
associated with transcription factors which are highly expressed and upregulated in cardiac 
cells like Csx/NKx2.5, GATA4/6 and Mef2c (Kumar et al., 2005). These are activated by 
some extracellular molecules such as WNT, BMP, DMSO, fibroblast growth factors (FGF), 
LPA and other chemicals (Bartunek et al., 2007). These factors possibly play a role in  
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suppressing OCT4, SOX and NANOG and specific kinases would, as a result, activate and 
initiate some signalling events such as MAPK ERK, P38 MAPK, PKC, PI3K, TAK1 and other 
pathways known to be established in their activation in myogenesis (Van Der Heyden et al., 
2003B). MLC-1v, MLC-2v, α and β- MHC, atrial natriuretic protein (ANP), cardiac Troponin 
C and other proteins are up-regulated and are expressed more in induced differentiated 
cardiac cells compared to the undifferentiated state (Van Der Heyden et al., 2003B; 
Bartunek et al., 2007; Kumar et al., 2005). However, it is not entirely clear how DMSO and 
LPA induce this differentiation, and which pathway is involved.  
 
4.3. Concentration-dependent expression of 
transcription factors and key miRNAs induced by LPA 
Having established and validated the regulation of P19 cells differentiation into 
cardiomyocytes, by exploring the expression of cardiac-specific proteins (MLC-1v & 
Troponin and pluripotent factors. Further studies carried out focused on miRNAs (mir-145 
and mir-1) and transcription factors (OCT4, Nkx2.5). mir-145 and mir-1 were selected 
because mir-145 is found to be highly over-expressed when cells are committed to 
differentiation (Xu et al., 2009). While mir-1 mainly linked to cardiomyocytes and CVDs 
(Roma-Rodrigues et al., 2015). OCT4 and NKX2.5 were selected to reflect the transition 
from pluripotency to cardiomyocytes. 
qRT-PCR is one the most appropriate methods for the identification of specific miRNA 
expression profiles (Tong & Nemunaitis, 2008; Hu et al., 2011; Callis & Wang., 2008; Wang 
K. et al., 2012). Multiple investigators looked at the miRNA’s expression profile specifically 
during cardiogenesis. Some miRNAs play critical roles in some of the biological systems 
that have thoroughly identified. However, these findings are related to different stem cell 
lines such as mesenchymal, human embryonic and induced pluripotent SCs, or using 
different differentiation inducers like DMSO. 
Similarly, isolated cardiomyocytes from animal models which do not need any external 
inducers also used for the same purpose. In our case, this project is unique in its idea 
because it is for the first time that the roles of miRNAs are to be investigated about the 
induction of cardiomyocytes differentiation by LPA in P19 cells. 
  
131 
 
qRT-PCR is one of the primary techniques for miRNA studies, especially in identifying critical 
roles for regulation (Hohjoh & Fukushima et al., 2007; Wilson et al., 2010). In our reviews, 
miRNAs chosen due to their close association with cardiogenesis and its up-regulation in 
the heart or its regulatory reciprocals with LPA receptors. mir-1, mir-133, mir-145 and U6 
gene chosen and ordered from Qiagen for that purpose and RNA extraction is one of the 
most critical steps before running qPCR that is involved. For specific and reliable results in 
this project, the RNA quality intended was high, which containing no degraded RNA and no 
DNA contamination (Swift et al., 2000; Pfaffl, 2004). RNA purity was measured at A260 and 
the ratio of A260/A280 in a spectrophotometer and used to determine the purity of the RNA 
isolated. Pure RNA ratio is between 1.8-2.1, while, less absorption means protein 
contaminants present (QIAGEN guidelines). The integrity and the size of the total RNA were 
further checked on a denaturing agarose gel stained by ethidium bromide. The ribosomal 
RNA (18s and 28s rRNA) should appear sharp, and with no smear; otherwise, it would 
indicate signs of degradation of RNA in the sample. In this report, the isolated RNA samples 
had sharp bands and clear 18s and 28s rRNAs, which assure no degradation of RNA. All 
RNA samples were transcribed into cDNA according to the method described above. This 
helps in preserving the samples as cDNAs are more stable, unlike RNAs.  
Optimisation of assays and primers is an essential phase before running samples on qRT- 
PCR. An effective way of optimising the qPCR assay is by running serial dilutions, and the 
results used to generate a standard curve. An optimised linear standard curve should be 
close to R2> 0.980 or r>I-0.990I. While high amplification efficiency should be between 90 
and 105% and consistency across replicates (Bio-Rad guidelines). In the optimisation steps, 
2 house-keeping genes (U6 and mir-15a) and the primers evaluated in this research were 
optimised as illustrated in the results section. 
All the required steps were achieved, and the qRT-PCR experiments for all conditions were 
performed and analysed under the optimised conditions. U6 (house-keeping gene) was 
used as a control gene. Samples were mixed with a carefully calculated SYBR green mixture 
(according to the protocol described in materials and methods).  
The mRNA expression for OCT4 was tested initially as a pluripotent gene. It was analysed 
on 3 different days (Day 3, 6 and 12) with 5 different concentrations of LPA. However, there 
was no significant difference over the 3 days but, a decline in the latter, especially on day 6  
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and 12, was evident and marginally significant on day 6 for the 5µM of LPA. It was reported 
that LPA did not affect the expression of OCT4 (mRNA) in the blastocyst stage of a bovine 
embryo (Torres et al., 2014), and was able to decrease or increase the effect of apoptotic 
agents and growth factors. This thesis focused on the context of cardiac cell progenitors. 
This suggests that the expression of OCT4 is dependent on the type of cells and the lineage. 
There is no published research on cardiomyocytes induced by LPA, which examines the 
expression of OCT4. Additionally, Gq and Gi proteins coupled receptors were able to affect 
the expression of OCT4 and NANOG in neuronal cells developed from P19 cells by retinoic 
acid (Heck et al., 1997). This was also suggested by Cappuccio et al. (2005) in ES cells 
induced by MGLU5 metabotropic glutamate. Although the protein expression of OCT4 
showed an evident increasing trend, the mRNA levels tested on day six was unexpected. 
This could be due to the post-transcriptional regulation and other factors like methylation or 
acetylation. This is because “overall low correspondence between mRNA and protein 
expression, implying strong contribution of post-transcriptional levels of regulation.” 
(Koussounadis et al., 2015). In other similar experiments, there was also a significant 
decrease in OCT4 mRNA, which could also be related to the same reasons. 
Similarly, NKX2.5 showed no significant change, but there was a clear increase in the 
expression on day 12 with 5, 10 and 20µM LPA. 
mir-145 was shown to be up-regulated in cardiomyocyte generated by LPA on day six 
compared to the untreated SCs. This confirms the role of mir-145, which is widely 
understood and observed to be down-regulated in self-renewing embryonic SCs (Xu et al., 
2009). This specific miRNA is distinct in inducing pluripotency (iPSC) or re-programming the 
cells which are already specialised with different kinds of cells. This is because mir-145 
down-regulates the main influential pluripotency-inducers and act to preserve the cells in the 
undifferentiated state, retains cells-renewal and cells-regeneration. Mir-145 regulates 
OCT4, KLF4 and SOX2, by repressing the un-translated 3’ regions. According to XU and 
his colleagues (2009), they found that OCT4 binds and repress the promoters of mir-145. 
This suggests the reciprocal relationship between OCT4 and mir-145. In conclusion, it can 
be confirmed from the outcomes in this project that LPA up-regulates mir-145, which can 
explain the regulation of OCT4, specifically on day 6. 
Mir-1 is overexpressed (p<0.05) when cells were treated with 2, 5 and 10µM of LPA on day  
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3 and at 5µM on day 6. While day 12, did not show any significant change in the expression. 
Unlike with mir-145, the effect on mir-1 seems to be happening earlier on day 3. mir-1 is 
widely known to be an anti-hypertrophic and one of the key players in heart failure (Da Costa 
Martins et al., 2012; Hou et al., 2012). β- adrenoreceptor (β-AR) induces contraction through 
Gs proteins and regulates the release of nitric oxide (NO) in the heart through Gi protein 
when the endothelial NO-synthase is activated (Hou et al., 2012). According to Hou et al., 
(2012), when β-AR is stimulated with Isoproterenol (ISO), mir-1 was found to be upregulated 
as NO was also released in accordance and this concluded the anti-hypertrophic role of mir-
1 as well as its link with heart and cardiac cells. This was again proposed in vivo experiments 
and the ability of mir-1 in reversing induced cardiac hypertrophy by preventing maladaptive 
cardiac remodelling promised some possible therapeutic roles (Karakikes et al., 2013). 
In 2013, Lu and his colleagues overexpressed mir-1 in a human cardiovascular progenitor 
cell differentiated into cardiomyocytes. They concluded that this was done by suppressing 
roles of mir-1 that targets the WNT and FGF signalling pathways at a very early stage of the 
cardiac commitment. Recently, it was shown in P19 cells that mir-1 is significantly increased 
in differentiated cells and promotes cardiogenesis. They also showed that when over-
expressed, it decreases apoptosis by downregulating caspase-3 and expressing Hand2 (Liu 
et al., 2017). Our findings in this regard, confirms that mir-1 is upregulated in cells induced 
to differentiate into cardiomyocytes, supporting the conclusions above. 
 
4.4. Inhibition of LPA receptors 
These experiments aimed to investigate the effect of each LPA receptor when pre-treated 
with its specific antagonist. In some of the inhibitors, there were multiple IC50s, which means 
each has a different affinity for the various receptor (Table 4.1). These receptors also have 
different downstream pathways and as a result, different roles and activities. Nevertheless, 
some of the receptors share the same or multiple pathways (Figure 4.1) 
.
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Antagonist Conc./IC50 Target Used conc. 
Target (based 
on Conc.) 
 
1 Suramin 43µM 
GPCRs (EDG-
3/S1P3), LPA 
receptor 4 
50µg/ml All 
2 LY294002 
0.31, 0.73, 1.06 and 
6.60µM 
PI3-kinase (PI3-Kβ, 
PI3-Kα, PI3-Kσ and 
PI3-Kγ) 
7µM All 
3 H2L5765834 94, 463 and 752nM 
LPA receptor 1, 5 
and 3 
0.5 & 0.8µM 
LPA R1 & 5 
LPA R1, 5 & 3 
4 H2L5186303 
8.9, 1230 and 
27354nM 
LPA receptor 2, 3 
and 1 1.25µM LPA R2 & 3 
5 
TC-LPA5-4 0.8µM LPA receptor 5 1.6µM 
LPA R5 
 
Figure 4.1: LPA receptors and downstream signalling pathways. 
LPA receptors from LPA receptor 1 to 6 are labelled with different colours on the 
membrane. The blue hexagonal structures represent the G protein-coupled receptors. The 
other structures represent the downstream signalling pathways (González-Gil et al., 2014; 
Riaz et al., 2016; Kihara et al., 2014; Gardell et al., 2006). This is reproduced from Chapter 
1, Figure 1.8. 
  
Table 4.1: Inhibitors and antagonists used and their targets. 
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LPAR4 
Suramin is a widely used inhibitor that targets the P2Y purinergic receptors, which are 
closely related to LPAR4, according to González-Gil et al. (2014). Cells were pre-treated 
with suramin and displayed effective antagonistic abilities on the expression of MLC-1v by 
significantly inhibiting the differentiation induced by LPA, which also suppressed the basal 
levels of MLC-1v. This exerted action could be linked with the block of LPAR4, which was 
consistently tested and discussed by Pramod (2017) in her work, by which similar impact 
was observed on MLC-1v in this thesis. 
LPAR5 
Next, the protein expression of MLC-1v induced by LPA was again tested, but this time 
against LPAR5. Previously, Pramod (2017) suggested that due to the absence of LPAR5, 
which was undetected by qPCR and on gel electrophoresis contrary to LPA1-4, that it could 
because it is not expressed in P19 cells. However, TC-LPA5-4 is a potent and specific 
inhibitor first discovered and identified by Kozian et al. (2012). They described TC-LPA5-4 
as “the first non-lipid, small molecule inhibitor for LPA5/GPR92, specifically inhibiting LPA-
mediated platelet activation in vitro.”. The LPA-mediated platelet activation role was tested 
by comparing the impact of this inhibitor against the other inhibitors which targeted 
selectively, LPAR1/3 and LPAR2 against LPAR5. In conclusion, their data showed that the 
antagonistic effect of LPAR5 interfered with 16:0 alkyl-LPA-mediated platelet activation 
(Kozian et al., 2012).  
Comparably, our results suggest an active role for LPAR5 and that it is indeed could be 
expressed in P19 cells induced by LPA. This comes from the significant enhancement in 
MLC-1v compared to the cells treated with the inhibitor only and a partial decrease of up to 
a mean of 30% compared to the LPA treated cells that occurred following the addition of 
LPA to the inhibited cells. Additionally, OCT4 at a protein and mRNA levels had also 
reversed the effect of LPA when cells were similarly pre-treated with LPAR5 inhibitor. 
Although, we established the crosslink between OCT4 and mir-145, however, the impact on 
the expression of mir-145 when LPAR5 was blocked seems to be minimal and does not 
reflect the expression of OCT4. This do not negate the involvement of mir-145 or the other 
miRNAs like mir-1 at least indirectly.  
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The possible reason for the loss or the non-detection of LPAR5 in Pramod’s (2017) research 
could be due to a non-specific primer which was used which resulted in the lack of 
amplification of LPAR5 mRNA which further would mean the loss of the band in the gel 
electrophoresis. This finding proposes that the effect of LPA is at least in part mediated 
through LPAR5 and hence opens another door for more extensive research and re-
evaluation which possibly can help in the prevention of the fatal consequences of 
atherosclerosis as Kozian et al. (2012) recommended. 
LPAR2 and LPAR3 
In conjunction with the previous inhibitors that we used, H2L5186303 is another interesting 
inhibitor aimed to block LPAR2 and 3 (Table 4.1) selectively. LPAR2 was not investigated 
by Pramod (2017) at the time due to the lack of any commercial inhibitors. However, she 
identified the highest mRNA expression for LPAR2 in between the other receptors. She also 
tested LPAR1/3 using Ki16425 by which her results suggested that LPA induced 
differentiation is maintained through both LPAR 1/3, including LPAR4. To further our 
understanding of the matter, 1.25µM of H2L5186303, which is a concentration that covers 
the IC50 of 8.9nM for LPAR2 and 1,230nM LPAR3, respectively (Fells et al., 2009). 
However, this concentration is more selective and potent to LPAR3 at the mentioned IC50 
than LPAR2. The results generated were unexpected, as the impact of this inhibitor was not 
extended to MLC-1v or the other cardiac markers. OCT4 was the key factor identified in both 
protein level and mRNA. The LPA induced OCT4 protein expression has increased 
significantly in addition to the mRNA decrease of the basal levels when the inhibitor is added. 
This could be associated with the changes in the expression of mir-145, an OCT4 regulator, 
as it evidently increased when LPA was added to a similar level to LPA-induced P19 cells. 
This could mean that LPA was blocked and had no effect on the expression of OCT4 at the 
basal level in the presence of the inhibitor, and this reflects the expression of mir-145, which 
was low. 
To conclude, inhibiting the dual LPAR (2&3) has partially blocked the differentiation through 
the regulation of OCT4 and mir-145 and did not affect protein expression of MLC-1v 
significantly. LPAR3 was shown by Pramod (2017) to be the least to express compared to 
LPAR2, which was the highest to express. As mentioned earlier, as the concentration used 
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was to target both receptors and seems to be more directed toward LPAR3 in terms of the 
IC50, this could be linked to the low expression of LPAR3 in P19 cells, which require further 
investigation and increase in the n values to reach to more conclusive answers.  
In contrast, we attempted to investigate another inhibitor, H2L5765834 which did not show 
any antagonistic actions except on one occasion. The basal mRNA of OCT4 decreased 
when LPAR3 was encompassed using the concentration required. This reaction of OCT4 
was not apparent when a lower concentration used. Initially to specifically target the dual 
LPAR1 & 5 to be assessed. This dual again, for some reason, didn’t seem to cause any 
changes, suggesting further evaluation to affirm the possible link between LPAR3 and OCT4 
and the actual role of LPAR1 and 5. 
 
4.5. Suppression of protein kinase-C inhibit 
differentiation 
Bisindolylmaleimide 1 (BIM-1), is an established protein kinase inhibitor of PKC isoform and 
MLC kinase. BIM-1 was used to ascertain the possible effect on differentiation and 
expression of key factors involved in the process of differentiation. It has been shown that 
PKC is one of the critical regulators of the differentiation. The total reduction in the 
expression of myogenic markers induced by LPA is confirmed in this thesis supported by 
the decrease in miRNAs due to the impact of BIM-1. This is consistent with the conclusion 
others reached that PKC is critical in the differentiation of stem cells into cardiomyocytes 
(Xu et al., 1991; Koyanagi et al., 2009). Even though different isoforms of PKC showed to 
have a contrary role in the development of myocytes (Mobley et al., 2010; Koyanagi et al., 
2009), however, the selective block to all the isoform by BIM-1 seems to be negatively 
affecting the cardio-myogenesis as also shown previously by my colleague Pramod (2017). 
Rawal et al. (2014) discussed the possible link between miRNAs and PKC signalling 
pathways specifically in the context of the protection of heart linked diseases (Liu et al., 
2018; Wang et al., 2016A). In this case, the data strongly support their suggestions and 
further propose that the regulation of miRNAs by LPA are critically dependent on the 
activation of a mixture of PKC and MLC Kinase. 
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4.6. Role of PI3K in LPA-induced regulation of MLC-1v 
and OCT4 
Next, cells treated with LY294002 were evaluated. The PI3 kinase is another downstream 
pathway which is activated by LPA through Gi GPCR (Figure 4.1). When activated, it is 
understood to play a role in cell proliferation, cancer, and cell cycle (Wang et al., 2003). In 
cancer, the over-activation of PI3k increase the resistance to apoptosis via the 
PI3k/AKT/mTOR pathway (McKenzie & Kyprianou, 2006; Tørring et al., 2003). It also plays 
a pro-apoptotic role, mediated by mir-210 in the development of atherosclerosis (Li et al., 
2017). miRNAs are evidently reported to be associated with atherosclerosis by developing 
the atherosclerotic plaques (Raitoharju et al., 2011; Li et al., 2017; Parahuleva et al., 2018). 
Mir-92a, mir-99a, miR-21, miR-210, miR-34a, and miR-146 are all upregulated and known 
to be involved in atherosclerosis (Raitoharju et al., 2011; Yu et al., 2014; Li et al., 2017; 
Parahuleva et al., 2018). mir-210 specifically, which is also a pro-apoptotic regulator acts 
through targeting PDK1 towards forming the plaques (Li et al., 2017. This is relevant to this 
thesis since miRNAs are shown to be one of the main regulators of diseases and cell 
development, which makes them a therapeutic target, as reviewed in Araldi & Suárez 
(2016).  
The link between LPA and PI3K pathway seems to be related to NHE3 mobility (Cha et al., 
2010). NHE3 mobility is a Na+/H+ exchange isoform found in the apical membrane, which 
also plays a role in the pH regulation (Alexander et al., 2005; Cha et al., 2010). Inhibition of 
PI3K leads to the induction of cell apoptosis in some cases, which correlates with the 
inhibition of in-vitro ovarian cancer models. In vivo, it can suppress tumour growth and 
induction of apoptosis (Semba et al., 2002) and in-vitro it can significantly downregulate the 
formation and growth of carcinoma in the ovary. As such, OCT4 is widely understood to be 
an crucial antiapoptotic agent (Wang et al., 2013; Wen et al., 2013; Zhang et al., 2016; Meng 
et al., 2018) and an essential factor in maintaining stem cells in their undifferentiated state 
and exerts the ability to regain the pluripotency of the cells (Takahashi & Yamanaka, 2006; 
Yu et al., 2007; Xu et al., 2009). This could relate to how the antagonist of a PI3K seems to 
be affecting the basal level of OCT4 by just less than a mean of 50%. This was also 
consistent with the mRNA levels of OCT4 which was very low, not only that, the latter was 
further demolished when LPA was mixed with the inhibitor which caused something like a  
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 double effect on the latter. Besides that, Rho, a downstream signalling pathway which is 
activated by several LPA receptors according to Alexander et al. (2005) showed that it exerts 
the ability to dictate the mobility of the Na+/H+ exchange through the LPA G-protein Gα12/13 
(Figure 4.1).  
miRNAs are a regulating sequence to most of the genes like OCT4 by mir-145. However, 
the expression of mir-145 was not implicated, which suggest that there is no direct link to 
the PI3 kinase. This was also the case with mir-1, which was very marginal with at least 1-
fold difference observed when LPA is blocked through the PI3k. The expression of mir-133 
was similarly partially blocked. This implies that miRNAs have no significant effect on the 
abnormal inhibitory regulation of some kinases, in our case, post-PI3 kinase inhibition based 
on the results. Our observations showed that the latter was without effect on basal MLC-1v 
and GATA4 protein expression but appear to suppress the induction caused by LPA 
partially. This was, however, found not to be statistically significant due to the possibly 
considerable variation in the individual experimental data. This comes in contrary to what 
Pramod (2017) found in her produced data, although the concentration used by herself was 
less, starting from 5µM (p<0.001) to a total demolition at 10 and 20µM of the MLC-1v 
expression induced by LPA. The outcome of our result could be due to the low concentration 
compared to the successful inhibition of differentiation occurred by several researchers 
(Klinz et al., 1999; Sauer et al., 2000; Humphrey, 2009). By which all these mentioned, has 
used an excess of 20µM up to 50µM to induce and establish the effect of the inhibition of 
the PI3K pathway. The low concentration that we used in our experiments (7µM) could be a 
factor in the unexpected results. This will require an increase in the n value in future studies 
as well as the elevation of the concentration. It is also possible that responses to LPA are 
only partially mediated via PI3 kinase as part of a signalling cascade as concluded by 
D'amico and his group (2016). They suggest that IL6 induce cardiac differentiation of 
embryonic stem cells through a signalling cascade that includes PTEN, PKC as well as 
PI3K.  
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4.7. Effects of transfection of siRNA (inhibitors) and 
mimic (overexpression) with or without LPA 
In this part of the research, the siRNA/mimic experiments with mir-145 and mir-1 following 
the successful previous link to the differentiation and MLC-1v was investigated. The analysis 
included testing protein expression and assessing the effect of the overexpression or 
inhibition at the translational level. qPCR experiments were also used to analyse the mRNA 
levels as a response to the transfection.  
Although there were no direct binding sites between mir-145 and myosin light chain, mir-
143 seems to have a binding site, as shown in figure 4.2. This was extracted from an online 
database tool called Target-Scan. mir-143 and mir-145 are found as clusters and shares 
various activities physiologically like switching the phenotype of vascular smooth muscle 
cells (Rangrez et al., 2011). Previously, mir-145 was shown as a tumour suppressor (Zhang 
et al., 2015B). According to Hong and his colleagues (2017), both modulate the synovial 
fibroblasts cells phenotype in samples of rheumatoid arthritis. Cell adhesion, proliferation 
and apoptosis, as well as the disruption of cervical epithelial barriers are activities that mir-
145/143 actively involved in (Anton et al., 2017). In addition, mir-145/143 function as tumour 
suppressors together as clusters, but this could be influenced by different factors 
(Johannessen et al., 2017). Tumour suppression was also reported by Chivukula et al. 
(2014) as roles for the cluster together in the colon and the intestinal epithelial cells. They 
highlighted the importance of mir-145/143 in the regeneration of mouse intestinal epithelial 
cells. 
 
 
Figure 4.2: The binding site of mir-143 Myosin light chain. 
 
mir-133 is shown in various researches to be a critical cardiology and differentiation inducer 
as well as a unique anti-hypertrophic factor (table 1.2) However; we were interested in 
finding if there is a relationship between mir-145 and mir-133. It is understood that mir-133   
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with mir-145 has been associated with some specific activities. Qui et al. (2014) concluded 
that both miRNAs regulate the expression of an MMP-9 and Cyclin DI because of targeting 
SP1. They also concluded that both inhibit the cell cycle, cell proliferation invasion and 
migration, specifically in cancer cells. This regulation and activities were also predicted in 
Target-Scan and reported in several published papers in different cells and tissues 
(Chiyomaru et al., 2010; Yoshino et al., 2011; Akanuma et al., 2014; Kano et al., 2010; Guo 
et al., 2013). As mentioned previously, mir-145 targets the main key pluripotency markers 
of stem cells, majorly OCT4 which we are in our work focusing on as it shares binding sites 
with mir-145 (Figure 4.3; Zhu et al., 2014). For that reason, mir-145 was targeted to be 
inhibited and overexpressed using a transfection technique to assess the importance of this 
miRNAs in the differentiation, including understanding the molecular mechanism that 
regulates the LPA-induced cardiomyocytes. 
 
 
 
 
 
In another very recent study, mir-145 and mir-133 were together associated closely in 
playing critical roles in regulating genes involved in atherosclerosis precisely in plasma (Klu 
et al., 2018). This critical regulation, however, was a cross-reaction activity by which mir-
133 was up-regulated, unlike mir-145, which was down-regulated. Another research on 
myogenesis in a rainbow trout has reported that mir-133 represented myogenic miRNAs 
(Koganti et al., 2017). Moreover, Narickas et al. (2016) reviewed the established role of both 
miRNAs in the vascular smooth muscle cells differentiation concluding the importance of 
understanding the cross-activity between miRNAs as well as considering the specific 
purpose of these miRNAs. Mir-133 and mir-1 are normally transcribed together and located 
in the same chromosomal loci. Both are linked closely to cardiomyocytes and early 
embryogenesis, specifically cardiogenesis.  
  
 
Figure 4.3: The binding site of mir-145 in OCT4 mRNA (Zhu et al., 2014). 
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As per our results, mir-1 has shown an increase in expression in response to the 
differentiation induced by LPA. It was earlier (From day 3) compared to mir-145 (day 6) and 
more apparent compared to mir-133. For that reason, a choice was made to also beside 
mir-145 to target mir-1 as a cardiac marker to investigated with specific mir-1 siRNA inhibitor 
and another specific mimic for mir-1. Our results of transfection support this. The 
overexpression of mir-1 has given rise to an overly enhanced expression of MLC-1v. This 
enhancement went even further when LPA was added. 
When mir-145 inhibited, LPA did not affect its expression, although we hypothesised that 
LPA might play a significant role in regulating miR-145 as shown previously. The addition of 
LPA minimally impacted overexpressed mir-145 using a mimic. All the other targeted 
proteins and mRNAs were also minimally affected by the addition of LPA when mir-1 was 
aimed (either inhibited or over-expressed), except that mir-1 when overexpressed showed 
a significant visible increase with and without LPA in OCT4 gene expression. This is 
unexpected as the increase in mir-1 should refer to the fact that the cells are committed to 
differentiate with the protein expression to decline rather than increase. Looking at the other 
results which were not implicated We can conclude that the inhibition and overexpression 
of mir-145 did not enhance or decrease any of the targets and this could be a failure in the 
technical experimental design. While mir-1 was similar except the effect observed on MLC-
1v and OCT4 protein, furthermore, questions about the transfection efficiency rightly could 
be asked. Other reasons could be the cell state and the confluence, as suggested by some 
scientists to be critical for efficiency. Toxicity of the solutions is another possible factor in 
which can decrease expression of the target. Another set of advice includes using miR-
negative control from a scramble mimic that is not like any other used sequences. 
Additionally, multiple sets of concentration of the target are to be used in conjunction with a 
similar concentration in the negative samples. This would attempt to identify the toxicity and 
effectiveness of each concentration in the future. 
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CHAPTER 5 
CONCLUSION and FUTURE WORK 
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5.1 Conclusion 
A model has been validated in this thesis, confirming an ability of LPA to induce the 
generation of cardiomyocyte from the embryonic p19 SCs. This induction was concentration 
and time-dependent. Also, this regulation was shown to be achieved through the activation 
of specific signalling pathways linked to LPA receptors, PKC and partially PI3 kinase. While 
LPA receptors like LPAR4 and LPAR5 selectively shown to be critical in generating 
cardiomyocytes while LPAR2 and LPAR3 has a partial mediation activity of the LPA-induced 
differentiation. These were also supported by examining changes in cardiac-specific 
miRNAs expression, which were altered significantly. Our results show a clear involvement 
of miRNAs in the generation of cardiomyocytes from P19 SCs. Specifically, mir-145 and mir-
1, by which the role of mir-145 was linked to the regulatory effect that it imposed on OCT4 
the pluripotent factor. mir-1, on the other side, had shown a close relation with differentiation 
as enhancer and activator of expression of MLC-1v. As part of our results, we also confirm 
that miRNAs could regulate LPAR5, which was only predicted by Belleannée et al. (2012) 
and not shown practically. 
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5.2 Future work 
The research conducted for this thesis has validated the in vitro model for generating 
cardiomyocytes from SCs and has further generated a novel data outlining the potential role 
of some key transcription factors and miRNAs in the differentiation process induced by the 
endogenous biolipid, LPA. The research has however raised further supplementary 
questions. The following bullet points have suggested a summary of future works: 
• The n value for several of the studies needs to be increased to determine the statistical 
significance of trends observed. This was not possible during this thesis because of time 
constraints. 
• Re-validation of the specific role each LPA receptor plays by using specific inhibitors with 
a range of concentrations exploring the molecular mechanism involved (miRNA).  
• For a more profound understanding of the role miRNA play in the regulation of 
differentiation of P19 SCs into cardiac cells, the studies should be extended to other 
potential miRNAs to determine the most critical ones.  
• Investigating the effect of the inhibition and overexpression of miRNA that could impact 
the differentiation using a properly designed experiment aiming a high efficiency and 
standardised negative control. 
• Using alternative techniques to validate all the results for robust conclusions. 
• A comparative study between P19 and embryonic human SCs in LPA induced 
differentiation of SCs into cardiomyocytes is also required to determine whether our 
observations are reflected in other SCs, preferably of human origin. 
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